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Development of new arterial-like vascular conduits for coronary and peripheral bypass 
grafting surgery is desirable to overcome the limitations of currently available biological 
and/or synthetic grafts; to reduce the incidence of early thrombosis, late intimal 
thickening and infection. One alternative is to use arterialised decellularised venous 
scaffolds. The aim of this PhD project was to assess the feasibility and suitability of 
human saphenous vein (hSV) decellularisation as a way to obtain effective biological 
acellular scaffold for vascular grafting. 
We identified the optimal sodium dodecyl sulphate (SDS) concentration needed to 
decellularise short segments of hSVs (~0.5 cm). Low concentration (0.01%) (w/v) SDS 
removed most of the nuclei, but this approach was not effective in removing nuclei 
when using ~4 cm long hSVs. Hence, a modified flow technique of decellularisation 
was established with successful decellularisation of longer hSV segments.  
Biocompatibility and integrity of decellularised hSVs were then evaluated. Methylene 
blue assay detected only trivial residual concentrations of SDS after decellularisation. 
This was biocompatible as this residual amount of SDS did not affect the viability of 
porcine carotid artery endothelial cells (pCA ECs) to populate the acellular hSV 
(AlamarBlue) and to proliferate (EdU proliferation assays). Next, the ECM integrity of 
acellular hSVs was assessed by quantifying major ECM proteins (collagen, elastin and 
glycosaminoglycan). Results revealed that decellularisation with ≤0.01% (w/v) SDS 
did not have a significant impact on ECM content. We then tested the feasibility, safety 
and capacity of acellular hSVs to arterialise following surgical implant with end-to-end 
anastomoses in pig without immunosuppression. This pilot study showed that porcine 
carotid artery xenograft of decellularised hSV was feasible and safe, with 50% graft 
patency rate at 4 weeks and signs of in situ vascular tissue engineering by host cells.  
In conclusion, effective decellularisation of hSV is feasible, safe and reproducible as 
potential acellular vascular scaffolds. Acellular hSVs may be used as vascular 
acellular scaffolds either for in situ vascular engineering by host cells or following ex 
vivo manipulation before implantation. However, this approach warrants further 
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 Cardiovascular Disease 
According to World Health Organization (WHO) reports, 31% of all global deaths are 
due to cardiovascular diseases (CVD) (Mendis, Puska, and Norrving 2011). The 
treatment of CVD has an enormous impact on healthcare systems cost. The National 
Health Service (NHS) in the United Kingdom (UK) spent more than £6.8 billion treating 
CVD in the year 2012/2013 (Porth, Matfin, and Porth 2009; Nichols et al. 2014). 
Although CVD is no longer the biggest killer in the UK (Bhatnagar et al. 2015), there 
is still a need to reduce CVD to improve the population health and decrease the 
economic burden of CVD on the NHS. It is important to highlight that CVD covers a 
range of heart and blood vessel related diseases including but not limited to coronary 
artery disease (CAD), valvular heart disease, cardiomyopathy and congenital heart 
disease and peripheral artery disease (PAD). Generally, CAD and PAD affect the heart 
(cardio) and/or peripheral blood vessels (brain, kidney, liver, gut, limbs, etc), 
respectively due to the narrowing and blocking of arteries.  
 
 Coronary Artery Disease  
In the UK, more than 2.3 million people are living with some form of CAD (Nichols et 
al. 2014), making CAD the most common type of heart disease. CAD occurs when 
coronary arteries are restricted or blocked by a build-up of fatty substances. The 
process of fatty deposits build-up is called atherosclerosis, and the initiating fatty 
deposits called atheroma that eventually will form atherosclerotic plaques. 
Atherosclerosis leads to narrowing of coronary arteries leading to reduced blood 
supply to the myocardium causing insufficient delivery of oxygen in which, if not 
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resolved can lead to ischemia and death of cardiomyocytes. In a clinical setting this 
condition is called myocardial infarction, or commonly known as a heart attack. 
Relating the terminology that medical professionals use in explaining CVD (as shown 
in Figure 1.1) helps in the understanding of the diagnosis of CV and the atherosclerotic 
plaque condition that substantiates the diagnosis. 
 
Figure 1.1 Pathophysiology of CAD. A schematic representation of the different 
terminology and its disease condition (Porth, Matfin, and Porth 2009). 
 
 Cellular and Molecular Mechanisms of Atherosclerosis, Pathophysiology 
and Clinical Diagnosis of CAD 
Atherosclerosis which starts with an early atheroma derives its name from Greek; for  
gruel (athere) and lumps (oma) (Grech 2003). These ‘gruel lumps’ consist of fat, 
cholesterol, calcium, connective tissue and inflammatory cells. The build-up of 


















lifestyle risk factors; the latter being modifiable. Smoking, high cholesterol, diabetes, 
obesity lack of exercise is among the risk factors that could be controlled via lifestyle 
changes (Sclavo 2001; Gensini, Comeglio, and Colella 1998; El-Menyar et al. 2011). 
 
Atheroma forms from a deposition of fatty built up in the luminal surface of an artery 
called a ‘fatty streak’ seen from an early age (Hong 2010; Misra 2000; Kannel 1976). 
Although termed fatty deposits they are not composed of just fat cells but as mentioned 
earlier are a mixture of fat, cholesterol, calcium, connective tissue and inflammatory 
cells. The accumulation of debris in established atheromas do not appear to be 
reversible via medications and life style change, but early intervention e.g. healthy 
lifestyle transformation and prescribed medications, can stabilised their composition 
and progression (Ahmed et al. 2012; Shai et al. 2010; Bedi et al. 2011; Han et al. 2012; 
Takayama et al. 2009).  
 
In Greek, the word ‘sclerosis’ means hardening (Singh et al. 2002). For that reason, 
atherosclerosis means the hardening of the gruel (fatty) lumps. Atherosclerosis also 
involves an inflammatory disease component (Ross 1999) and has  been defined as 
“a focal, inflammatory fibro-proliferative response to multiple forms of endothelial 
injury” (George and Johnson 2010). A normal artery has a lining of single endothelial 
cells (ECs) on the luminal surface which forms the intima. The ECs are arranged in 
the direction of the flow on the internal elastic lamina. Beneath the intimal layer is the 
medial layer that consists of a few layers of concentrically arranged smooth muscle 
cells (SMCs) and extracellular matrix (ECM) proteins that is bordered by the external 
elastic lamina (Figure 1.2 A). Atheroma is initiated by one; the disruption of the 
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endothelial lining due to various factors including the risk factors mentioned previously 
and two; another factor include the physical forces imposed on the ECs due to the 
location in the circulatory system. This damage of the ECs leads to the accumulation 
of reactive oxygen species (ROS), upregulation of several adhesion molecules, 
increased permeability of the arterial wall and activation of circulating platelets. These 
cumulative events cause the recruitment of low-density lipoproteins (LDL) and 
leukocytes within the arterial wall (Figure 1.2 B). Once inflammatory cells migrate 
within the arterial wall, monocytes will differentiate into macrophages and 
subsequently may become foam cell macrophages following uptake of LDL, which has 
been oxidised within the artery. At this stage, atheroma or ‘fatty streaks’ are formed 
these are asymptomatic but have the capacity to progress into atherosclerotic lesions 
with continued exposure to risk factors (Figure 1.2 C).  
 
The further accumulation of foam cell macrophages in the artery wall results in foam 
cell death and the cells break down, they excrete their cytoplasmic contents that are 
full of lipids. This leads to the formation of necrotic core within atherosclerotic plaque. 
The formation of the necrotic core in turn induces further inflammation and proliferation 
of SMCs that deposit ECM proteins which together result in the formation of a fibrous 
cap that overlies the necrotic core and can protrude into the lumen of the vessel and 
partially decrease the lumen size. A thick and intact fibrous cap provides strength to 
the atherosclerotic plaque and therefore such plaques are classified as stable 
atherosclerotic plaques (Figure 1.2 D). A thin fibrous cap has enhanced propensity to 
rupture and consequently plaques with a thin cap are categorised as unstable 
atherosclerotic plaques (Figure 1.2 E). Rupture of the fibrous cap exposes the 
contents of the plaque including necrotic core, cell debris and ECM, to the circulating 
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blood and leads to the activation of circulating platelets and formation of thrombus that 








Figure 1.2 Atherosclerotic plaque formation. A simplified schematic representation 
of atherosclerotic plaque formation of the cellular and molecular level from a normal 
coronary artery (A), endothelial dysfunction (B), fatty streak formation (C), stable 
atherosclerotic plaque (D), unstable atherosclerotic plaque (E), to a ruptured 
atherosclerotic plaque (F) (George and Johnson 2010).  
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Patients with stable atherosclerotic plaques, may not present with any symptoms at 
rest but may experience symptoms while doing exertive activity due to increased 
myocardial demand for blood supply and oxygen, that subsides shortly after ceasing 
the activity. Patients may experience symptoms such as chest discomfort and 
shortness of breath. These symptoms prompt diagnostic tests to be undertaken and 
stable angina is diagnosed when certain criteria as ruled out in the ESC guidelines are 
present (Montalescot et al. 2013, 2014; Roffi et al. 2016). As atherosclerotic plaques 
progress and fibrous caps are formed, the lumen diameter becomes smaller thus 
making it harder to pump blood through the diseased coronary artery. Patients will 
experience the same symptoms as with stable angina but these are more frequent 
and severe i.e. under mild activity or even at rest. These symptoms may last for several 
minutes and will subside with rest or with the prescription of anti-angina agents or 
drugs e.g. diuretics, nitrates, statins, Angiotensin-converting enzyme (ACE) inhibitors, 
calcium channel blockers and a few others are among the most common drugs in 
treating CVD as they can reduce workload of the heart. At this stage, the diagnosis is 
classified as unstable angina (Thygesen et al. 2012; Ambrose and Dangas 2000).  
 
Further progression of atherosclerotic disease triggers more serious clinical effects; 
either non-ST elevated myocardial infarction (NSTEMI) or ST elevated myocardial 
infarction (STEMI). STEMI and NSTEMI could be distinguished via electrocardiogram 
(ECG) patterns; with elevated ST segments in STEMI case due to sudden total 
blockage of artery/ies. Whereas NSTEMI is often clinically indistinguishable from 
unstable angina during initial presentation at the hospital. Therefore, the guidelines in 
management of patients presented with ACS are used as a reference in making a 
diagnosis (Roffi et al. 2016).  
8 
 
In general, patients admitted to hospital with chest pain/angina undergo an 
electrocardiogram (ECG) test as well as blood tests to assess the circulating levels of 
troponins which act as markers of cardiomyocyte death. In the case of confirmed MI 
with elevated blood troponin, the ECG will help to distinguish between STEMI and 
NSTEMI. Persistent ST elevation on the ECG is diagnosed as STEMI, which generally 
reflects a major MI event with substantial myocardial injury in one of the coronary 
artery territories. If there are abnormalities or undetermined ECG results, further 
biochemistry testing will be done. Further diagnosis being dependent on the troponin 
level in the blood: normal troponin level indicates unstable angina; increased or 
decreased of troponin diagnoses NSTEMI. Simplified diagnosis guidelines are shown 




Figure 1.3 Guidelines in diagnosis management of ACS. A simplified flow diagram 
in diagnosis management of ACS patients published by the European Society of 
Cardiology (ESC) that is referred to by the majority of medical professionals (Mann et 
al. 2015; Anderson and Morrow 2017) 
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The rupture of atherosclerotic plaques with resulting thrombi can lead to total occlusion 
of the coronary artery, preventing blood flow to the related myocardial territory, hence 
depriving the heart muscle of oxygen, a condition termed as ischemia and leading to 
MI. Within 20 minutes to two hours after the on-set of ischemia, the changes to the 
heart cells are irreversible (Kumar et al. 2010), and without immediate 
revascularisation and blood reperfusion of the ischemic territory, the cardiomyocytes 
will undergo necrosis Figure 1.4). This in turn will affect the mechanical ability of the 
heart to pump blood to the entire body (Flachskampf et al. 2011). Therefore, 
management of the disease before it progresses further is critical.     
 
Figure 1.4 Consequences of atherosclerosis progression.  A schematic 
representation of atherosclerotic disease progression after total coronary artery 
occlusion as a result of a ruptured atherosclerotic plaque (Mann et al. 2015). 
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 Currently Applied Treatments and Prevention of CAD Progression 
The current treatment options for severe CAD include drug prescription, coronary 
angioplasty (Figure 1.5), surgery (Figure 1.7) or heart transplantation (Montalescot et 
al. 2013, 2014; Roffi et al. 2016). There are a variety of pharmaceutical approaches 
that can be used for patients with CAD. Anti-platelets, statins, beta-blockers and 
nitrates are among the most common drugs prescribed for patients with CAD as they 
can reduce thrombus formation, normalise the cholesterol levels, reduce the oxygen 
demand of the heart and increase the coronary blood flow. In the case of patients with 
history of MI, at time diuretics are also used to reduce the workload of the heart. These 
pharmacological approaches do not treat or reverse the disease but help in preventing 
progression and curbing the symptoms in the early stages of disease.    
 
Coronary angioplasty is a procedure done to widen the narrowed or blocked arteries 
with balloon catheter and is also known as percutaneous transluminal coronary 
angioplasty; PTCA. Angioplasty is also done with the incorporation of a stent where 
the combinatory use of both angioplasty and stent is called percutaneous coronary 
intervention; PCI. PCI procedures utilise a variety of commercially available stents. 
Stents are metal mesh tubes delivered percutaneously into the diseased artery 
through a needle in a wire catheter and deployed with a balloon. They are used to 
resolve the narrowing induced by the atherosclerotic blockage to normalise blood 





Figure 1.5 Balloon Angioplasty and Stent Implantation Procedure. A special 
balloon tipped catheter is inserted into the coronary artery. The balloon is inflated 
which widens the lumen (A). In most cases a stent is implanted within the artery (B) 
(Torpy, Lynm, and Glass 2004).  
 
Bare metal stents (BMS) were the first type of stent device developed to treat CAD. 
BMS were proven to show better outcome than balloon angioplasty as it lowers the 
restenosis occurrence to 17 to 41 % (with BMS) from 32 to 55 % (with balloon 
angioplasty)(Buccheri et al. 2016). Unfortunately, BMS caused high rates of in-stent 
re-blockage (restenosis) as the permanently deployed metal device triggered chronic 
SMC proliferation and inflammation within the vascular wall due to EC denudation. 
Consequently, the intervention that was undertaken to slow down the disease 




Bhatia, and Dhindsa 2004).Complications after PCI are usually in-stent restenosis 
(ISR)  were observed within 6 months after the intervention procedure as shown in 
Figure 1.6 (Mohr et al. 2013; Torrado et al. 2018). ISR is defined by >50% blockage 
or stenosis at the stent segment or 5 mm adjacent to the stents (Mehran et al. 1999; 
Kuntz and Baim 1993). Often patients are readmitted to hospital for very expensive 
repeat revascularisation with additional stents or for CABG surgery.  
 
Figure 1.6 Complications of PCI procedures. PCI approaches and the consequent 
limitations that arise after the procedures due to thrombus formation early-on between 
periprocedural and up to 6 months follow-up (FU), neointima hyperplasia (NIH) at in 
the 6 months follow-up, and ISR thereafter (Torrado et al. 2018). (BA: Balloon 




Therefore, drug eluting stents (DES) were developed. The first generation of DES 
includes the use of BMS with the incorporation of anti-proliferative drug to hinder the 
SMC invasion and proliferation. The main anti-proliferative drugs used in DES are 
rapamycins and taxanes which has different mode of actions. Rapamycins are called 
limus-drugs and its analogues (e.g. sirolimus, everolimus, zotarolimus, biolimus etc.) 
act to inhibit SMC proliferation by acting on the mammalian TOR receptor (mTOR) 
thus blocking the cell cycle at G1 and S phase (Wessely and Andres 2012; Ielasi, 
Latib, and Colombo 2014; Yin, Yang, and Wu 2014). Whereas, tanaxes (e.g. 
paclitaxel) disrupt the cell cycle at G0/1 and G2/M phases by inhibiting the microtubule 
depolymerisation (Kellogg et al. 2017; Abal, Andreu, and Barasoain 2003). Initial 
results showed that DES does in fact reduce early ISR to less than 10% occurrence 
and the need for repeat revascularisation (Chen and Lin 2009; Buccheri et al. 2016; 
Kastrati et al. 2005). Despite the early positive outcome, the first generation DES 
causes elevated rates of late and very late stage stent thrombosis (ST) due to inhibition 
of EC proliferation and repair as the drugs acts non-selectively to different cell types 
(Lüscher et al. 2007; McFadden et al. ; Iakovou et al. 2005).  
 
The second generation DES include a combination of anti-proliferative drugs and 
improvement of materials used in the development of stent using polymers instead of 
metal for their biocompatibility properties e.g. polystyrene-b-isobutylene-b-styrene, 
polyethylene-co-vinyl acetate (PEVA) and poly n-butyl methacrylate (PBMA). More 
recently advances are the bioabsorbable and biodegradable stents (commercially 
known as bioresorbable vascular scaffolds (BVS)) have been developed which aim to 
limit the occurrence of intimal hyperplasia due to their degradable nature. The 
feasibility, safety and efficacy of BVS is still being evaluated following the first human 
15 
 
implants undertaken by a Japanese group in 2000 (Iqbal, Gunn, and Serruys 2013). 
The European Medical Agency (EMA) approved the use of BVS in 2011, initiating  the 
fourth evolution in interventional cardiology (Iqbal, Gunn, and Serruys 2013; Bowen et 
al. 2016). Unfortunately, the outcome of the first generation of BVS has not met 
expectations and evidence suggest that they may be associated with higher rate of 
adverse cardiovascular events compared to DES (Serruys et al. 2016; Ali et al. 2018). 
Hence, the manufacturer has taken the BVS out of the market voluntarily to improve 
their technology and they are working with the regulatory bodies, e.g. EMA and Food 
and Drug Administration (FDA) to address these issues (Henriques and Elias 2017).  
 
Until early 2000, CABG surgery was the gold standard route of revascularization for 
CAD patients. This remains the case for complex CAD cases with left main stem (LMS) 
disease, multi-vessel disease (MVD), and impaired LV function, as supported  by the 
landmark SYNTAX trial(Mohr et al. 2013; Serruys et al. 2009). Recent years have 
shown a shift to PCI procedures for patients with no LMS or MVD disease due to the 
cost effectiveness of PCI versus CABG even when long-term results of CABG remain 
superior (Habib et al. 2015; Locker et al. 2016; Ariyaratne et al. 2014; Raja et al. 2015).  
 
Unfortunately, all of the available treatments for CAD have limitations. The 
pharmacological treatments cause life–long dependencies to administered drugs and 
are not always effective for reducing symptoms. In addition, in-stent restenosis and 
thrombosis are common problems with PCI-stent. Transplantation related to CAD is 
only be considered for end-stage heart failure in CAD patients either suffering several 
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heart attacks leading to extensive myocardial scarring or afflicted by diffuse coronary 
disease not amenable to conventional PCI-stent or CABG. 
 
CABG is the most effective treatment in terms of relief of symptoms and long-term 
benefits (Ariyaratne et al. 2014; Habib et al. 2015; Locker et al. 2016; Raja et al. 2015). 
CABG consists of harvesting autologous arterial and/or venous conduits from the 
patient and using the conduit to construct grafts that bypass the blocked segment of 
the artery to improve/normalise blood supply. The most commonly used conduits for 
CABG are internal mammary artery (IMA) and saphenous vein (SV). Less often radial 
artery (RA) or other conduits were used. On average patients undergoing CABG 
surgery have three bypass grafts using autologous vessels, as mention earlier IMA 
from the chest and SV from the legs (Otsuka et al. 2013). The autologous SV is the 
most common conduit used for CABG surgery covering approximately 70-75% of all 
bypass grafts (Chlupac, Filova, and Bacakova 2009). The remaining 25-30% of all 




Figure 1.7 Coronary artery bypass graft (CABG). The procedure involves 
identifying the location of the blockage in the coronary artery and grafting a vascular 
conduit to bypass the blockage. The conduit is usually a portion of the saphenous vein 
of the leg (SV) or the internal mammary artery (IMA). The conduit  is grafted with the 
use of very fine sutures (Mann et al. 2015). 
 
Evidence suggests that an IMA graft to the left anterior descending (LAD) coronary 
artery is associated with improved life expectancy benefits and very high patency rates 
(92-95 %) at 15-20 years (Cosgrove et al. 1986; Loop et al. 1986). Confirmatory 
studies demonstrate improved 10-year survival rates associated with the use the IMA 
conduit as opposed to only SV grafts (Cosgrove et al. 1986; Loop et al. 1986). In 
keeping with these findings, another confirmatory study suggests that not using an 
IMA graft is associated with increased risk of late MI, recurrence of angina, and need 
for repeat revascularisation (Cosgrove et al. 1986; Loop et al. 1986).  Unfortunately 
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10-15% of SV grafts become occluded at 1-year after surgery due to early vein graft 
thrombosis and up to 50% are occluded at 10 years due to intimal hyperplasia and 
superimposed atherosclerosis (Figure 1.9)(de Vries and Quax 2018; de Vries et al. 
2016).  
    
Figure 1.8 Long-term failure of SVG. (A) Angiogram of an occluded SV graft (red 
arrow indicates the location of the occlusion) due to atherosclerosis (insert). (B & C) 
Further histological analysis of the failed SVG identifies the presence of intimal 
hyperplasia (IH), necrotic core (NC), foam cells (#) and neo-vessels (*). Adventitia 
layers, medial layers and lumen are indicated by A, M and L, respectively (de Vries et 
al. 2016).   
 
The development of vein graft failure is a major concern in vein grafting. SVGs are 
more prone to atherosclerosis than RA grafts, and IMA grafts display overall resistance 
to atherosclerosis (Pashneh-Tala, MacNeil, and Claeyssens 2015). The vein grafting 
procedures causes endothelial damage on the vein graft because of the differences 





procedures (de Vries et al. 2016; Harskamp et al. 2013). Within days after vein graft 
procedures, endothelial dysfunction results in platelets and leukocytes adhesion that 
releases a range of growth factors and cytokines which leads to the initiation of the 
coagulation cascade with fibrin deposition (de Vries et al. 2016). These factors in turn 
will lead the way to thrombus formation within the first month after CABG.  
 
When monocytes infiltrate in the vessel wall and differentiate into macrophages, this 
will cause SMC death and release of cytoplasmic contents and factors that causes the 
remaining of SMC to undergo phenotypic switch from contractile to synthetic 
phenotype (de Vries and Quax 2018). Synthetic SMC has higher proliferation and 
migration rate thus causes the development of neointimal hyperplasia within a month 
to a year after vein grafting. Further development intimal hyperplasia is due to the 
migration of adventitial fibroblast and SMC secreting ECM within vessel wall and 
increase thickening of the vessels wall and decreasing lumen size. Atherosclerosis 
occurs after more than 2 years after CABG (de Vries et al. 2016; Hess et al. 2014).    
 
Therapeutic approaches currently applied to combat vein-graft disease include the 
practise of “no-touch technique” and “endoscopic vein-graft harvesting” of SVG to help 
minimise trauma during harvesting and preserving endothelial layer of SVG (Parang 
and Arora 2009). Prescription of antiplatelet agents such as aspirin and clopidogrel 
and longer dual antiplatelet therapy post-operative were one other approach 
undertaken to hinder platelet adhesion on vessel wall that leads to the activation of 
various factors that marks the beginning of atherosclerosis as mention in figure 1.9 
(de Vries and Quax 2018; Becker et al. 2008; Mangano 2002). Glyceryl trinitrate and 
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verapamil solution which are vasolidator were also use to increase the vessel lumen 
thus improve the long term patency of vein graft (Roubos et al. 1995).  
 
Figure 1.9 Vein graft failure timeline. Sequential events that leads to vein graft 
failure started as early as a few hours after procedures with endothelial layer 
dysfunction that causes the recruitment and infiltration of platelets and leukocytes and 
would further enhanced acceleration of atherosclerosis formation (de Vries and Quax 
2018).  
 
The interdisciplinary collaboration between basic science and clinical research help in 
understanding the mechanism of vein graft failure and the translational application of 
any possible treatment in a clinical setting. One other hypothesis is that the 
development of atherosclerosis in grafts maybe due to the anatomic and physiological 
properties of the conduit (Table 1.1). Anatomically, IMA has a smaller diameter (IMA: 
1.9 – 2.6 mm and SV: 3.1 – 8.5 mm) and more compact wall thickness about 180 – 
430 µm than SV which varies from 180 – 650 µm (Barner 2013; Barner and Farkas 
2012). IMA has a thick endothelial layer with very few endothelial fenestrations which 
21 
 
are the contrary of SV. A well define internal elastic lamella (IEL) with high heparin 
sulphate content were also observed in IMA but not in SV (de Vries and Quax 2018). 
The SMCs in the medial layer are arranged circumferentially in between IEL of IMA 
but SMCs has a dual conformational alignment with longitudinally arranged inner layer 
and circumferentially aligned outer layer (Sur, Sugimoto, and Agrawal 2014). Unlike 
SV, IMA has minimal dependence on vasa vasorum and has no valves along the 
length of the vessel. In addition to that, SV has eight times more basic fibroblast growth 
factors (bFGF) receptors than IMA. In terms of the physiological properties of IMA and 
SV, their flow reserve, shear stress and production of vasodilators (e.g. nitric oxide 
and prostacyclin) are the same. The differences are in their contrary vasomotor 
response to thrombin, vasoconstrictor and vasodilator sensitivity. The lipid lysis, 
synthesis and uptake were also on the opposing spectrum which heighten the 
atherosclerosis progression in SV than IMA (Sur, Sugimoto, and Agrawal 2014; 




Table 1.1 Comparison of anatomic and physiological properties of IMA and SV 
(Motwani and Topol 1998; Otsuka et al. 2013). 
Properties IMA SV 
Anatomic properties 
Diameter 1.9 – 2.6 mm 3.1 – 8.5 mm 
Wall thickness 180 – 430 microns 180 – 650 microns 
Endothelial fenestrations Few Many 
Intercellular (IC) processes Many Few 
IC junction permeability Low High 
Internal elastic lamina (IEL) Well defined Poorly defined 
Heparan sulphate in IEL/media High Low 
Dependence on vasa vasorum Minimal High 
Valves Absent Present 
Size match with grafted native vessel Good Poor 
Resistance to trauma of harvesting High Low 
Physiological properties 
Flow reserve High Low 
Shear stress High Low 
Nitric oxide/prostacyclin production High Low 
Vasomotor response to thrombin Relaxation Constriction 
Vasoconstrictor sensitivity Low High 
Vasodilator sensitivity High Low 
Basic fibroblast growth factor 
receptors 
Few 
Many (8 times more 
than IMA) 
Lipolysis Rapid Slow 
Lipid synthesis Less active More active 
Lipid uptake Slow Rapid 
 
Arterial grafts are therefore considered desirable for CABG. Despite being the graft of 
choice, surgeons are still not inclined to practice bilateral IMA (BIMA) grafts. Evidence 
shows there are basically no differences in short-, mid- and long-term patency rates 
between single or bilateral IMA in CABG (Vallely, Edelman, and Wilson 2013), yet 
surgeons do not opt for BIMA. This may be due to the fact that total arterial grafting is 
more time consuming, technically more difficult, and at times may not be advisable 




In order to treat severe CAD, IMA are a better graft than SV but multiple IMA grafts 
are not preferred due to several clinical and surgical reasons and due to the lack of 
sufficient IMA for all the required grafts. The next best conduit is SV, but they do have 
lower graft patency affecting long-term outcome. The questions remain how can SV 
graft patency be improved and would arterialisation of veins in vitro before implantation 
be an alternative?     
 
 Peripheral Arterial Disease 
Three- to six-fold increase in the risk of CV death is associated with PAD (Davies et 
al. 2017). PAD covers various diseases that affect non-cardiac and non-intracranial 
arteries. The main cause of PAD is atherosclerosis. Atherosclerosis can cause a 
stroke when it occurs in neck and brain arteries, and can cause PAD when it is located 
in the arms, legs and aorta. PAD prevalence in the Western World population is 13% 
in those older than 50 years (Crawford et al. 2016). Based on a systemic review by 
Fowkes et al., it is estimated that the number of people living with PAD increased 
23.5% between 2000 to 2010. By the end of 2010 more than 202 million people are 
reported to be affected by PAD globally (Fowkes et al. 2013). The prevalence of PAD 
is therefore higher than that of HIV with 34 million people living with HIV, which is 
classified as a pandemic disease (Hirsch and Duval 2013). 
 
 Pathophysiology and Clinical Diagnosis of PAD  
PAD is usually asymptomatic with almost 65-75% of patients not realising they suffers 
from the disease (Morley et al. 2018; Abdulhannan, Russell, and Homer-
Vanniasinkam 2012). The classical presenting symptom is usually intermittent 
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claudication (IC) which occurs the same way as angina occurs but with pain in the leg 
with PAD, when insufficient blood supply to the leg occurs. The term claudication is 
derived from the Latin word claudicatio, meaning “to limp” (Mann et al. 2015). 
Claudication is a condition where pain is experience in the lower extremities during 
exercise which resolved when at rest. The differential diagnosis of claudication into 
arterial, neurogenic and venous claudication are based on its pathology, sites of pain 
laterality, pain onset, and presenting symptom. The pathology of arterial claudication 
is described as stenosis of major lower limb arteries where muscle is identified as the 
site of pain usually the calf muscle but may affect thigh and buttock. Gradual onset 
after walking certain distance and symptom disappear after 1 to 2 minutes cessation 
of walking (Abdulhannan, Russell, and Homer-Vanniasinkam 2012; Davies et al. 2017; 
Hankey, Norman, and Eikelboom 2006; Walker et al. 2015).        
 
In diagnosing PAD, the patient’s medical history is screened for risk factors and family 
history, and physical examination of the leg and ankle brachial index (ABI) are 
performed. ABI was developed and proposed as a definitive test for PAD in the early 
1950s as a mean to distinct claudication from other leg pain such as spinal stenosis 
which has similar symptoms to claudication during exercise. ABI is a simple 
measurement of the ratio of systolic blood pressure at the ankle to that of the arm at 
rest and after exercise. A low ABI reading is suggestive of atherosclerosis of the lower 
extremities. A definitive cut off point for presence of PAD is generally accepted as an 
ABI <0.9. For patients with ABI <0.9, their extremities risk is assessed and classified 
into claudication or critical limb ischemia (CLI) based on their anatomical and 




Figure 1.10 Diagnosis and management of PAD patients. The scheme illustrates 
patients that are at risk of PAD (A), patients with symptoms of PAD (B), patients 
diagnosed with PAD (C). AAA: Abdominal aortic aneurysm; CHF: Congestive heart 
failure; CTA: Computed tomographic angiography; MRA: Magnetic resonance 




 Currently Applied Treatments and Prevention of PAD Progression 
The currently applied treatments for PAD patients are aimed to reduce the risk of 
stroke and death, protection of the feet and legs to reduce the risk of ulceration and 
amputation, and to improve quality of life. The approaches utilised for treating patients 
with PAD are similar to CAD, where patients are first being managed through medical 
therapies (lifestyle changes and prescription drugs), followed with catheter based 
revascularisation (balloon angioplasty or stent deployment), and surgical based 
approach (reconstructive surgery via graft placement).  
 
Medical therapies of PAD include management of risk factors such as smoking, 
dyslipidaemia, diabetes mellitus, hypertension, with lifestyle modifications and drug 
therapies. The two most relevant lifestyle changes in dealing with PAD are exercising 
regularly and cessation of smoking. PAD symptoms could be reduced and reversed 
by exercising regularly as recommended by  National Institute for Health and Care 
Excellence (NICE) (Morley et al. 2018). Smoking had been proven to increase the risk 
of CVD and worsen PAD development, therefore cessation of smoking or nicotine 
replacement are recommended therapies for PAD patients (Lu and Creager 2004; Lu, 
Mackay, and Pell 2014; Sotoda et al. 2015). The American College of 
Cardiology/American Heart Association (ACC/AHA) recommendations for patients 
with PAD include a set of goals to manage risk factors such as: (a) for dyslipidaemia 
management a serum low-density lipoprotein (LDL) cholesterol goal reduced to 70 
mg/dL with the prescription of statins; (b) blood pressure target at <140/90 mmHg for 
non-diabetic patients and <140/90 mmHg for diabetic patients with the help of 
antihypertensive agents including beta blockers; (c) standard target of Haemoglobin 
A1c <7% in managing diabetic patients (Rooke et al. 2013; Hankey, Norman, and 
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Eikelboom 2006; Abdulhannan, Russell, and Homer-Vanniasinkam 2012). Antiplatelet 
(e.g. aspirin and clopidogrel) therapy is another medical management prior to 
endovascular and surgical approach with the consideration of anticoagulant (e.g. 
warfarin) for patients diagnosed with CLI.   
 
Endovascular treatment of PAD is a catheter-based revascularisation via balloon 
angioplasty or stent deployment similar to the treatment for CAD as mention in section 
1.2.2.  The choice of stents is similar to those use in CAD treatment. When medical 
and endovascular approaches are inadequate or fail, open surgical revascularisation 
is utilised. When PAD affects a large surface area of the lower extremities the graft 
length required may be extensive (Figure 1.10). Unfortunately for PAD, IMA conduits 
are not suitable and the only available conduits are SVG or synthetic grafts. Therefore, 
fostering research on synthetic and alternative graft for the treatment of PAD, which 
results in the use of synthetic grafts such as Dacron and polytetrafluoroethylene 
(PTFE). Regrettably, patients with PAD are confronted with the fact that SVG and 





Figure 1.11 Treatment of PAD. (A) Endovascular approach via balloon angioplasty 
or stenting. (B) Surgical approach to bypass the blocked artery using either vein or 
synthetic graft (Creager, Beckman, and Loscalzo 2012).  
 
Given the huge need to treat patients affected by severe CAD and/or PAD effectively, 
improving the outcome of bypass grafts using SVG (CAD) and synthetic grafts (PAD) 
is desirable. This has prompted the scientific community over the last decade to adopt 
a combination of tissue engineering and regenerative medicine technologies to 
investigate the feasibility of the production of conduits in vitro with arterial features that 
are suitable to treat CAD and PAD diseases.  
 
 Tissue Engineering and Regenerative Medicine 
The term “Tissue Engineering” was coined in 1983 and was officially presented and 
defined at the Granlibakken conference in 1987 (Skalak and Fox 1988). The 
‘Principles of Tissue Engineering and Methods of Tissue Engineering’ published in 




primary references for researchers embarking in this field. However, research which 
we now call tissue engineering (TE) can be tracked back to the 1970s. Even though 
this field is still in its infancy, the success stories are numerous and include clinical 
trials at various phases. Some tissues have been successfully engineered including 
skin, bone, cornea, cartilage and nerves (Levine 2007; Kay 2007; Hodges and Atala 
2007; Setton, Bonassar, and Masuda 2007; Sambanis 2007; Smith and Sharpe 2007; 
Mansbridge 2007).  
 
Tissue engineering is an ever-expanding field, and this is shown by the increase of 
related published articles in PubMed from just less than a thousand articles in 1990 to 
more than 70 000 articles to date. Tissue engineering is an alternative approach to 
drug therapy, gene therapy and whole organ transplantation. It attempts to replace 
cells that are missing within an otherwise functional tissue or organ, and hence it is 
considered part of regenerative medicine. The basic principle of tissue engineering 
involves three main components; biomaterials, cells and regulatory signals. This is 





Figure 1.12 The tissue engineering triad. The triad consists of (a) biomaterials; to 
which the cells attach and migrate into and it provides supports for cell growth, (b) 
cells are the source of matrix remodelling and (c) regulatory signals that induce cell 
differentiation and tissue formation (Murphy et al. 2013). 
 
The most successful results in tissue engineering are perhaps related to skin. There 
are several “off-the-shelf” products available of engineered skin since the first FDA 
approved TransCyte in 1997, such as EpiDex, Dermagraft, Integra, Epicel, Alloderm 
and Xenoderm (Bello, Falabella, and Eaglstein 2001; Pape and Byrne 2000; Ortega-
Zilic et al. 2010; Hafner, Kuhne, and Trueb 2006). In addition, promising results have 
been achieved in the areas of  cartilage and bone tissue for example with the 
introduction of Carticel for replacement of damaged cartilage and Osteogenic Protein 
1 (OP-1) Implant, for severe case of recalcitrant long bone non-unions (Ratcliffe 2011; 




Theoretically any tissue could be engineered. However, every single component and 
the combinations need to be critically selected, analysed and the combination 
optimized. Skin, cartilage and bone have been successfully engineered from extensive 
research in each field and through interdisciplinary collaboration; medical, engineering 
and science researchers work together to produce a feasible product for patients. The 
tissue engineering concept has only been successful due to the interdisciplinary 
collaboration.   
 
 Tissue Engineered Vascular Grafts (TEVG) 
The relationships between the components of the triad and the dynamics involved in 
combining them are studied independently or collectively by interdisciplinary groups. 
Pasneh-Tala and colleagues wrote a very comprehensive review on the tissue 
engineered vascular graft that covers the 3 TE triads; the past, present and future of 
TEVG in CABG (Pashneh-Tala, MacNeil, and Claeyssens 2015).       
  
 Biomaterial 
The selection and construction of the biomaterial is a whole new field of research that 
stems from the tissue engineering field. The progression of the field has led to the term 
‘biomaterial’ to be redefined from ‘a nonviable material used in a medical device, 
intended to interact with biological systems’; to ‘material intended to interface with 
biological systems to evaluate, treat, augment or replace any tissue, organ or function 
of the body’. There are a variety of factors to consider in producing a TEVG. Key 
factors to consider in designing a TEVG include biodegradability, mechanical 
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properties, scaffold architecture, manufacturing technology and biocompatibility  
(O'Brien 2011).  
 
Early TEVG were designed using polymers such as polyethylene terephthalate (PET) 
(e.g. Terylene or Dacron) or PTFE (e.g. Teflon or Gore-Tex) (Chlupac, Filova, and 
Bacakova 2009). PTFE and Dacron were shown to be effective, although mostly at 
early and mid-term stage, feasible for large diameter (>5 mm) vessels such as those 
use for grafting of the aortic bifurcation, aorto-femoral, femoro-femoral and axillo-
femoral (Chlupac, Filova, and Bacakova 2009; Peck et al. 2012). For example, this 
type of  results were obtained in patients with ischemic limbs where grafting of naked 
PTFE grafts were performed in 822 patients with a mean age of 70 years and with 
equal gender distribution (Sauvage et al. 1986; Veith, Ascer, and Gupta 1986). 
Unfortunately, when used for some smaller diameter vessels (<5 mm), the mid- and 
long-term patency of these grafts was poor due to thrombogenicity and compliance 
mismatch (E. Niklason and S. Langer 1997; Edelman 1999; Desai, Seifalian, and 
Hamilton 2011).  
 
Advances in synthetic TEVG design have led to the use of biodegradable scaffolds 
that support cell adhesion, cell repopulation on grafts, deposition of natural ECM 
proteins secreted from the recruited cells and thus create a naturally assembled TEVG 
by the host (Huang and Niklason 2014). These types of TEVGs are foreseen as the 
precursors of bioengineered vascular grafts that may be able to modulate the 
recipient’s body to heal themselves. Polymers that could be degraded into harmless 
components and could be metabolised and eliminated by the host body such as 
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polyglycolic acid (PGA), were primarily used. Indeed, PGA could be absorbed and 
eliminated as water and carbon dioxide within 6 months in vivo; but it loses its 
mechanical strength within 4 weeks (Ravi and Chaikof 2010), with potential risk of graft 
rupture. Hence, to improve graft strength, safety and patency, biodegradation of PGA 
could be controlled/engineered via co-polymerization with other polymers. Poly-L-
lactic acid (PLLA), polyhydroxyalkanoate (PHA), poly(lactic acid)/polycaprolactone 
(PLA/PCL)  and polyethylene glycol (PEG) are such copolymerization products that 
are widely used to design more effective TEVGs (Ravi and Chaikof 2010). However, 
methodological refinement is required to achieve optimised manufacturing methods of 
TEVGs that could fulfil the rigid requirement of a good TEVG for human use.  
 
Alternatively, a number of naturally derived scaffolds have been considered for 
designing effective TEVGs. Fibrin, chitosan, collagen and elastin have been used as 
the bases of biological scaffolds (Niklason et al. 1999; Zhang et al. 2006; Swartz, 
Russell, and Andreadis 2005). Tranquillo et al. and Andread et al. attempted using 
fibrin gel encapsulated with dermal fibroblasts, SMCs, ECs or ECs and SMCs 
progenitor cells, and subsequently implanted these in an ovine model (Huynh and 
Tranquillo 2010; Swartz, Russell, and Andreadis 2005). The purpose of cell 
encapsulation was to improve the mechanical properties of the natural scaffold to 
match those of native blood vessels. An additional advantage of this approach is that 
SMCs are the main contributors in synthesising the ECM in blood vessels.  
Self-assembly has also been investigated as an alternative mode of producing TEVG. 
This is achieved in the form of sheet-based tissue engineering and more recently 
investigators have utilised cell printing (Huang and Niklason 2014). L’Heureux and 
colleagues were the first to design a TEVG via layers of cells sheets that were then 
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shaped into a tube using a mandrel (Peck et al. 2012; L'Heureux et al. 1993). 
Unfortunately, the entire process of producing a TEVG took up to 3 months, since 4 
weeks are needed to produce the cell sheets and an additional 8 weeks required for 
the cells to be fused to the sheets (L'Heureux et al. 2001).   
 
Therefore, the scientific community turned to the use of decellularised natural blood 
vessels; such as the SV, as a way to shorten the TEVG’s manufacturing steps and 
duration. This is an excellent option providing a readily available naturally aligned 
vascular ECM, supplying a scaffold with good mechanical properties. This ECM can 
then be used in a variety of ways, for example to anchor seeded cells and organise 
them into tissues, coordinate cellular functions, allow cell migration, permit normal 
metabolism function and act as the base for signal transduction pathways for growth, 
differentiation, proliferation and gene expression. This option may require less lab-
based processing, hence have greater translational potential. To this end, a selection 
of suitable blood vessels is available, with the source/donor being either autologous, 
or allogeneic or even xenogeneic. Rationally, an autologous source is more preferable 
to omit or lower translational application hurdles e.g. ethical approval process and 
immunological responses.          
 
Of interest, whatever the biomaterial used, their mechanical properties such as burst 
pressure, suture retention strength and compliance are important aspect in designing 
a translatable TEVG. The target mechanical properties to emulate are either the artery 
to be replaced, or the graft with best patency, such as IMA or the more widely used 
SVG. For reference, the mechanical properties of IMA and SVG are as shown in Table 
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1.2. Burst strength is a measure of the graft’s ability to withstand internal pressure 
which would be crucial in determining the patency of the graft in vivo. Whereas, the 
circumferential compliance is the ability of a graft to elastically expand and contract in 
the circumferential direction in response to a pulsatile pressure. IMA could withstand 
higher burst strength (3073 versus 2134 mmHg) but has a low suture retention 
strength (1.72 versus 1.92 N) and low compliance at 11.5 than 25.6 %/100 mmHg than 
SV (Pashneh-Tala, MacNeil, and Claeyssens 2015).  
 
Table 1.2 Mechanical properties of IMA and SV used in CABG (Pashneh-Tala, 
MacNeil, and Claeyssens 2015).  
Mechanical Properties IMA SV 
Burst pressure (mmHg) 3073 2134 
Suture retention strength (N) 1.72 1.92 
Compliance (%/100 mmHg) 11.5 25.6 
 
For synthetic TEVGs, while some mechanical parameters e.g. burst pressure could 
exceed those of IMA and SV, other parameters such as suture retention strength are 
reduced compared to IMA and SV (Johnson 2015). Interestingly, other synthetic 
material such as PCL and PTFE have high suture retention strength, but the burst 
pressure is not comparable to IMAs (Soletti et al. 2010; Nezarati et al. 2015).  
 
Tranquillo et al. report that after seeding fibrin-based TEVGs in vitro, they 
decellularised the TEVG. The decellularised construct exhibited burst pressures 
above those of native vessels (5160 ± 680 mmHg before decellularisation and 4200 ± 
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180 mmHg after decellularisation). However,  the suture retention strength was 
reduced compared to native vessels (see Table 1.2) with 0.58 ± 0.04 N and 0.60 ± 
0.05 N before and after decellularisation, respectively (Syedain et al. 2014). Similar 
results were observed with synthetic TEVG as reported by Kim et al. where the suture 
retention strength of 1.5mm thick Poly (L-lactide-co-ε-caprolactone) (PLCL) scaffold  
was 10.28±1.69 N and ePTFE grafts with 9.02±0.45 N, which is way above the IMA 
and SV values but the compliance was 2.0±0.3 %/100 mmHg for 1.5 mm and 2.1±0.3 
%/100 mmHg for ePTFE, which is below the native IMA and SV values (see Table 
1.2)(Kim et al. 2013).  
 
To date, there are no reports of TEVGs that possess all of the mechanical properties 
that closely resembling those of the IMA graft (Pashneh-Tala, MacNeil, and 
Claeyssens 2015) or other native arteries. It is also obvious that while the 
manufacturing of TEVGs from synthetic materials is favourable in terms of overall cost 
needed and availability of the material, the patency rates and long-term results of 
these grafts are not encouraging in terms of translation to bed-side with suboptimal 




The second component of the tissue engineering triad is the cells. To create a 
functional TEVG, incorporation of ECs and SMCs is considered desirable, since the 
cells are key constituents that regulate the homeostasis of blood vessels. Therefore, 
most attempts to produce TEVG include seeding of cells onto the biomaterial. The key 
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cell types within blood vessels are EC, vascular SMC and fibroblasts. These cells are 
organized in three layers within the vascular wall; the inner layer (tunica intima) 
composed mainly of EC, the middle layer (tunica media) composed mainly of SMCs 
and the outer layer (tunica externa/adventitia) is composed mostly of fibroblasts, as 
well as nerves and inflammatory cells (Figure 1.12). One of the differences between 
an artery and vein is the presence of prominent IEL and EEL in artery and not vein.  
 
 
Figure 1.13 Structure of Blood Vessels. A micrograph showing the relative 
differences in wall thickness and schematic representation of the structure of an artery 
and a vein. They share the same general features, but the artery walls are generally 
thicker (Marieb and Hoehn 2015). 
 
Interestingly, the cells in arteries and in veins are found to be genetically pre-
determined even before the heart starts to beat (Castillo and Alvarez 2011). Apart from 
the local hemodynamic cues and cell localization, the predetermined cell fate could 
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also be contributing to the lower patency of venous grafts compared to arterial grafts. 
One such predetermining characteristic may be the proliferation of each cell type. SMC 
from veins for example are reported to have a higher proliferation rate than those from 
arteries (Turner et al. 2007; Waybill and Hopkins 1999; Waybill, Chinchilli, and 
Ballermann 1997; Kim et al. 2004; Wong, Nili, and Strauss 2005).  
 
1.5.2.1 Endothelial Cells 
ECs form a single layer of cells covering the lumen of vascular system hence 
representing the interface with circulating blood. ECs are the precursors in providing 
structural integrity of the blood vessel as they have the ability to produce elastin and 
form a selectively impermeable surface and thrombo-resistant wall. ECs also play a 
role in controlling blood flow and vessel tone via mechano-receptors that sense shear 
stress as a result of blood flow and facilitate the vasodilatation of blood vessels through 
signalling to surrounding cells to manage a flow change (Wagenseil and Mecham 
2009; Nemeno-Guanzon et al. 2012). The ECs play a role in suppressing platelet 
activation, adhesion, and aggregation, leukocyte adhesion and SMC migration, 
proliferation (Lassance et al. 2012).  
 
During embryogenesis, the fate of endothelial phenotype either arterial or venous; is 
determined even before circulation begins. Both types of ECs possess vascular 
endothelial growth factor receptor 2 (VEGFR2). During embryogenesis, the floor plate 
of the neural tube (NT) and notochord (Nc) work together and express sonic hedgehog 
(Shh) which in turn induce somites to increase the expression of vascular endothelial 
growth factor (VEGF). For arterial ECs, VEGF initiates a downstream activation of 
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Notch and ERK pathways thus leading to the expression of ephrinB2. Whereas in 
venous-fated ECs, the Notch and ERK activation is blocked by COUP-TFII, 
consequently leading to the expression of EphB4 (Lamont and Childs 2006; dela Paz 
and D'Amore 2009) (Figure 1.13).    
 
 
Figure 1.14 Model of EC specification between arterial and venous. The proposed 
cascade activation of genetic expression between arterial- and venous-fated 
endothelial cells based on a mouse and zebrafish experimental data (Lamont and 
Childs 2006).  
 
Aside from the EC phenotypic specialisation in early embryonic development, another 
type of EC develops, called hemogenic EC, through a process named endothelial-to-
hematopoetic cell transition (EHT) (Kanz et al. 2016; Chi et al. 2003; Adamo and 
Garcia-Cardena 2012). The idea that hematopoetic stem cells originate from the EC 
has been hypothesised since the last century but was just recently described through 
EHT. This cell transition is of great importance as it shows the transdifferentiation of 
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mature ECs to become hematopoetic stem cells that could potentially be a source of 
autologous cells for biomaterial cell repopulation in tissue engineering application.   
 
The different gene expression of both mature arterial and venous EC has been 
reported. Arterial EC specific gene expression of connexin 40, delta-like 4, EphrinB2 
and notch relate back to the embryonic development of EC as mention above. The 
same with venous EC with the expression of EphB4 and CoupTFII (dela Paz and 
D'Amore 2009). The differentiation of human mesenchymal stem cell (hMSC) to EC 
was done previously but the resulting EC-like cells express both Flk1, an arterial 
specific markers and Tie-2 which is a venous specific marker (Gang et al. 2006). VEGF 
and the Notch pathway was found to be a crucial determinant in the mechanism behind 
the phenotypic expression of these marker (Liu et al. 2003; Zhang et al. 2008). The 
promotion of stem cell differentiation through the manipulation of VEGF where higher 
VEGF in culture increase the expression of arterial EC markers e.g delta-like 4 and 
EphrinB2 and this arterialisation of EC could be reversed by inhibiting the Notch 
pathway (Aranguren et al. 2007; Zhang et al. 2008; Lanner, Sohl, and Farnebo 2007). 
 
The genetic make-up of arterial and venous endothelial cells is recognised and the 
different physiological environment both phenotype was exposed too are apparent and 
contribute to the main function aside from their genetic make-up. The epigenetic 
factors involved in endothelial cell specification especially the influence of oxygen and 
hemodynamic flow in pushing specific cell type are not fully understood. Nonetheless, 
with low oxygen level, hypoxia induce factor (HIF) is activated thus producing more 
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VEGF that would leads to more arterialise EC specification (Silvestre and Mallat 2006; 
Yurugi-Kobayashi et al. 2006; Hirashima and Suda 2006).    
 
1.5.2.2 Smooth Muscle Cells  
The major function of SMCs is to synthesise and organise the ECM that provides the 
mechanical properties of the blood vessel (Wagenseil and Mecham 2009) as well as 
facilitating the contraction of the wall and thereby the progression of blood flow. During 
embryonic development, SMCs stem from the epicardial derived cells (EPDC) that 
undergo epithelial to mesenchymal transition (EMT) (Mikawa and Gourdie 1996; 
Kovacic et al. 2012). SMCs can take on one of three phenotypes in blood vessels that 
are termed “contractile or differentiated”, “synthetic or dedifferentiated” or 
“inflammatory” phenotype (Creager, Beckman, and Loscalzo 2012). These 
phenotypes are based on the SMC functions and cell marker expression (Shanahan, 
Weissberg, and Metcalfe 1993).  
 
The contractile phenotype is the main one observed under normal physiological 
conditions. In culture, the contractile SMC has an elongated, spindle-shape 
morphology that express contractile protein expression e.g. smooth muscle myosin 
heavy chain (SM MHC) and smoothelin and express higher collagen I and IV (Rensen, 
Doevendans, and van Eys 2007). Contractile SMCs was found to have a low matrix-
metalloproteinases (MMPs) which are responsible to breakdown matrix component 
such as collagen IV and laminin (LN) thus, higher tissue inhibitor of matrix 




Under pathological conditions that cause disturbance of flow in the vessel, the change 
of phenotype from contractile to synthetic is observed (Majesky et al. 2011). Synthetic 
SMC has the “hills and valley’ in vitro culture morphology and they are found to be 
more proliferative, migratory, high MMPs and low TIMPs expression compared to their 
contractile counterpart (Beamish et al. 2010; Worth et al. 2001). These phenotypic 
expression was observed to be among the factors that causes hSV graft failure 
(Beamish et al. 2010; Kim et al. 2004; Orr et al. 2010). SMCs cultured in vitro in an 
extended period are synthetic in phenotype as opposed to contractile due to the 
absence of normal physiological signals to maintain the contractile phenotype 
(Proudfoot and Shanahan 2012; Thyberg 1996). The intermediate SMCs are called 
the inflammatory SMC (Hilenski and Griendling 2013) where the cells become motile 
and move towards the lumen causing a cascade of signalling pathway activation that 
can lead to intimal thickening and atherosclerosis (Yang et al. 1998; Orr et al. 2010).  
 
There are factors that modulate the phenotypic expression of cells aside from genetic 
pre-programme cues. Factors such as environmental chemical, structural and 
mechanical signals that could be grouped as the regulatory signals (Figure 1.15). 
Therefore, it is important to use for arterial tissue engineering cells of arterial origin 
such as ECs and SMCs, especially to arterialise SV conduit ECM in a physiological 







Figure 1.15 VSMC phenotypes. The three main VSMC phenotype with some of their 
characteristic and the regulatory signals involved; Col: collagen; ECM: extracellular 
matrix; FN: fibronectin; LN: laminin; MMPs: matrix metalloproteinases; TIMPs: tissue 
inhibitors of MMPs (Hilenski and Griendling 2013). 
 
 Regulatory Signals 
The regulatory signals in tissue engineering include growth factors, chemical 
compounds and mechanical stimuli. Cell function is regulated by a combination of 
factors that include cell-cell interactions, ECM components, humoral factors, local 




1.5.3.1 Humoral factors 
Humoral factors include soluble and non-soluble factors in the circulation that affect 
the cell growth and differentiation. Growth inducing factors such as platelet-derived 
growth factors (PDGF), basic fibroblast growth factors (bFGF), epidermal growth 
factors (EGF) and insulin growth factors (IGF) activate signalling pathways when they 
bind to the receptor tyrosine kinases (RTKs) on the cell membrane surface(Yang et al. 
1998). Other factors such as angiotensin II (AngII)(Touyz and Berry 2002; Griendling 
et al. 1997), cytokine transforming growth factor β (TGF-β)(Tsai et al. 2009; 
Suwanabol et al. 2012; Guo and Chen 2012) and members of the bone morphogenetic 
protein (BMP) family (Zhang et al. 2014; Willette et al. 1999; Perez et al. 2011) utilise 
another cascade of signalling pathways that promote the expression of genes to 
regulate the cell phenotype, in addition to cell growth, migration and apoptosis. These 
factors are applied in vitro and in vivo through their incorporation in the culturing media 
or intravenous (IV) delivery, respectively. Subsequently, the cells and tissue response 
has been studied to assist with understanding the importance of each factor in creating 
a TEVG, and how to manipulate them to get a suitable outcome (Fasciano et al. 2005; 
Libby and O'Brien 1983; Karakiulakis, Papakonstantinou, and Roth 2001; Thyberg 
1996).  
 
As shown in Figure 1.14, VSMCs phenotypic modulation is influenced by cell-cell and 
cell-matrix interactions. In the vascular bed, a balanced EC and SMC interaction are 
required to maintain their functions especially in response to injury or disease. 
Vascular endothelial cadherin (VE-Cad) for example is an important adhesion 
molecule of the EC adherent junction that plays a crucial role in preserving the 
endothelial barrier integrity (Corada et al. 1999; Flemming et al. 2015). By which the 
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lack-of or disturbance of VE-Cad leads to increase permeability of the endothelial 
barrier thus allowing invasion of immunocompetent and inflammatory cells e.g. 
macrophages, dendritic cells, T-cells etc. (Bobryshev et al. 1999).  Therefore, by 
understanding the molecular modulation and processes involved in cell-cell 
interaction, a potential pharmacological therapy could be formulated to control the 
permeability of the endothelial layer and thus slowing down disease progression 
(George and Dwivedi 2004).   
 
The vascular ECM is composed of a large number of matrix proteins (Figure 1.16) 
including; elastin, collagens, fibronectins, laminin and proteoglycans (Wagenseil and 
Mecham 2009; Bowers, Banerjee, and Baudino 2010). Various ECM components 
depicted in figure 1.16 has its own role in vascular regulation and maintenance. The 
two major matrix proteins that are essential in maintaining vascular mechanical 
properties are elastin and collagen. Elastin imparts the elasticity properties of the 
vessel while collagen is mainly responsible for imparting strength to the vessel wall. 
Hence, both elastin and collagen influence the vessel burst strength, suture retention 
strength and compliance. The ECM serves a variety of functions including maintaining 
the tube structure, regulating blood flow, providing a structure for attachment of cells 
and triggering certain signalling pathways that maintain the contractile phenotype of 
SMC and suppress proliferation and migration (Opitz et al. 2004).  
 
Elastin was found to maintain the quiescent state of contractile VSMCs in normal 
physiological vasculature but when disrupted leads to phenotypic changes of VSMCs 
to the contractile phenotype that is proliferative and invasive (Shanahan, Weissberg, 
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and Metcalfe 1993), henceforth becoming the precursors of intimal thickening and 
atherosclerosis. The differences in glycosaminoglycan species in arterial and venous 
wall become one of the compounding factors that leads to lower hSV graft patency. 
Both arterial and venous vessel wall has the same amount of dermatan sulfate but 
arteries has significantly higher heparan sulfate than veins. GAGs species influence 
the LDL uptake in the vessel wall especially in injury site where the deposition of lipid 
will lead to the initiation of atherosclerosis formation (Leta, Mourão, and Tovar 2002; 







Figure 1.16 Composition of the ECM within the arterial wall. The vessel wall has 
a three-layered architecture: the tunica intima (TI), tunica media (TM) and tunica 
adventitia (TA). The arterial wall is composed of cells (endothelial cells (EC), smooth 
muscle cells (SMC) and adventitial fibroblasts (AFs)) and ECM (BM: basement 
membrane; IEL: internal elastic lamina;  EEL: external elastic lamina; HSPG-2: 




1.5.3.2 Mechanical factors 
Various studies have been undertaken to understand the mechanics of blood flow and 
its implication on the cells and composition of the vasculature (Anwar et al. 2012; 
Muller-Marschhausen, Waschke, and Drenckhahn 2008; Li, Haga, and Chien 2005; 
Wang et al. 2001; Ives, Eskin, and McIntire 1986). Due to the viscosity of blood 
composed of both semisolid and liquid materials e.g. cells, proteins, lipoproteins and 
ions, the fluidity of blood does not always conform to the Newton’s law of viscosity 
(Zaman et al. 2015). Therefore, understanding the mechanics of blood flow, especially 
in arterial circulation where the blood flows in a pulsatile fashion could not be explained 
with Poiseuille equations that need a laminar flow of a Newtonian fluid in a long 
cylindrical tubing with constant cross-section (Glagov et al. 1988).  
 
Generally, the vascular system is exposed to two haemodynamic forces; cyclic strain 
or stress (including hydrostatic pressure) and shear stress. Cyclic strain take place 
when the vessel wall is distended by transmural pressure whilst shear stress is 
generated by the frictional forces of the blood flow (Birukov 2009). EC are exposed to 
both forces (shear and cyclic stress) whereas only cyclic strain influence SMCs as 
they are not in contact directly with the blood flow (Figure 1.16). Shear stress differs 
for both artery and vein based on their flow velocity differences; 10 – 40 dynes/cm2 
and 1 – 5 dynes /cm2, respectively (dela Paz and D'Amore 2009). Under physiological 
condition, the cyclic strain is around 5-10%, whereas >20% is considered as the 







Figure 1.17 Hemodynamic forces in vasculature. Cyclic strain and shear stress 
acts on both ECs and SMCs thus influence the genetic and phenotypic regulation 
during physiological and pathological condition (Anwar et al. 2012).      
 
Blood vessels are constantly exposed to blood flow; its mechanical forces and shear 
stress and these factors differ between arteries and veins. Therefore, when designing 
a TEVG, blood flow and shear stress are important mechanical factors to consider. 
Previous studies have investigated the role of mechanical stimuli in creating or 
maintaining an engineered tissue. Sun et al. observed higher proliferation rates of ECs 
and SMCs co-cultured on a PTFE conduit under 100 mmHg hydrostatic pressure for 
7 days as compared to when exposed to zero pressure. Collagen deposition was also 
increased by exposure to the higher pressure (Sun et al. 2005). Kanda et al. found 
that SMC phenotype could be influenced by different types of stretch stress imparted 
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on the cell (Kanda, Matsuda, and Oka 1993). SMCs cultured under static conditions 
exhibited markers of the synthetic phenotype whereas under dynamic stress where 
they were periodically stretched and recoiled with 10% amplitude of relaxed scaffold 
length at 60 rpm frequency, more contractile markers were observed (Kanda, 
Matsuda, and Oka 1993). 
 
For that reason, pre-conditioning the mechanical environment of the SV, which is a 
commonly used graft, would hopefully increase the graft patency. In summary, it is 
clearly apparent that the combination of all components of TE triads are of importance 





 Thesis Rationale 
 Hypothesis 
It was hypothesised that saphenous veins could be effectively decellularised to obtain 
an acellular matrix/scaffold to be used for in vitro and/or in situ tissue engineering and 
ultimately an arterial-like graft with improved long-term patency rates compared to 
autologous vein or synthetic conduits.    
 Project objectives 
1.6.2.1 Overall Aims  
1. Establish a reproducible protocol for effectively decellularization of human veins 
to create a human biological vascular scaffold. 
2. Determine whether the decellularised human vein is mechanically suitable for 
arterial tissue engineering. 
3. Investigate the biocompatibility of the decellularised human vein using cultured 
cells and peripheral whole blood (PWB). 
4. Examine the behaviour of the decellularised human vein after implantation as 
a xenograft in a porcine model. 
1.6.2.2 Specific Objectives 
1. Validate an effective and reproducible decellularisation protocol for segments 
of human saphenous veins which yields an acellular human vascular 
extracellular matrix (ECM) for use as a scaffold.  
2. Examine the effect of the decellularisation protocol on tissue integrity in terms 
of major ECM protein content (collagen, elastin and glycosaminoglycan. 
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3. Test the biocompatibility of decellularised saphenous veins using different cell 
types. Firstly, isolate, expand and characterise endothelial cells (ECs) and 
smooth muscle cells (SMCs) derived from porcine Carotid Artery (pCAs). 
Secondly, test the viability and proliferation of pECs and pSMCs from pCA on 
decellularised human saphenous vein scaffold in vitro. Finally, test the 
feasibility of porcine peripheral whole blood cell population to adhere, grow and 
differentiate on decellularised saphenous veins in vitro. 
4. Assess re-cellularisation and patency of decellularised human saphenous veins 
when implanted as a xenograft in a porcine carotid artery interposition graft 




2 MATERIALS, METHODS AND METHODOLOGY 
 Sample Collection and Processing 
 Human 
Segments of surplus hIMA and hSV were collected from patients undergoing coronary 
artery bypass grafting (CABG) on completion of the procedure at the Bristol Heart 
Institute, Bristol, UK. The tissue was obtained in accordance with ethical standards of 
the local committee (REC. reference number: 10/H0107/63). The tissue segments 
were placed into a 50 mL Falcon tube containing sterile Dulbecco’s modified 
Eagle's medium (DMEM) (D6421; Sigma); 200 µg/mL of Penicillin-Streptomycin 
(P4333-100ML, Sigma); 2 mM of GlutaMAX™-I Supplement (G7513-100ML, Sigma) 
and were transported to the laboratory for processing. 
 
 Pig 
Segments of porcine carotid arteries (pCA) were collected from animals undergoing a 
termination procedure at the completion of other unrelated in vivo studies at the 
Translational Biomedical Research Centre, Bristol, UK. The tissue was obtained in 
accordance Home Office ethical standards (PPL number: 3002 854). The tissue 
segments were placed into a 50 mL Falcon tube containing sterile Dulbecco's modified 
Eagle's medium (DMEM) (D6421; Sigma) supplemented with; 200 µg/mL of Penicillin-
Streptomycin (P4333-100ML, Sigma); 2 mM of GlutaMAX™-I Supplement (G7513-




 Human Saphenous Vein (hSV) - Decellularisation Protocol 
 Decellularisation Protocol Optimisation 
Initially small segments of veins were used to determine the minimum concentration 
of SDS needed to achieve a successfully decellularised vein while preserving the 
integrity of the hSV extracellular matrix (ECM). Decellularisation was performed using 
a method previously described by Schaner et al.(Schaner et al. 2004) with a few 
modifications. Briefly, h-SV segments were obtained from the cannulated end of the 
h-SV. The vein was released from the cannula by cutting the silk suture to optimize 
the available vein length (approximately 5 cm). The vein segments were cut to 
approximately 1 cm in length using a scalpel then incubated in different concentrations 
(0.01; 0.025; 0.05; 0.075 and 0.1% (w/v)) of Sodium Dodecyl Sulphate (SDS) 
(S/5200/53; Fisher) in a 5 mL bijou tubes on a tube roller at 60 rpm (Stuart, UK) for 24 
hours at room temperature. To wash the vein segments, they were transferred to a 
new bijou tube containing sterile Phosphate Buffer Saline (PBS: P4417-100TAB; 
Sigma) and incubated for 48 hours on a roller at room temperature with two changes 
of PBS every 24 hours. The processed vein segments were then used for analysis or 
stored in fresh PBS at 4°C until required. Two commercially available biological 
patches widely used for cardiac surgery (Supple Peri-Guard® (Synovis Life 
Technologies Inc.; PC-0608SN) and Porcine Pericardial Patch (BioIntegral Surgical 
Inc.; NRPP-05x05)) were used as controls. A segment of fresh unprocessed 







Figure 2.1 Decellularisation protocol set-up. (i) Optimisation protocol on a roller using different concentration of SDS (0.01, 0.025, 
0.05, 0.075 and 0.1% (w/v) SDS). Decellularisation of larger vein segments; (ii) roller method (iii) flow method. All set-up is with the 
incubation in SDS for 24 hours at room temperature and followed with two 24 hour washes in PBS before analysis. 
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 Decellularisation Protocol for larger vein segments; Roller method 
After optimisation of decellularisation of small segments, it was attempted to scale-up 
the decellularisation protocol using larger vein segments ~4 cm in length in 40 mL 
0.01% SDS. The efficacy of the decellularisation process was reassessed with 
histological and ECM analysis (Figure 2.1 ii).  
 
 Decellularisation Protocol for larger vein segments; Flow method 
A modified technique of decellularisation using a flow system was assessed. SDS was 
circulated through the vein and also outside it to ensure thorough SDS exposure with 
the aim of enhancing decellularisation (Figure 2.1 iii). Segments of hSV (n=3) were 
divided into two ~4 cm lengths and a small piece of native tissue control was fixed in 
10% formalin as a control. For the flow method, veins were cannulated at either end 
and the tubing and chamber primed with 120 mL 0.01% (w/v) SDS which flowed 
through the hSV and recirculated around the outside continuously 6 mL/min. For the 
roller method, the hSV was placed in a 50 mL Falcon tube in 40 mL SDS and rolled at 
60 rpm. After 24 hours the vein segments were washed twice in PBS in the flow 






 Primary Cell Propagation 
 Collection of Human Internal Mammary Artery and Porcine Carotid Artery  
Human internal mammary arteries (hIMAs) were harvested as a pedicle, which 
includes internal mammary vein, muscle, fascia and the surrounding adipose tissues. 
The distal segment of the hIMA is often discarded at the completion of surgery (on 
average >1 cm in length) and this surplus segment was utilised in this study. In a class 
II tissue culture hood, the IMA was identified and dissected from the surrounding 
tissues with scissors and forceps. Porcine carotid artery (pCA) specimens (about 3-5 
cm length) were collected during termination procedures.  
ECs and SMCs were extracted and propagated from h-IMA and pCA segments using 
a previously described method (Castronuovo Jr, Smith, and Price 2002; Yang et al. 
1998) with a few modifications as described below. 
 
 Endothelial Cells Isolation and Expansion 
Firstly, fibronectin-coated plate was prepared before tissue processing and cell 
isolation by dispensing 500 µL of 100 µg/mL fibronectin (F0895-1MG; Sigma) making 
sure to cover all surface area of one well of the 6-well plate and aspirating excess 
solution and was then left to dry in the hood for 30 minutes. After removal of most of 
the surrounding tissue from both hIMA and pCA, samples were cut longitudinally with 
scissors and pinned down with 19G needles, lumen facing up, on a sterile glass culture 
dish containing 5 mm thick set Sylgard gel. A scalpel was then lightly rubbed across 
the luminal surface to scrape off the endothelial cells. The endothelial cells on the tip 
of the scalpel were transferred into a 50 mL Falcon tube containing media (Table 2.1 
#1) and subjected to centrifugation at 300 relative centrifugal force (rcf) for 5 minutes 
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at 37°C. The supernatant was discarded, and the pellet obtained was re-suspended 
with 1 mL of media (Table 2.1 #1) and seeded on a fibronectin-coated 6-well plate 
filled with another 1 mL of media (Table 2.1 #1) and then incubated in 5% CO2 at 
37°C. The cultures were examined after 3 days to assess cell grow and attachment 
with the culture media being changed every other day for the two weeks and then the 
culture was maintained with media changes twice a week until cells were 70-80% 
confluent before trypsinization for further analysis. 
 
 Smooth Muscle Cells Isolation and Expansion 
The exposed medial layer of h-IMA and p-CA was then scored transversely near the 
ends with a scalpel and the medial layer was carefully peeled from the adventitia layer 
using forceps. The medial tissue was then finely cut into approximately 1 mm2 explants 
using a scalpel, as described previously (Rodgerson et al. 2000). The explants were 
then transferred into a T25 flask and cultured in media as described in Table 2.1 #1. 
Explants were then incubated in 5% CO2 incubator at 37°C for 3 weeks changing the 
media every other day. Detached SMC explants were removed with aspiration of 
media, and fresh culture media added once cells were observed to be proliferating on 
the surface of the flask. The culture was examined after 3 days to assess cell 
attachment and the culture media was changed every other day for the first three 
weeks and then the culture was maintained with media changes twice a week until 




 Cell and Tissue Culture Maintenance, Sub-culturing and Cell Counting 
Each cell type was maintained in their respective specific tissue culture medium as 
shown in Table 2.1. 
 















Dulbecco's modified Eagle's medium (DMEM) 
(D6421; Sigma) containing 10% (v/v) Fetal 
Bovine Serum (FBS) (10500064, Life 
Technologies); 200µg/mL of Penicillin-
Streptomycin (P4333-100ML, Sigma); 2 mM of 





Smooth Muscle Cell Growth Medium 2 
(SMCGM2) containing 5% Fetal Calf Serum 
(FCS); 0.5 ng/mL Epidermal Growth factor 
(EGF); 2 ng/mL Basic Fibroblast Growth Factor 
(bFGF); 5 µg/mL Insulin (C-22062, PromoCell); 








Endothelial Cell Growth Medium MV2 
containing 2% (v/v) Fetal Calf Serum (FCS); 5 
ng/mL Epidermal Growth factor (EGF); 10 
ng/mL Basic Fibroblast Growth Factor (bFGF); 
20 ng/mL Insulin-like Growth Factor (IGF); 0.5 
ng/mL Vascular Endothelial Growth Factor 165 
(VEGF 165); 1 µg/mL Ascorbic Acid; 22.5 
µg/mL Heparin; 0.2 µg/mL Hydrocortisone (C-
22022, PromoCell); 200 µg/mL of Penicillin-







Dulbecco's modified Eagle's medium (DMEM) 
(D6421; Sigma) containing 10% (v/v) Fetal 
Bovine Serum (FBS) (10500064, Life 
Technologies); 200µg/mL of Penicillin-
Streptomycin (P4333-100ML, Sigma); 2 mM of 
















Wash medium: 25 mM Hepes-buffered RPMI 
1640 supplemented with 2 mM L-glutamine, 8 
μg/mL gentamicin, 100 IU/mL penicillin and 100 
μg/mL streptomycin (42401018; Life 
Technologies) 
Culture media: Sodium bicarbonate-buffered 
RPMI 1640 supplemented with 30% FCS, 2mM 
L-glutamine, 8 μg/mL gentamicin, 100 IU/mL 
penicillin, 100 μg/mL streptomycin, (31870025; 
Life Technologies) and 10 μM 
bromodeoxyuridine (BrdU) (B5002; Sigma) 
 
Cell cultures were trypsinized once cultures reached 70-80% confluency. Cells were 
washed with PBS and then were incubated with 0.05% (v/v) Trypsin/EDTA (15400-
054, Life Technologies) at 37°C for 2 minutes. The culture plate was then gently 
agitated, and the bottom of the culture flasks and plates were tapped to aid cell 
detachment. An equal volume of fresh media was added to inactivate Trypsin/EDTA. 
The cell suspension was transferred to a 50 mL Falcon tube and subjected to 
centrifugation at 300 rcf for 5 minutes at 37°C. The supernatant was discarded, and 
the pellet obtained was re-suspended with tissue culture media. Cells were then 
counted on a Countess® Automated Cell Counter (Life Technologies, UK). Briefly, 10 
µL of cell suspension was mixed with 10 µL of 0.4% (v/v) Trypan Blue Stain (T10282; 
Life Technologies). 10 µL of this solution was then inserted into each chamber of a 
Countess Chamber Slide (C10228; Life Technologies) and analysed by the cell 




 Histological Analysis 
Tissue samples were fixed overnight in 10% (w/v) neutral buffered formalin, NBF 
(HT501128, Sigma) and stored in PBS at 4°C before processing in the Shandon 
Excelsior ES Tissue Processor (Thermo Scientific, UK) and paraffin-wax embedding 
using the Shandon Histocentre™ 3 Embedding Center (Thermo Scientific, UK). 
Sections of 3-5 µm were cut using a microtome and placed on Superfrost Plus 
(10149870; Fisher) microscope slides. The slides were stored at room temperature 
and incubated at 37°C for 20 minutes prior to further analysis. 
 
 Hematoxylin and Eosin (H&E) staining 
H&E staining was used to detect nuclei in decellularised tissue segments. H&E was 
performed using an automated staining machine, Varistain 24-4 Shandon™ (Thermo 
Scientific, UK). Coverslips were mounted on stained slides using DPX mountant 
(100503-836; VWR). Samples were viewed with a bright field microscope and images 
captured using the ImagePro software.  
 
 Morphological analysis 
Low-powered field images were taken at 10 to 40X magnification to quantify the wall 
thickness and lumen diameter using ImageJ software. Wall thickness of transverse 
sections were measured and presented as mean ± SEM. Lumen perimeter is 
measured, and diameter calculated using the following formula; 
 
 
Lumen diameter =    Circumference  
π
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 Decellularisation percentage analysis 
All nuclei (stained blue) present in the intima, media and adventitia of high-powered 
fields (400X magnification) were counted automatically using a macro in ImageJ 
software. Four quadrants in four transverse sections (total of 16 high-power fields) 
were averaged for each untreated venous control (n=10) and for each decellularised 
(n=10) vein segment. The percentage of decellularisation was calculated using the 
following formula:  
 
 Elastin Van Gieson (EVG) staining 
EVG staining was used to visualise and semi-quantitate elastin composition in tissue 
samples before and after the decellularisation process. EVG staining was performed 
using an automated staining machine, Varistain 24-4 Shandon™ (Thermo Scientific, 
UK). Coverslips were mounted on stained slides using DPX mountant (100503-836; 
VWR) and samples were viewed with a bright field microscope. Images were captured 
using the ImagePro software. The area occupied by elastin (purple/black colour) per 
high-powered field (400X magnification) was measured by pixel counting using 
ImageJ software. Four areas in four transverse sections (total of 16 high-power fields) 
were averaged for each fresh native control (n=10) and each processed vein (n=10). 
Percent of decellularisation = 
 
Nuclei count for fresh control − nuclei count for processed vein   
X 100% 
(nuclei count for control vein)      
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The percentage content of elastin was calculated using the following formula: 
 
 Picrosirius Red (PSR) staining 
Picrosirius red staining enables visualisation and semi-quantitative measurement of 
collagen fibres in tissue samples. The slides were dewaxed and rehydrated by 
immersing in three changes of Clearene (3803600E; Surgipath) for 5 minutes each 
and then were rehydrated in three changes of 100% Industrial Methylated Sprits (IMS) 
for 5 minutes each, followed by 90% IMS for 3 minutes and lastly in 70% IMS for 
another 3 minutes. Finally, the slides were placed in distilled water for 3 minutes to 
complete the rehydration step before followed by incubation in picrosirius red (365548; 
Sigma) for one hour. Slides were then washed in two changes of acidified water 
(0.005% (v/v) glacial acetic acid (537020; Sigma) in distilled water). Most of the water 
was then removed by shaking the slides vigorously. Slides were then dehydrated in 
three changes of 100% ethanol, cleared in xylene and then mounted with DPX 
mountant (100503-836; VWR). 
 
Samples were viewed with a bright field microscope and images were captured using 
the ImagePro software. The area occupied by collagen (red) on a pale-yellow 
background per high-powered field (400X magnification) was measured by pixel 
counting using ImageJ software. Four areas in four transverse sections (total of 16 
high-power fields) were averaged for each fresh native control (n=10) and for each 
Percent fibres =  
 
Average EVG positive area per high-power fields 
           total area of high-power fields                       x 100%
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processed vein (n=10). The percentage content of collagen was calculated using the 
following formula:  
 
 
 Alcian Blue  
Alcian Blue was utilised to visualise and as a semi-quantitative measurement of 
glycosaminoglycans (GAGs) in tissue samples. The slides were dewaxed and 
rehydrated. Briefly, slides were immersed in three changes of Clearene (3803600E; 
Surgipath) for 5 minutes each and then were rehydrated in three changes of 100% 
Industrial Methylated Sprits (IMS) for 5 minutes each, followed by 90% IMS for 3 
minutes and lastly in 70% IMS for another 3 minutes. Finally, the slides were placed 
in distilled water for 3 minutes to complete rehydration. 
 
The slides were then incubated in alcian blue (A5268; Sigma) solution for 30 minutes 
and then washed in running tap water for 2 minutes followed by a quick rinse in distilled 
water. The nuclei were then counterstained in nuclear fast red (N8002; Sigma) solution 
for 5 minutes and washed in running tap water for 1 minute. Slides were then 
dehydrated in three changes of 100% ethanol, cleared in xylene and then were 
mounted using DPX (100503-836; VWR). 
 
Percent collagen content =  
 
Average PR positive area per high-power fields 
           total area of high-power fields                       x 100%
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Samples were viewed with a bright field microscope and images were captured using 
the ImagePro software. The area occupied by GAGs (blue) per high-powered field 
(400X magnification) was measured by pixel counting using ImageJ software. Four 
areas in four transverse sections (total of 16 high-power fields) were averaged for each 
fresh control (n=10) and each processed vein (n=10). The percentage content of 
GAGs was calculated using the following formula:  
 
 
 Picogreen Assay 
The deoxyribonucleic acid (DNA) content of native vein and vein segments subjected 
to the decellularisation protocol (each treatment group; n=10) was quantified by the 
Quant-iT Picogreen Assay (P11496; Life Technologies), as previously described 
(Vavken, Joshi, and Murray 2009; Böer et al. 2015; Quint et al. 2012). Quant-iT™ 
PicoGreen® dsDNA reagent is an ultra-sensitive fluorescent nucleic acid stain for 
quantitating double-stranded DNA (dsDNA) in solution. Detecting and quantitating 
small amounts of DNA as little as 25 pg/mL of dsDNA.  
 
DNA from fresh tissue was extracted using the salting-out method as described by 
Miller, et al. with minor modifications (Miller, Dykes, and Polesky 1988). Briefly, tissue 
samples of approximately ≈10 to 25 mg were cut into small pieces using a scalpel. 
The samples were then transferred into 1.5 mL microcentrifuge tubes and 600 µL of 
TNES buffer and 50 µL of Proteinase-K (20 mg/mL) added. After mixing by inverting 
Percentage GAG content =  
 
Average Alcian blue positive area per high-power fields 
total area of high-power fields                       x 100%
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the tubes several times the samples were incubated overnight at 50ºC or until the 
tissue were completely lysed. The tubes were occasionally mixed by inverting the 
tubes. 167 µL of 6 M NaCl was added to the lysed samples and vigorously mixed for 
20 seconds. The tubes were then subjected to centrifugation at full speed ≈14,000 rpm 
for 10 minutes at room temperature. The supernatants were then transferred to new, 
labelled 1.5 mL microcentrifuge tubes and 800 µL of cold 100% ethanol added and 
then the tubes were inverted a couple of times to mix. The DNA was precipitated out 
of solution by incubation at -20ºC for a few hours or overnight. The samples were then 
subjected to centrifugation at 14,000 g for 20 minutes at 4ºC. The supernatants were 
then removed by pipette while taking care not to dislodge the pellet of DNA. The DNA 
pellets were then washed with 700 µL of 100% ethanol by gentle inversion. The 
ethanol was poured off and the tubes were briefly centrifuged to keep the DNA pellet 
at the bottom of the tube. A further wash with 70% ethanol was performed as described 
for 100% ethanol. The samples were then allowed to air dry for 30 minutes. As soon 
as the samples were dry, the DNA pellets were re-suspended in 200 µL of Tris-EDTA, 
pH 7.5.  
 
Subsequently 1 μl of extracted DNA for each sample in duplicate was transferred to 
wells of a black chimney µClear® flat bottom 96 Well Microplates (655090; Greiner). 
A duplicate of standard curve with a range of 0 (blank), 1, 10, 100, 1000 ng/mL 
prepared from 2 μg/mL Lambda DNA standard in 1X TE (10mM Tris-HCl, 1mM EDTA, 
pH 7.5) was also added to the 96 well plate. 100 μL of diluted PicoGreen reagent 
(1:200 in 1X TE buffer) was added to each standard and sample. The microplate was 
covered with aluminium foil and incubated at room temperature for 2-5 minutes. The 
DNA content was quantified by reading on a microtiter plate fluorescence reader 
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(413.3020; FLUOstar® Optima) at excitation of 485 nm and measurement at 520 nm. 
A reference standard graph where Absorbance (Abs) was plotted against known 
Lambda DNA Concentration (ng/mL) was used to calculate the DNA content of the 
test samples. 
 
 Hydroxyproline Assay 
The hydroxyproline content of native vein and vein segments subjected to the 
decellularisation protocol (each treatment group; n=10) was quantified using a 
Hydroxyproline Assay Kit (MAK008; Sigma) according to the manufacturer’s 
instructions. Hydroxyproline was used as a measure of collagen content in the tissue 
samples, as described previously (Meyer et al. 2006; Stegemann and Stalder 1967). 
Hydroxyproline (4-hydroxyproline) is a non-proteinogenic amino acid formed by the 
post translational hydroxylation of proline. Hydroxyproline is a major component of 
collagen, where it serves to stabilize the helical structure and because hydroxyproline 
is largely restricted to collagen, hence it is a good indicator for collagen content in 
tissue. The hydroxyproline content of both wet tissue samples and paraffin wax 
embedded was quantified.   
 
 Wet tissue Sample Extraction  
Approximately 10 mg of tissue was cut into small pieces using a scalpel and then 
transferred to a 2.0 mL polypropylene tube containing 100 µL of water. After vortexing 
100 µL of concentrated hydrochloric acid (HCl, ~12 M: 320331; Sigma) was added 
and then the tube was placed on a heating block at 120°C overnight to hydrolyse the 
tissue. The following day 30 µL of the supernatant was then transferred in duplicate to 
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a well of a 96 well flat bottom microplate which was then placed in a 60°C oven to dry 
the samples for 3 hours. 
 
 Paraffin Wax Embedded Sample Extraction  
Using a microtome 10 µm of paraffin wax embedded tissue was cut and then 
transferred to a 1.5 mL polypropylene tube containing 100 µL of water. After vortexing 
for 100 µL of concentrated hydrochloric acid, HCl ~12 M (320331; Sigma) was added 
and then the tube was placed on a heating block at 120°C overnight to hydrolyse the 
tissue. The following day 30 µL of the supernatant was then transferred to a well of a 
96 well flat bottom microplate and placed in a 60°C oven to dry the samples for 3 
hours.   
 
 Sample analysis 
The assay reagent and standard curve were prepared just prior to the start of the 
assay. A duplicate standard curve range of 0 (blank), 0.2, 0.4, 0.6, 0.8, and 1.0 µg/well 
was then prepared in the same 96 well microplate from diluted standard solution (0.1 
mg/mL Hydroxyproline). For every reaction and standard well, a mix of 6 µL of 
Chloramine T Concentrate and 94 µL of Oxidation Buffer was added and then the plate 
was incubated at room temperature for 5 minutes. Subsequently for each well, 50 µL 
of (Dimethylamino) benzaldehyde (DMAB) concentrate was mixed with 50 µL of 
Perchloric Acid/Isopropanol Solution and added to the well and mixed via pipetting. 
The plate was incubated for 90 minutes at 60°C. The hydroxyproline concentration 
was determined by the reaction of oxidized hydroxyproline with DMAB, which resulted 
in a colorimetric product that was quantified by a microtiter plate reader (24200; 
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DYNEX Technologies) at 570 nm. A reference standard graph where Absorbance 
(Abs) was plotted against the Hydroxyproline concentration was used to calculate the 
hydroxyproline content (mg/mL) of the test samples, which correlates to the collagen 
content. The concentration in wet tissue was expressed as µg/mg wet tissue and in 
paraffin wax embedded tissue the concentration was expressed as ng/µg total protein. 
 
 Fastin Elastin Assay 
The elastin content of native vein and decellularised vein segments (each treatment 
group; n=10) was quantified by the Fastin Elastin Assay Kit (F2000; BioColor) 
according to the manufacturer’s instructions. The Fastin Elastin Assay is a quantitative 
dye‐binding method for the analysis of elastin extracted from biological materials(Lü 
et al. 2009; Lee, Stolz, and Wang 2011). The Fastin Elastin Assay is able to measure 
insoluble cross-linked elastin that are extracted from tissue in the form of soluble 
cross-linked polypeptide elastin fragment; ɑ-elastin. The ɑ-elastin content from both 
wet tissue samples and paraffin wax embedded were analysed.   
 
 Wet tissue Sample Extraction  
Approximately 10 mg of wet tissue was cut into small fragments and placed into 
centrifuge tubes. 500 μl of 0.25 M oxalic acid was then added into each sample tube. 
Tubes were then placed tissue on a heating block at 100ºC for 60 minutes with 
loosened tube caps. The tubes were removed from the heat and cooled to room 
temperature before they were subjected to centrifugation at 10,000 rcf for 10 minutes. 
The supernatant was transferred using a pipette into a new labelled tube. Another 500 
μl of 0.25 M oxalic acid was then added to the residual tissue in the tubes and heated 
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again for another 60 minutes. Three heat extractions with 0.25 M oxalic acid were 
performed to ensure complete solubilisation of the tissue elastin.  
 
 Paraffin Wax Embedded Sample Extraction  
Using a microtome 10 µm paraffin wax embedded tissue was cut using a microtome 
and transferred to a 1.5 mL polypropylene tube. 500 μl of 0.25 M oxalic acid was added 
to each sample tube. Tubes were then placed tissue on a heating block at 100ºC for 
60 minutes with loosened tube caps. The tubes were removed from the heat and 
cooled to room temperature before they were subjected to centrifugation at 10,000 rcf 
for 10 minutes. The supernatant was transferred using a pipette into a new labelled 
tube. Another 500 μl of 0.25 M oxalic acid was then added to the residual tissue in the 
tubes and heated again for another 60 minutes. Three heat extractions with 0.25 M 
oxalic acid were performed to ensure complete solubilisation of the tissue elastin. 
 
 Sample analysis 
A set of 1.5 mL microcentrifuge tubes were labelled for reagent blanks (0.25M oxalic 
acid), ɑ-elastin standard at 0.025, 0.05 and 0.1 µg/mL in 0.25M oxalic acid and all test 
samples. 500 µL of Elastin Precipitating Reagent was added to each tube and briefly 
vortexed to mix contents before incubation for 10 minutes to complete the precipitation 
of elastin at room temperature. The tubes were then subjected to centrifugation at 
>10,000 rcf for 10 minutes. The supernatant was discarded, and all excess fluid was 
removed by tapping the inverted tube onto a single thickness absorbent paper towel. 
1 mL of Dye Reagent was added to all tubes. The tube contents were mix by inverting 
the tubes and dispersing the elastin precipitate using a vortex mixer. The tubes were 
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incubated for 90 minutes on a shaker at room temperature. The tubes were then 
subjected to centrifugation at >10,000 rcf for 10 minutes. The supernatant that 
contained unbound dye was discarded and most of the remaining fluid was remove 
from the tube by tapping the lip of the tube onto an absorbent paper towel. A reddish-
brown deposit which was composed of the elastin-dye complex at the bottom wall of 
the tube could be observed. 
 
250 μl of Dye Dissociation Reagent was added to each tube followed by vortexing to 
release the dye into solution. Vortex mixing was repeated after 10 minutes so as to 
ensure all bound dye has been released into solution. 250 μl of each sample was 
transferred to a well of a 96 well flat bottom microplate. The elastin content of the 
assayed samples was determined by the amount of bound dye released from the 
elastin which was quantified by a microtiter plate reader (24200; DYNEX 
Technologies) at 490 nm. A standard curve where Absorbance (Abs) was plotted 
against known Elastin Concentration (µg/mL) was used to determine the elastin 
content of the test samples. The concentration in wet tissue was expressed as µg/mg 
wet tissue and in paraffin wax embedded tissue the concentration was expressed as 
ng/µg total protein. 
 
 Glycosaminoglycan Assay 
The sulfated proteoglycans and glycosaminoglycan (GAG) content of native vein and 
vein segments subjected to the decellularisation protocol (each treatment group; 
n=10) was quantified by the Blyscan Assay Kit (B1000; BioColor) according to the 
manufacturer’s instructions. The Blyscan Assay is a quantitative dye‐binding method 
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for the analysis of sulfated polysaccharide component of proteoglycans or the protein-
free sulfated glycosaminoglycan chains extracted from biological materials (Lü et al. 
2009; Lee, Stolz, and Wang 2011). The ɑ-elastin content from both wet tissue samples 
and paraffin wax embedded were analysed.   
 
 Wet tissue Sample Extraction  
Approximately 20 to 50 mg of wet tissue was cut into small fragments and placed into 
centrifuge tubes. 1 mL of Papain Extraction Reagent (consist of: 0.2M sodium 
phosphate buffer, (Na2HPO4 – NaH2PO4), pH 6.4; 400 mg sodium acetate; 200 mg 
EDTA, disodium salt; 40 mg cysteine HCl and 250 µL of a papain suspension, 
containing about 5 mg of the enzyme (P3125; Sigma-Aldrich)) was then added. The 
microcentrifuge tubes were then placed in a heated block at 65°C overnight. After 
digestion, the tubes were subjected to centrifugation at 10,000 rcf for 10 minutes and 
the supernatant was removed for further analysis in the protocol below (2.8.3). 
 
 Paraffin Wax Embedded Sample Extraction 
Using a microtome 10 µm paraffin wax embedded tissue was cut and transferred to a 
1.5 mL polypropylene tube. 1 mL of Papain extraction reagent (consist of: 0.2 M 
sodium phosphate buffer, (Na2HPO4 – NaH2PO4), pH 6.4; 400 mg sodium acetate; 
200 mg EDTA, disodium salt; 40 mg cysteine HCl and 250 µL of a papain suspension, 
containing about 5 mg of the enzyme (P3125; Sigma-Aldrich) was then added. The 
micro-centrifuge tubes were then placed in a heated block at 65°C overnight. After 
digestion, the tubes were subjected to centrifugation at 10,000 rcf for 10 minutes and 
the supernatant was removed for further analysis in the protocol below (2.8.3). 
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 Sample analysis 
A set of 1.5 mL microcentrifuge tubes were labelled for reagent blanks (deionised 
water), glycosaminoglycan standards (1.0, 2.0, 3.0, 4.0 and 5.0 µg/mL in deionised 
water) and all test samples. 1 mL of Blyscan dye reagent was added to each tube and 
the content was mixed by inversion and then the tubes were placed in a gentle 
mechanical shaker for 30 minutes. The tubes were then subjected to centrifugation at 
12,000 rcf for 10 minutes. The tubes were carefully inverted, allowed to drain and then 
the inverted tube was gently tapped on a paper tissue to remove remaining liquid 
droplets from the tubes. Then 500 µL of dissociation reagent was added to the tubes. 
The tubes were vortexed for 10 minutes to release the bound dye into solution. The 
tubes were then subjected to centrifugation at 12,000 rcf for 5 minutes. 200 µL of each 
sample was transferred to individual wells of a 96 micro well plate. The plate was then 
read at 630 nm using a microtiter plate reader (24200; DYNEX Technologies). GAG 
concentrations were calculated from the standard curve. The concentration in wet 
tissue was expressed as µg/mg wet tissue and in paraffin wax embedded tissue the 
concentration was expressed as ng/µg total protein. 
 
 Total protein Assay 
Normalisation of the ECM protein extracted was done with the Pierce Detergent 
Compatible Bradford Assay (23246, ThermoFisher). Due to the use of SDS which is 
in fact a detergent in the decellularisation protocol, this assay kit is used to omit the 
interference in the reading. Just as in normal Bradford method, Coomasie dye binds 




 Sample extraction 
All ECM proteins (collagen, elastin and GAGs) tissue extract from Section 2.6 to 2.8 
were used for total protein quantification.   
 
 Sample analysis 
A set of 1.5 mL microcentrifuge tubes were labelled for reagent blanks (deionised 
water), Bovine Serum Albumin (BSA) standards (as shown in manufacturer’s manual 
concentration range from 2.5 to 25 µg/mL in deionised water) and all test samples. 
 
150 µL of each standard or unknown sample are dispense into the appropriate 
microplate wells. Followed by addition of 150 µL of Pierce Detergent Compatible 
Bradford Assay Reagent to each well, and each sample were mix with reagent. Plate 
were then incubated for 10 minutes at room temperature. The absorbance was then 
measured at 595 nm with a microtiter plate reader (24200; DYNEX Technologies). The 
average 595 nm measurement for the blank replicates were subtracted from the 595 
nm measurements of all other individual standard and unknown sample replicates. A 
standard curve was plotted with the average blank-corrected 595 nm measurement 
for each BSA standard vs. its concentration in µg/mL. The protein concentration was 
estimated using the standard curve for each unknown sample. 
 
 AlamarBlue® Cell Viability 
Resazurin is an oxidation-reduction indicator that changes colour and has enhanced 
fluorescence as a result of cellular metabolic reduction. AlamarBlue® works similarly 
75 
 
to MTT assay. Viable cultured cells continuously convert resazurin to resofurin thus 
increasing the overall fluorescence and the colour of the tissue media of the cultured 
cells.  
 
 Cells cultured in tissue culture plates 
Cells (ADSC, HUVEC and hSV SMC) were seeded at 5.0 x 104 cells/well in a 96 well 
plate and were incubated in 5% CO2 at 37°C. After 24 hours, the tissue culture media 
was discarded and 100 μl of respective tissue culture media as shown in Table 2.1 
supplemented with 10% (v/v) AlamarBlue® (DAL1100; Qiagen) was added and the 
plate was incubated for another 24 hours in 5% CO2 at 37°C. 
  
 Cells cultured in cell crowns 
Decellularised vein segments were cut longitudinally with scissors to expose the 
luminal surface and a 4mm disc was punched-out using a biopsy punch (PUNC010; 
Premier Healthcare & Hygiene Ltd.). The discs were then attached onto 96 well plate 
CellCrowns™ (Z682004-6EA; Sigma) with the luminal surface facing up, prior to 
placing into the 96 well cell culture plate as shown in Figure 2.3. The discs were then 
pre-conditioned overnight with the cell specific tissue culture media for the cell type 
that was to be seeded (refer to Table 2.1). Cells were seeded at 5.0 x 104 cells/well 
and the Cell Crowns were incubated in 5% CO2 at 37°C. After 24 hours, the media 
was discarded and 50 μl of tissue culture media supplemented with 10% (v/v) 
AlamarBlue® (DAL1100; Qiagen) was added and the plate was incubated for another 
24 hours in 5% CO2 at 37°C. The tissue culture media was collected after 24 hours 





Figure 2.2 Schematic diagram of CellCrown™ apparatus used in 96 well plates. 
Discs of dellularise hSV were placed in CellCrowns which were inserted into 96 well 
plates prior to cell seeding. 
 
 Sample analysis 
The absorbance was read using a microtiter plate reader (24200; DYNEX 
Technologies) at the lower wavelength filter (570 nm) and at the higher wavelength 
filter (595 nm). Readings from both lower and higher wavelengths were recorded to 
ensure an accurate method for deriving the amount of reduced AlamarBlue® present 
in each sample. The absorbance of 50 μl tissue culture media only was also measure 
at both lower and higher wavelengths.  
 
Decellularised hSV 
96 well insert body 
96 well insert base 
96 well insert, 
assembled 
      96 well plate 
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The absorbance value of tissue culture media only was subtracted from the 
absorbance values of AlamarBlue® in tissue culture media in contact with cell to 
calculate the absorbance of oxidized AlamarBlue®; AOLW = absorbance of oxidized 
form at lower wavelength, and AOHW = absorbance of oxidized form at higher 
wavelength. The correction factor (RO) was calculated using this formula: RO = AOLW/ 
AOHW.  
 
Therefore, the percent of reduced AlamarBlue® (ARLW) was calculate using this 
formula: ARLW = ALW – (AHW x RO) x 100. 
Accordingly, the percent difference between treated and control cells in 
cytotoxicity/proliferation assays was determine using this formula: 
 
 
For better result presentation of cytotoxicity/proliferation, a reference standard graph 
where the percent difference in reduction (using the formula above) was plotted 
against the seeding density of each cell type was used to calculate the total number 
of cells present in the test samples. 
 
Percent difference in reduction = 
                   (ALW – (AHW x RO) for test well)                  
X 100% 
(ALW - (AHW x RO) positive growth control)
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 Methylene Blue Assay 
SDS was used for decellularisation and its cytotoxicity was proven via action in 
disruption of cells. The methylene blue (MB) two-phase titration method is a rapid and 
efficient method for determining the concentrations of anionic surfactants. SDS is the 
main ingredient in many detergent products consequently the MB assay is used for 
detecting SDS in the environment (Hayashi 1975). It was critical to detect the level of 
SDS in the effluent and hSV tissue after the decellularisation protocol. Firstly, to 
demonstrate the effectiveness of the washing steps and secondly to show that the 
decellularised tissue were biocompatible for cells to grow on. 
 
 Effluent samples 
The assay was modified from Zvarova et. al. where an aliquot of 1 mL of effluent was 
collected after each solution change (0.01% SDS, wash 1 and wash 2) and kept at 4° 
until the analysis (Zvarova et al. 2016).   
 
 Tissue extract sample 
The assay was modified from Mathapati et. al. where approximately 50 mg of 
decellularised hSV was crushed under liquid nitrogen using a pestle and mortar. 1ml 
of distilled water was added to the homogenised tissue and the 3 mL of 100% ethanol 
was added. The samples were subjected to centrifugation at 140 000 rcf for 10 minutes 
(Mathapati et al. 2010). The supernatant was collected into newly labelled tubes and 





 Sample Analysis 
A set of 1.5 mL microcentrifuge tubes were labelled. 50 µL of reagent blanks (DPBS), 
SDS standards (0, 0.00001, 0.00005, 0.0001, 0.0005, 0.001, 0.005, 0.01 % w/v in 
DPBS) and all test samples was added to tubes. 50 µL of Methylene Blue; 0.0125% 
w/v (M6900; Sigma) was then added to the tubes and the tubes were vortexed 
vigorously. Next, 200 µL of chloroform was then added. The tubes were vortexed for 
1 minute and then the tubes were incubated for 30 minutes, at room temperature. A 
two-phase layer was observed and 150 µL of the bottom layer was transferred into a 
96-well polypropylene (PP) plate (736-0122; VWR). The plates were then immediately 
read at 630 nm using a microtiter plate reader (24200; DYNEX Technologies). 
 
 Agarose Gel Electrophoresis 
The minimum criteria of decellularisation is less than 200 base pair (bp) dsDNA in 
decellularised tissue (Crapo, Gilbert, and Badylak 2011). To determine the size of the 
DNA content of decellularised hSV DNA fragments were extracted from decellularised 
tissue and gel electrophoresis was completed to examine the size of DNA. Agarose 
gel (0.5% (w/v)) was prepared by dissolving 1 g of agarose powder (MB1200; Melford) 
in 1X TAE buffer (consist of: 40 mM Tris, 20 mM acetic acid, 1 mM EDTA (B49; Sigma-
Aldrich)) and with 200 µL SYBR™ Safe stain (S33103; Invitrogen) by heating in a 
microwave. The molten agar was cooled to ≈ 60°C before pouring into the gel tray with 




Once the gel was set, it was placed in the electrophoresis tank and the tank was filled 
with 1X TAE buffer until the gel was submerged. The first well was then loaded with 5 
µL HyperLadder™ 50 bp (BIO-33054; Bioline Reagents Ltd.) and subsequent wells 
were loaded with a mix of samples with loading dye (1:5 dilution).  Electrical leads 
were then appropriately attached, and the set-up was then run at ~80 to 100V for about 
30 minutes. The gel was then transferred to be visualised and analysed using with Gel 
Doc™ XR+ System and Quantity One® 1-D analysis software (Bio-Rad Laboratories, 
Inc., UK). 
 
 Click-IT® Plus EdU Cell Proliferation Assay 
Proliferation of ECs and SMCs from porcine carotid artery in the presence of different 
concentration of SDS was quantified with the Click-iT EdU Alexa Fluor 555 Imaging 
Kit (C10638; Life Technologies). ECs or SMCs were seeded separately in 96 well 
tissue culture treated plates (655090; Greiner Bio-One Ltd.) at a seeding density of 
100 000 cell/cm2 and allowed to grow overnight. Cells were then cultured with tissue 
culture media with 2% (v/v) FBS overnight to suppress proliferation. The cells were 
then exposed to different SDS concentrations in tissue culture media with 10 μM EdU 
overnight. Cells were then washed twice with PBS and fixed using 3% (v/v) 
paraformaldehyde in PBS for 15 minutes. After rinsing with 3% (v/v) BSA in PBS twice, 
cells were permeabilised at room temperature for 20 minutes with 0.5% (v/v) Triton-
X100 in PBS. The staining solution was prepared according to the manufacturer’s 




The Click-iT Plus reaction cocktail were prepared as follows: 88 µL 1X Click-iT reaction 
buffer, 2 µL copper protectant, 0.25 µL Alexa Fluor picolyl azide and 10 µL reaction 
buffer additive were mixed in the listed order to make a final volume of 100.25 µL for 
each well. At the end of permeabilisation incubation, 0.5% (v/v) Triton-X100 in PBS 
was discarded, and the cells were washed twice with 3% (v/v) BSA in PBS. Each well 
was added with 50 µL of Click-iT Plus reaction cocktail prepared earlier (and within 15 
minutes of preparation for optimal reaction results). The plate was protected from light 
with aluminium foil and incubated for 30 minutes at room temperature. Wells were then 
washed twice with 3% (v/v) BSA in PBS followed by a wash with PBS. Nuclei staining 
was performed with 2 µg/mL of Hoechst 33342 in PBS, 50 µL was dispense in each 
well and incubated for another 30 minutes at room temperature protected from light. 
Wells were then washed twice with PBS and wet mounting media Fluoromount-G (00-
4958-02; Life Technologies) was added before imaging was performed using the 
EVOS FL Cell Imaging System at medium-powered field (medium power fields = 200X 
magnification). Five views of each well under the medium power field were captured 
and nuclei counting using ImageJ software. Proliferation was determined with cells 
grown under normal media served as a positive control with 100% proliferation. The 
percentage of proliferation was calculated using the following formula: 
  
Percent of proliferation= 
 
          Positive nuclei (red) count after 48 hours       
X 100% 
       




 BrdU incorporation in Organ Cultures 
In order to ascertain that the decellularised vein did not harbour viable cells, the 
number of proliferating cells in hSV was determined by Bromodeoxyuridine (BrDU) 
incorporation within organ cultures of decellularised hSV. Native un-decellularised 
hSV served as a positive control. Surplus hSV was cut into segments; a 2 cm length 
was immediately processed for organ culture and the rest was decellularised in a tube 
placed on a roller as described previously as described in Section 2.2.2.  The segment 
isolated for organ culture was placed in a petri dish filled with wash medium (detailed 
in Table 2.1). A piece of 0.5 cm length was fixed in 10% formalin for 24 hours and 
placed in PBS before processing, to be used as an untreated control (Day 0).  
 
The rest of the tissue was cleaned by removing as much of adventitial layer as 
possible. Using scissors, the untreated hSV and decellularise hSV were then cut 
longitudinally to expose the luminal surface. The opened untreated hSV and 
decellularised hSV were transferred luminal surface uppermost onto a piece of plastic 
mesh in a small glass petri dish coated with 5mm thick set Sylgard resin and pinned 
down using a minute pins at all four corners. The vein was then cultured in 5 mL of 
tissue culture media (detailed in Table 2.1) for 14 days with tissue culture media 
change every 2 to 3 days. At the end of two weeks, the vein was fixed in 10% formalin 
for 24 hours and kept in PBS before further processing.   
All collected fixed tissue samples; 
a) positive control tissue (un-decellularised)  
i. untreated with BrdU and fixed on Day 0  
ii. treated with BrdU and fixed on Day 14  
83 
 
b) decellularised tissue  
i. untreated with BrdU and fixed on Day 0  
ii. treated with BrdU and fixed on Day 14  
were stored in PBS before further processing protocol in the Shandon Excelsior ES 
Tissue Processor (Thermo Scientific, UK) and paraffin wax embedding using the 
Shandon Histocentre™ 3 Embedding Center (Thermo Scientific, UK). Sections of 3-5 
µm were cut using a microtome and placed on Superfrost Plus (10149870; Fisher) 
microscope slides. The slides were stored at room temperature and incubated at 37°C 
for 20 minutes prior to staining.  
 
The slides were dewaxed and rehydrated as follows: slides were immersed in three 
changes of Clearene (3803600E; Surgipath) for 5 minutes each and then rehydrated 
in three changes of 100% (v/v) Industrial Methylated Sprits (IMS) for 5 minutes each, 
followed by 90% (v/v) IMS for 3 minutes and lastly in 70% (v/v) IMS for 3 minutes. 
Finally, the slides were placed in distilled water for 3 minutes. 
 
The slides were then incubated in 3% (v/v) hydrogen peroxide, H2O2 (H3410; Sigma) 
for 5 minutes at room temperature and then washed twice with PBS. The slides were 
then incubated in 10 mM citrate buffer pH 6.0 for 20 minutes in a boiling water bath. 
The slides were allowed to cool at room temperature before washing twice with PBS. 
The surrounding sections were wiped dry with paper tissue and sections were marked 
with a wax pen. Slides were incubated in 50 µL of 8.6 μg/mL mouse anti-BrdU IgG 
(B2531; Sigma) diluted in 1% (v/v) horse serum in 1% (v/v) BSA/PBS for 90 minutes 
at 37°C or overnight at 4°C. Slides were then washed four times with PBS before 
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addition of 50 µL biotinylated horse anti-mouse IgG in 1% (v/v) BSA/PBS diluted 1 in 
200 for 30 minutes. After washing four times with PBS, 50 µL of Extravidin™-HRP 
(E2886; Sigma) diluted 1 in 200 with 1% (v/v) BSA/PBS was added to each section 
and incubated for 30 minutes at room temperature. After four washes with PBS, each 
section was incubated with 250 µL of Fast DAB Peroxidase Substrate (D4293; Sigma) 
for 10 minutes at room temperature. Slides were washed with distilled water and 
counter-stained with Mayer’s haematoxylin for 30 seconds. Final washing with tap 
water was performed before mounting slides with VectaMount Permanent Mounting 
Medium (H-5000; Vector Laboratories).  
 
Sections were viewed with a bright field microscope and images were captured using 
the ImagePro software. All positive nuclei (stained brown) and negative cells (stained 
blue) in the intima, media and adventitia, seen via high-powered field (high power 
fields = 400X magnification) were counted automatically using a macro in ImageJ 
software. Four quadrants in four transverse sections (total of 16 counts) were 
averaged for each un-decellularised control (n=5) and decellularised (n=5) vein 
segments. The percentage of proliferation was calculated using the following formula:  
 
  
Percent of proliferation= 
 
          Positive nuclei (brown) count at day 14        
X 100% 
      




 Surgical Procedures for Porcine Implant 
Surgical implants were undertaken by a team of clinical experts lead by Professor 
Raimondo Ascione in accordance with Home Office, Clinical, and Good Laboratory 
Practice Monitoring Authority (GLP MA) standards at the Translational Biomedical 
Research Centre, University of Bristol, Bristol, UK under Project Licence Number 
30/3064 (Figure 2.3 A and B).  Large White Landrace female pigs weighing between 
55 to 65 kg were put on 75 mg aspirin daily for 1 week before surgery. After an 
overnight fast, the pigs were sedated, anaesthetised, and ventilated by standard 
clinical protocols, similar to that used in clinical practice. A venous catheter was 
inserted through an ear vein and used for continuous administration of saline and 
anaesthetic drugs. Continuous monitoring of ECG, systemic blood pressure, body 
temperature, and  peripheral saturation was performed throughout according to 
established protocols (Theisen and Grundy 1987; Snider and Vincenzoni 2001; Allain 
et al. 2005). All animals were anesthetized with an intramuscular injection of ketamine 
(20 mg/kg), which was followed by an intravenous injection of thiopentone (20 mg/kg).  
 
Anesthesia was achieved by using diazepam (1 mg/kg), fentanyl (15 μg/kg for initial 
dose and 50 μg/kg/h for maintenance), and propofol (1 mg/kg for initial dose and 6 
mg/kg/h for maintenance). Animals were placed in a supine position and an 
endotracheal tube was inserted for mechanical ventilation, which started with 10 mL/kg 
tidal volume, 15/min frequency, 100% of oxygen, and 0 mmHg of end-expiratory 
pressure. To obtain favourable arterial carbon dioxide tension (PaCO2) (35.0–45.0 mm 
Hg) and pH (7.35–7.45), tidal volume was changed before surgery. Following 
heparinisation, activated clotting time (ACT) values were maintained above 300 




Figure 2.3 Arterial Porcine Xenografting Procedure Set-up. (A) Hybrid Preclinical 
Theatre at TBRC Bristol. (B) full monitoring of vital signs during surgery; (C) healed 
surgical wound at 4 weeks post implant of acellular hSV; (D) Acellular hSV implanted 
in carotid artery position (white arrow). 
 
Following skin prepping according to clinical standards using Betadine solutions, an 
8-10 cm skin incision was made in the neck, 2.5 cm on the right lateral side to the 
midline. The right carotid artery was then exposed and isolated with vessel loops as 
shown in Figure 2.4C.   
 
Doppler ultrasound of native vessel was performed at clinical standard where colour 
doppler was used to record the systolic and diastolic blood flow velocity and the M-
Mode was used for wall compliance were recorded as shown in Figure 2.5. After a 
bolus of 100 IU/kg heparin intravenously, the carotid artery was clamped proximally 
and distally of the anastomotic sites. A 0.5 to 1 cm segment of the native carotid artery 
was then excised as control. The tissue was sectioned into three pieces, one piece 
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was placed in 10% formalin, one piece was place in 4% paraformaldehyde, and the 
last piece was snap frozen in liquid nitrogen.   
 
Figure 2.4 Surgical procedure to expose right carotid artery. (A) Anatomic 
illustration of the location of the porcine right carotid artery. (B) 8 to 10 cm neck skin 








Figure 2.5 Doppler ultrasound observation of a native vessel. (A) Colour Doppler 
was used to record the systolic and diastolic blood flow velocity and (B) M-Mode was 
used for wall and lumen observation.  
 
The decellularised hSV was sutured in place with end-to-end anastomoses performed 
with 7-0 polypropylene material (Ethicon, US) by a senior surgeon using 3.5 
magnification surgical loupes (see Figure 2.5). On completion, the vascular clamps 
were removed to permit perfusion. The patency was assessed by checking the flow 
across the graft directly as well as by checking the transmission of the pulsatile flow 
distal to the implant. In addition, doppler ultrasound scanning of the implanted graft 
was recorded similar as shown in Figure 2.5. After 30 minutes of observation the 
surgical incision was closed in layers using biodegradable clinical sutures. The skin 
was sprayed with an antiseptic spray according to the veterinary clinical practice. 





Animals were taken to the recovery room, monitored and extubated according to 
standard protocols within 30 to 60 minutes. Post-operative pain control was 
established as stated by clinical protocols. Animals were administered on 75 mg/day 
(for the first three implants) and 300 mg/day (for the latest three implants aspirin with 
food from four hours post-surgery until termination. Animals were then transferred to 
their maintenance areas, kept in groups for the following four weeks and fed standard 
porcine diet ad libitum. Daily monitoring was undertaken as per routine practice by a 
veterinary technician. After 1 month and after an overnight fast, the pigs were sedated, 
anaesthetised, and ventilated by standard clinical protocols. Under controlled and 
sterile conditions the implanted grafts were exposed and subjected to additional follow-
up vascular doppler scanning as shown in Figure 2.6. Following administration of 
5000 UI of heparin the right CA were clamped and 5 to 6 cm long segments were 
explanted, inclusive of the hSV segments. The vascular grafts were excised and 
transported to the laboratory in 50 mL facon tube fill with 40 mL of PBS. The tissue 
was sectioned into three pieces, one piece was placed in 10% formalin, one piece was 
placed in 4% PFA, and the last piece were snap frozen in liquid nitrogen. The animal 




Figure 2.6 Doppler ultrasound observation of implanted graft. (A) Colour doppler 
was used to record the systolic and diastolic blood flow velocity and (B) M-Mode was 
used for wall and lumen observation.  
 
 Peripheral whole blood collection  
Large White Landrace female pigs weighing between 55 to 65 kg were sedated, 
anaesthetised, and ventilated by standard clinical protocols, and right external jugular 
vein and carotid artery were exposed as described in section 2.15. The pig’s vein was 
punctured with 16 G needle on the Compoflex® Blood Bag for collection of whole blood 
in anticoagulant citrate phosphate dextrose adenine solution (CPDA-1) and about 500 
to 600 mL whole blood were collected from each pig (PS11150; Fresenius Kabi). Blood 
bag was then transferred to the laboratory for further processing where the whole 
blood was transferred to a 200 mL sterile media bottle and used for the bioreactor 
experiment or diluted with 2% (v/v) FBS/PBS (10500064, Life Technologies) as shown 





Figure 2.7 Pig peripheral whole blood collection and processing. (A) 200 mL of 
PWB was transferred into 250 mL sterile media bottle and were later use for bioreactor 
reseeding experiment. (B) 15 mL of PWB was diluted with 2% (v/v) FBS/PBS and were 
used to extract MNCs. (C) 5 mL of PWB was transferred into 15 mL tube and then 
later use for the roller reseeding experiment. 
 
 Mononuclear cell fraction extraction  
SepMate™ 50 tube (15460, StemCell Tech.) was prepared by adding 15 mL of density 
gradient medium, Ficoll® Paque Plus (GE17-1440-02, Sigma) to the bottom of the tube 
through the central hole in the insert. Then, 15 mL of diluted whole blood (refer to 
Figure 2.7 ii) was carefully added on the side of the SepMate™ tube that was placed 
vertically. The tubes were then subjected to centrifugation at 1200 rcf for 10 minutes 
at room temperature with the break on. The centrifugation will separate the sample 
based on density gradient which result in 3 distinct layer as shown in Figure 2.8. The 
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top layer which contains MNCs were then quickly (<2 seconds) poured into a new 
falcon tube. The plasma and MNCs collected were then used for seeding experiment.       
 
Figure 2.8 Porcine plasma and MNCs extraction and collection. Plasma and 
MNCs collected through density gradient centrifugation in SepMate™ 50 tube was 
collected in a 15 mL tube and later used in roller reseeding protocol.  
 
 Recellularisation Experiment 
A few experiments were designed to assess the feasibility of using PWB to repopulate 




 Roller Seeding Protocol 
First, a simple set-up was employed by placing the decellularised hSV in a cylindrical 
tube containing sufficient PWB or mononuclear cells (MNC) to submerge the scaffold 
and sealed with a filtered cap to allow gas exchange. The filled tubes were then placed 
on an angled roller, at 10 rpm in the incubator at 39°C, 5% CO2 for 48 hours.  
 
Figure 2.9 Decellularised vein seeding using a roller at 10 rpm in the incubator 
at 39°C, 5% CO2 for 48 hours. (A) MNCs in plasma and PWB were placed with 
decellularised hSV scaffolds in cylindrical tubes fitted with filtered cap to allow gas 
exchange (B) Close-up view of the decellularised vein in filtered cap tubes filled with 








 Bioreactor Seeding Protocol 
On the other hand, a second method utilised a bioreactor system set up in the 
incubator at 39°C, 5% CO2, where decellularised veins were mounted on a holder in 
a chamber filled with media and PWB was circulated at either low or high flow 25 or 
200 mL/minute for 48 hours. 
 
Figure 2.10 Decellularised vein seeding using a bio-reactor at 39°C, 5% CO2 for 
48 hours. (A) Bioreactor set-up to perfuse blood through decellularised veins at either 
low or high flow; 25 or 200 mL/minute respectively for 48 hours. (B) Close-up view of 
the decellularised vein mounted in the bioreactor chamber. 





 Immunostaining  
 Immunocytochemistry  
Cells, either ECs or SMCs were seeded separately in 96 well tissue culture treated 
plates (655090; Greiner Bio-One Ltd.) at a seeding density of 100 000 cell/cm2 and 
allowed to grow overnight. Cells were then washed twice with PBS and fixed using 3% 
(v/v) paraformaldehyde in PBS for 15 minutes. Cells were rinsed with 3% (v/v) BSA in 
PBS twice. Triton-X100 (concentration according to each antibody as shown in Table 
2.2) in PBS was added to wells and the plate was incubated for 10 min at room 
temperature. Wells were then washed twice with PBS before incubation with primary 
antibody according to the cell type (refer to Table 2.2) at 4°C. Wells were washed 
twice with PBS before incubation with secondary antibody for 1 hour at room 
temperature. Wells were then washed twice with PBS. Nuclei staining was performed 
with Hoechst 33342 for another 30 minutes at room temperature whilst plate was 
protected from light with aluminium foil. Wells were then washed twice with PBS and 
aqueous mounting media Fluoromount-G (00-4958-02; Life Technologies) was added 
before imaging was performed using the EVOS FL Cell Imaging System at medium-
powered field (medium power fields = 200X magnification). Five views of each well 
under the medium power field were captured and positive cells and nuclei counted 
using ImageJ software. Antibodies and dilutions used are listed in Table 2.2. 
 
 Immunohistochemistry 
Decellularised tissue re-seeded with cells was stained with different antibodies for 
different cell specific markers e.g. ECs were stained with CD31 and SMCs were 
identified with -smooth muscle actin. Additionally, tissues collected after in vivo 
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explants were also stained with cells specific marker to investigate the localisation of 
different cell types within the re-cellularised graft.   
 
Tissue samples were fixed overnight in 10% formalin and store in PBS before 
processing in the Shandon Excelsior ES Tissue Processor (Thermo Scientific, UK) 
and paraffin wax embedding using the Shandon Histocentre™ 3 Embedding Center 
(Thermo Scientific, UK). Sections of 3-5 µm were cut using a microtome and placed 
on Superfrost Plus (10149870; Fisher) microscope slides. The slides were stored at 
room temperature and incubated at 37° for 20 minutes prior to analysis. Slides were 
dewaxed and rehydrated as follows: slides were immersed in three changes of 
Clearene (3803600E; Surgipath) for 5 minutes each, and then were rehydrated in 
three changes of 100% (v/v) IMS for 5 minutes each, followed by 90%(v/v) IMS for 3 
minutes and lastly in 70% (v/v) IMS for another 3 minutes. Finally, the slides were 
placed in distilled water for 3 minutes. 
 
The slides were incubated in 10 mM citrate buffer pH 6.0 for 20 minutes in a boiling 
water bath and were then allowed to cool at room temperature before washing twice 
with PBS. The surrounding sections were wiped dry with tissue paper and sections 
were mark with a wax pen. Slides were incubated in blocking buffer (5% (v/v) BSA and 
0.1% (v/v) Triton in PBS) for 30 minutes at room temperature. Excess buffer was 
removed before incubation in primary antibody (as shown in Table 2.2) overnight at 
4°C. Slides were washed three times with PBS before incubation with secondary 
antibody (refer to Table 2.2) for 1 hour at room temperature whilst protected from light 
with aluminium foil. Slides were then washed three times with PBS and cover-slipped   
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with ProLong® Gold Antifade Mountant with DAPI (P36931; Thermo Fisher Scientific). 
Imaging was performed with a fluorescent microscope and images were captured 
using the ImagePro software at high-powered field (high power fields = 400X 
magnification) for a descriptive analysis.  
 
 Statistical Analysis  
For analysis of data in two groups statistical analysis was performed with a Student’s 
two-sample t-test, assuming equal variances. One-way analysis of variance (ANOVA) 
was used to identify significant differences between three or more groups with post 
hoc comparison. Two-sided P values less than 0.05 indicated statistical significance. 
Numeric values are presented as the mean ± SEM. Reported n represents the number 
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3 DECELLULARISATION OF HUMAN SAPHENOUS VEIN FOR USE AS A 
GRAFTING CONDUIT  
 Introduction 
Decellularisation is a method used to remove the cellular component whilst retaining 
tissue extracellular matrix (ECM). It is considered that removal of the cellular 
component reduces the likelihood of immune rejection when used in clinical 
transplantation. This technique has been applied to produce various decellularised 
tissues and organs for transplantation including skin tissue, pericardium, heart valve 
(Fu et al. 2014; Guyette et al. 2014; Crapo, Gilbert, and Badylak 2011). 
Decellularisation is of interest as has enhanced biocompatible compared to synthetic 
materials and the production is less time consuming than the synthetic alternatives. In 
simple terms, decellularisation is achieved by removing all the cells from a given tissue 
and the resultant acellular scaffold is then available for various biomedical purposes.  
A review of the literature reveals that the set of criteria accepted by the scientific 
community which defines effective decellularisation include: (i) lack of detected 
nuclear material in a decellularised tissue section when stained with haematoxylin and 
eosin (H&E), (ii) <50 ng DNA per mg dry weight of ECM and (iii) <200 bp of dsDNA 
fragment length (Crapo, Gilbert, and Badylak 2011; Rambol et al. 2018; Kargar-
Abarghouei et al. 2018; Wilson et al. 2013; Destefani, Sirtoli, and Nogueira 2017).  
 
To achieve effective decellularisation, several methods have been developed based 
on mechanical, chemical and biological approaches that are used either alone or in 
combination (e.g. mechanical-chemical, chemical-biological, mechanical-biological or 
mechanical-chemical-biological). Combination approaches have been tested since it 
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was considered that a single method approach may yield sub-optimal decellularisation 
(Crapo, Gilbert, and Badylak 2011; Azhim et al. 2011). The selection of method is also 
dictated by the type and size of tissue or organ to be decellularised. For example, 
decellularisation of a whole heart, as opposed to a piece of vein, requires a more 
robust protocol given the obvious qualitative and quantitative differences in cellular 
and structural composition. 
 
Since the ultimate aim of this project was to decellularise human saphenous vein for 
clinical application, the simplest protocol consisting of various concentrations of 
sodium dodecyl sulphate (SDS) was selected. Following treatment with SDS the 
decellularisation efficacy was evaluated by examining the residual cellular 
components. In addition, the integrity of extracellular matrix and the mechanical 
strength of the resultant scaffold was determined. Of note, SDS, otherwise known as 
sodium lauryl sulphate or sodium lauryl sulphate (SLS), is a detergent commonly used 
in personal hygiene products as well as domestic and industrial cleaning products. 
The structure of SDS structure is shown in Figure 3.1 A (Kim et al. 2016). It acts  an 
emulsifying agent because of its negatively charged functional group making it an 
anionic surfactant that acts on the plasma cell membrane thus disrupts cell structure 
and stability (Figure 3.1 B) (Seddon, Curnow, and Booth 2004). Previous studies 
report that the efficacy of decellularisation using SDS is determined by the type/or size 
of tissue targeted and the concentration used (Syed et al. 2014; Gilpin et al. 2014; 





Figure 3.1. SDS used in the decellularisation protocol. (A) The structure of SDS 
illustrating its hydrophobic and hydrophilic regions. (B) The action of SDS (detergent) 
on the plasma cell membrane enabling it to disrupt the cell phospholipid bilayer 
through forming mixed micelle.  
 
SDS is also used as a cell lysis buffer because as in addition to disrupting the plasma 
membrane structure, it also binds to and eventually denatures proteins by unfolding 
the protein 3-dimensional formation rendering them linear. Consequently, it is vital to 
optimise the exposure time and concentration of SDS on the tissue to be decellularised 
to avoid undesirable destruction of the tissue.  
 
It was hypothesised that saphenous veins could effectively be decellularised using 
SDS and that the resultant acellular matrix scaffold could be used for in vitro and/or in 
situ tissue engineering for arterialisation. The ultimate goal of this process was to 





veins. To achieve this aim, a combination of mechanical and chemical decellularisation 
as describe by Schaner and colleagues was adopted (Schaner et al. 2004). In this 
chapter, the effectiveness of the decellularisation protocol, its effect on tissue integrity 
including ECM composition, biocompatibility of resultant tissue with cells for the 
purpose of recellularisation and feasibility of in situ recellularisation as a xenograft 
implant in in vivo porcine model of carotid replacement surgery was investigated.  
 
 Results 
 Decellularisation of human Saphenous Vein (hSV)  
In brief, the decellularisation protocol included a 24-hour incubation of hSV in SDS at 
room temperature, followed by washing twice with PBS for 24 hours with PBS (as 
illustrated in Figure 3.2).   
Figure 3.2 Decellularisation protocol. Decellularisation of hSV were done with 
different SDS concentration for 24 hours followed by two PBS washes every 24 hours 
for 48 hours on a roller at 60 rpm in room temperature.  
 
Tissue to be 
analysed 




Wash 1 with 
PBS




 Effectiveness of decellularisation protocol  
The effectiveness of the decellularisation protocol is conventionally determined 
through the evaluation of cell numbers (most commonly by quantification of nuclei) 
remaining in the ECM scaffold following decellularisation (Crapo, Gilbert, and Badylak 
2011). Therefore, the number of nuclei remaining on the ECM was quantified using 
H&E staining. It was demonstrated that incubation in 0.05% (w/v) SDS resulted in 
almost complete elimination of nuclei (95 ± 12%) whereas no nuclei were observed in 
the vein segments treated with 0.075 and 0.1% (w/v) SDS (100 ± 0.01% and 100 ± 
0.16%, respectively). Of note, 0.01 - 0.025% (w/v) SDS achieved lower 
decellularisation (65 ± 8%) than 0.1% (w/v) SDS (69 ± 9%) despite a significant 
reduction in the number of` nuclei compared to the control vein segments (Figure 3.3 
A).  
 
A visual comparison of the SDS-treated tissue was made with two commercially 
available decellularised grafts including CorMatrix® ECM® for vascular repair and No-
React® Porcine Pericardial Patch. Nuclei in 0.01% (w/v) SDS revealed faded as 
compared to the native hSV that act as a control (Figure 3.3 B: shown by arrow). 
The commercially available grafts contained noticeably more nuclei than that of dhSV 
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Native hSV 





Figure 3.3 Efficiency of the decellularisation protocol with various SDS 
concentrations. Decellularisation protocol optimisation using 0.01, 0.025, 0.05, 0.075 
and 0.1% SDS (w/v) compared to native control hSV. (A) Percentage of 
decellularisation was calculated by quantifying the nuclei (purple-black) in H&E stained 
paraffin wax embedded sections of decellularised compared to native veins. Values 
are presented as mean ± SEM, 1-way ANOVA, Dunnett's multiple comparisons test, * 
indicates p<0.001, n=6. (B) Representative images of decellularised and native veins 
stained with H&E. (C) Commercially available grafts; CorMatrix® ECM® for vascular 
repair and No-React® Porcine Pericardial Patch stained with H&E. Collagen and 
muscle are pink, cytoplasm is purple-red and nuclei are purple-black. Scale bars 
represent 300 µm and 200 µm for 100X and 200X magnifications respectively. Arrows 
indicate some of the detected nuclei (purple-black).  
CorMatrix® ECM® (C) No-React® Porcine Pericardial 
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The H&E staining showed that although a low number of nuclei are detectable after 
SDS treatment, qualitative observation shows the decellularisation protocol achieved 
better decellularisation compared to commercial biological patches. Indeed, the H&E 
staining showed that the lowest concentration of SDS used (0.01% (w/v) significantly 
reduced the number of detectable nuclei compared to the native vein. The PicoGreen 
assay, which quantifies dsDNA was also utilised to assess decellularisation efficiency. 
The results showed that there was no significant reduction of dsDNA in all 
decellularised hSV. Therefore, indicated that the decellularisation protocol does not 
eliminate dsDNA (Figure 3.4 A). 
 
DNA samples extracted from native and 0.01% (w/v) SDS decellularised hSV samples 
were subjected to gel electrophoresis, to ascertain the size of dsDNA in the tissues 
after decellularisation protocol. The size of the dsDNA detected in both native hSV 
and 0.01% (w/v) SDS decellularised hSV was >1000 bp but it was noted that 
dramatically lower amounts of dsDNA were detectable in the decellularised hSV 
compared to native hSV. Contrasting to the PicoGreen analysis, which may be due to 
the fact that PicoGreen could detect smaller DNA fragments that could not be detected 





Figure 3.4 Effect of SDS treatment on DNA content. (A) PicoGreen assay to 
quantify dsDNA on each group of decellularised and native tissues. Values are 
presented as mean ± SEM, 1-way ANOVA, Dunnett's multiple comparisons test, n=6. 
(B) Representative gel electrophoresis image of native hSV (Native) and 0.01% (w/v) 
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To determine whether viable cells remained in the treated vein segments, BrdU 
incorporation within organ cultures of treated and untreated veins was quantified. BrdU 
incorporation indicative of proliferation was observed in 81 ± 4% cells within native 
hSV organ culture. In contrast, BrdU incorporation and thereby proliferation was not 
detected in decellularised hSV. This confirmed that cell proliferation did not occur 
within decellularised veins, hence confirming viable cells did not remain after the 


















Figure 3.5 Detection of proliferating cells in organ cultures. (A) The percentage 
of proliferating cells was calculated by quantifying the number of nuclei with BrdU 
incorporation (brown) using peroxidase-based immunohistochemical BrdU-detection 
within native hSV and 0.01% (w/v) SDS decellularised hSV. Values are presented as 
mean ± SEM, * indicates p<0.0001, paired t-test, two-tailed, n=5. (B) Representative 
images of native hSV and 0.01% (w/v) SDS decellularised hSV sections subjected to 
immunohistochemistry for BrdU at 200X magnification. Scale bar represent 20 µm and 
applies to both panels.  Arrows indicate some of the positive cells. 
















N a t iv e  h S V 0 .0 1 %  S D S  (w /v )  










 Effect of decellularisation protocol on hSV ECM structural integrity  
The structural integrity of the decellularised vein segments is of key importance in 
terms of safety aspects for future transplantation of these decellularised scaffolds into 
the arterial circulation in a large animal preclinical model resembling human arterial 
size and anatomy. In addition to confirmation of decellularisation, demonstration of 
structural integrity is critical before implanting as a graft or attempting to reseed the 
decellularised vascular scaffolds with arterial cells. Hence, to confirm integrity the main 
structural components of the ECM including collagen, elastin and GAGs content within 
the decellularised vein segments were examined and compared with native vein.  
 
To assess ECM content picrosirius red (PSR), elastin van Geison (EVG) and alcian 
blue staining were first performed to quantify the percentage of vein composed of 
collagen, elastin and GAGs, respectively. As histological staining is only 
representative of 3 µm section of the whole tissue, specific protein assays for collagen, 
elastin and GAGs and normalised with total protein content were also performed using 
paraffin embedded segments. Both approaches yielded similar results (Figure 3.6 to 
3.8 A and B). Using histological staining and colour pixel quantification it was 
determined that over 60% of the vein section was composed of collagen. Treatment 
with SDS at any concentration did not significantly reduced the amount of collagen 
(Figure 3.6A and C). Hydroxyproline assay of native hSV shows it is consisting of 0.8 
ng/µg collagen. Using the same assay, collagen content however was significantly 
reduced by 40% in vein segments treated with 0.05, 0.075 and to 0.1% (w/v) SDS, 
than native vein (Figure 3.6B). Native hSV were observed to be composed of 30% 
elastin from quantification using colour pixel histological staining. No significant 
difference in elastin content of decellularised hSV as compared to native with a  
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variable outcome was also observed (Figure 3.7A and C). Whereas almost 80% of 
native hSV were of GAGs. The decellularisation protocol doesn’t seems to affect the 
GAGs content in decellularised hSV (Figure 3.8A and C). Due to the variability of the 
colour pixel quantification, Elastin and GAGs content in the tissues was further 
detected using Fastin Elastin™ and Blyscan™ assay. Native hSV showed they are 
consisting of 8 ng/µg and 1.7 ng/µg of elastin and GAGs, respectively. The same 
assays were done with decellularised tissue and shows that the SDS doesn’t affect 
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0.05% SDS (w/v) 0.025% SDS (w/v) 




Figure 3.6 Collagen content after decellularisation. (A) The percentage of collagen 
was determined by counting the red pixels within the PSR stained decellularised and 
native vein segments. Values are presented as mean ± SEM, 1-way ANOVA, 
Dunnett's multiple comparisons test, n=6. (B) Quantification of collagen content using 
the hydroxyproline assay. Values are presented as mean ± SEM, * indicates p<0.05, 
1-way ANOVA, Dunnett's multiple comparisons test, n=6. (C) Representative images 
for each group of decellularised and native tissues at 100X magnification. Collagen is 
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Figure 3.7 Elastin content after decellularisation. (A) The percentage of elastin 
was determined by counting the purple/black pixels within the EVG stained 
decellularised and native vein segments. Values are presented as mean ± SEM, 1-
way ANOVA, Dunnett's multiple comparisons test, n=6. (B) Quantification of elastin 
content using the Fastin Elastin™ assay. Values are presented as mean ± SEM, * 
indicates p<0.05, 1-way ANOVA, Dunnett's multiple comparisons test, n=6. (C) 
Representative images for each group of decellularised and native tissues at 100X 
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Figure 3.8 GAGs content after decellularisation. (A) The percentage of GAGs was 
determined by counting the purple-blue pixels within the EVG stained decellularised 
and native vein segments. Values are presented as mean ± SEM, 1-way ANOVA, 
Dunnett's multiple comparisons test, n=6. (B) Quantification of GAGs content using 
the Blyscan™ assay. Values are presented as mean ± SEM, * indicates p<0.05, 1-
way ANOVA, Dunnett's multiple comparisons test, n=6. (C) Representative images for 
each group of decellularised and native tissues at 100X magnification. GAGs are 
stained purple-blue, nuclei are stained red and cytoplasms are stained pink. Scale bar 
represent 300µm.  
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 Effect of Decellularisation Protocol on hSV ECM Mechanical Properties  
Mechanical properties of the decellularised graft was taken into consideration hence 
samples were sent to Amrita Centre for Nanoscience, India for an ISO accredited 
testing; n=5 control human saphenous veins, decellularised saphenous veins and 
porcine carotid arteries where burst strength and compliance test were done. No 
significant differences were observed on both burst strength and compliance of human 
saphenous veins, decellularised saphenous veins and porcine carotid arteries 
therefore the decellularised hSV were deemed suitable for porcine model carotid 
artery implantation.  
 
 
Figure 3.9 Grafts burst strength (kPa). Native hSV, 0.01% SDS w/v decellularised 
hSV and pCA segments burst strength comparison. Values are presented as mean ± 


























Figure 3.10 Grafts compliance test (%/mmHg). Native hSV, 0.01%SDS w/v 
decellularised hSV and pCA segments burst strength comparison. Values are 
presented as mean ± SEM, 1-way ANOVA, Tukey's multiple comparisons test, n=5. 
 
 Biocompatibility of decellularised tissue  
As one goal is to reseed the decellularised vein scaffolds with arterial cells either in 
vitro, ex vivo or in vivo, the scaffold must facilitate adhesion and viability of seeded 
cells. Thus, confirmation of biocompatibility of the decellularised veins is an important.  
SDS as an anionic detergent, is cytotoxic to cells, with the potential to disrupt the 
plasma cell membrane. Therefore, methylene blue assay was performed on the 
effluent from the PBS washes and the decellularised vein to analyse whether the SDS 
washing-out protocol was effective in removing SDS from the tissue.  
 
It was observed that the first washing step significantly reduced SDS content by 10 





























steps significantly reduced the SDS concentration in the effluent a further 100 fold. 
The SDS content within the vein tissue showed that further washes did extract all SDS 
and the remaining concentration of SDS was 0.002% (w/v) SDS.   
 
 
Figure 3.11 Effectiveness of the removal of SDS in the decellularisation protocol. 
The concentration of SDS in the effluent after each wash step and in the hSV tissue 
after treatment with 0.01% (w/v) SDS was quantified using methylene blue that detects 
SDS. Values are presented as mean ± SEM, * indicates p<0.05 vs. wash 1, wash 2 
and tissue, and # and $ indicates p<0.05 vs. wash 1 and wash 2, respectively, 
Repeated measure 1-way ANOVA, Tukey's multiple comparisons test, n=6. 
 
To assess biocompatibility, hSV segments were treated with 0.01% (w/v) SDS, as this 
concentration significantly reduced the number of nuclei and had the least effect on 
ECM integrity and collagen content as described above (see 3.2.2 and 3.2.3). 
123 
 
Following washing with PBS twice described above, the hSV scaffolds were seeded 
with ADSCs, HUVECs and hSV SMCs. The cell number was quantified with the 
AlamarBlue® assay at 24 and 72 hours after seeding. A total of 5,000 cells was seeded 
in every well. With all three cell types less than 4,000 adherent and viable cells were 
detected after 24 hours incubation, illustrating the decellularised scaffold provided a 
suitable surface for the seeded cells. Interestingly, the number hSV SMCs almost 
doubled between 24 and 72 hours post seeding suggesting good biocompatibility of 
the decellularised hSV scaffold for this cell type (Figure 3.12). In contrast, the number 
of HUVECs and ADSCs did not significantly increase between 24 and 72 hours. 
 
 
Figure 3.12 Assessment of biocompatibility using the cell viability assay. 0.01% 
(w/v) SDS decellularised vein segments were seeded with ADSCs, hUVECs and hSV 
SMCs and cultured for 24 and 72 hours. The cell number was estimated with the 
Alamar Blue assay. Values are presented as mean ± SEM, * indicates p<0.05, 
Repeated measure 2-way ANOVA, Bonferroni’s multiple comparisons test, n=6. 
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 Implantation of decellularised human saphenous veins as a xenograft in 
a porcine model 
With confirmation of in vitro biocompatibility and integrity, to the next aim was to 
confirm mechanical strength and examine recellularisation in vivo. Decellularised hSV 
was implanted as a xenograft into a porcine model of carotid artery replacement at 
clinical standards.  The aim was to induce in situ re-cellularisation of the decellularised 
hSV scaffolds by host cells and assess at 4 weeks after implantation with a focus on 
patency rate, thrombogenesis, suturability, flow dynamics, wall thickness, structural 
and cellular content.  
 
The result of this first wave of pilot in vivo implants showed excellent feasibility of 
suturing all of the hSV at surgery. In addition, there was excellent suturability (passing 
through of the fine 7-0 prolene stitches and no oozing or bleeding from the suture line 
following arterial reperfusion with systemic arterial pressure maintained at normal 
physiological standards). In addition, there was excellent transmission of arterial pulse 
across the decellularised hSV when assessed by finger palpation in all three arterial 
implants with confirmation of patency at 30 minutes post reperfusion. Also, there was 
no obvious mismatch in lumen diameter and wall thickness between decellularised 
hSV and pCA pre-implantation. Similar observation was done right before extraction 
of decellularised hSV graft. Pulsatility of the graft pre-explantation were observed in 
the first 2 explant and the rhythm were observed dampen down in the last graft. High 
pressure blood flow through the graft in the first graft but not the latter two. The lumen 
diameter of the patent graft in the pCA appeared expanded outward and dilated 
reaching almost twice the lumen diameter of the native pCA with no apparent wall 
thickness differences. Macroscopic observation of the second explant shows 
125 
 
expansion of the lumen similar to the first explant but the graft was occluded. Further 
staining of the post-implant pCA proximal to the graft shows the formation of 
atherosclerosis plaque. Whilst in the third graft, the formation of thrombus was 
detected in the lumen of the pCA proximal to the graft (Figure 3.13).  
 
Post-implantation, the collagen content of the hSV graft was not significantly different 
to the decellularised vein prior to implantation or pre- and post-implant pCA (Figure 
3.14 A). Collagens were observed to be in evenly distributed layers in the vascular 
wall in all pre-implant tissue and post-implant pCA. Interestingly, all hSV graft explant 
shows more irregular distribution of collagen with most of them concentrated in the 
adventitia layers (Figure 3.14 B). Similar observation was noted with elastin content 
as that of collagen content (Figure 3.15). The GAG content of pCA and hSV was 
similar pre-implantation and at explant, but a significantly increased amount of GAGs 
was detected when comparing post-explant pCA levels compared to pre-implant hSV 
(Figure 3.16).  
 
Marked in situ repopulation by host cells was apparent within the hSV when explanted 
from the CA position. Identification of the different cell types repopulating the 
decellularised veins was attempted through immunostaining for proteins that are well 
recognised as specific cell type markers (SMCs: αSMA and SM-MHC, ECs: DBA, 
CD31 and eNOS, macrophage/monocytes: CD203 and fibroblasts: vimentin). 
Sections of the native pCA removed at implantation of the decellularised hSV and 
sections of the pre-implant decellularised hSV were also subjected to immunostaining 
for these markers.   
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Figure 3.13 Structural characteristics of pCA and decellularised vein pre- and post-implant. (A) Lumen diameter pre- and post-
implant of pCA and 0.01% (w/v) SDS decellularised hSV. Values are presented as mean ± SEM, Repeated measure 2-way ANOVA, 
Sidak's multiple comparisons test, n=3. (B) Wall thickness pre- and post-implant of pCA and 0.01% (w/v) SDS decellularised hSV. 
Values are presented as mean ± SEM, Repeated measure 2-way ANOVA, Sidak's multiple comparisons test, n=3. (C) H&E images 
for pre- and post-implant of pCA and 0.01% (w/v) SDS decellularised hSV. Collagen and muscle are stained pink, cytoplasm is 



















Figure 3.14 Collagen content of pCA and decellularised vein pre- and post-implant. (A) Quantification of collagen content within 
pre- and post-implant of pCA and 0.01% (w/v) SDS decellularised hSV using hydroxyproline assay. Values are presented as mean 
± SEM, Repeated measure 2-way ANOVA, Sidak's multiple comparisons test, n=3. (B) PSR images for pre- and post-implant of pCA 
and 0.01% (w/v) SDS decellularised hSV where collagen is red on a pale-yellow background at 200X magnification. ;  and  


































































































































Figure 3.15 Elastin content of pCA and decellularised vein pre- and post-implant. (A) Quantification of elastin content within 
pre- and post-implant of pCA and 0.01% (w/v) SDS decellularised hSV using Fastin Elastin™ assay. Values are presented as mean 
± SEM, Repeated measure 2-way ANOVA, Sidak's multiple comparisons test, n=3. (B) EVG images for pre- and post-implant of pCA 
and 0.01% (w/v) SDS decellularised hSV where elastic fibres are stained purple-black, collagen is red and other tissue elements are 






























































































































Figure 3.16 GAGs content of pCA and decellularised vein pre- and post-implant. (A) Quantification of GAGs content within pre- 
and post-implant of pCA and 0.01% (w/v) SDS decellularised hSV using Blyscan™ assay. Values are presented as mean ± SEM, 
Repeated measure 2-way ANOVA, Sidak's multiple comparisons test, n=3. (B) GAGs images for pre- and post-implant of pCA and 
0.01% (w/v) SDS decellularised hSV where GAGs are stained purple-blue, nuclei are stained red and cytoplasm are stained pink at 



















































































































Initial dual immunostaining of all hSV explant resulted in the detection on 
neovascularisation in all hSV graft positively stained with both DBA and αSMA 
localised in the adventitial later of the grafts (Figure 3.17). DBA was initially used due 
to limited established porcine antibodies. The immunostaining was then followed with 
other antibodies that has reacts with porcine antigens was established and optimised 
e.g. αSMA, SM-MHC, CD31, eNOS, CD203 and vimentin. Isotype control for each 
antibody showed that the antibodies are specific as all the IgG control used shown 
negative staining (Figure 3.18-3.20A). Porcine CA was used as a positive control 
tissue and decellularised hSV pre-implant was used as a comparison.  
 
Interestingly, αSMA was detected in the decellularised tissue but not CD31 (Figure 
3.18A). ECs layers on the patent graft luminal surface from the first explant were 
observed but not as brightly stained as DBA. CD31 were also detected to be less as 
compared to DBA. Adventitial neovascularisation was also confirmed with CD31 
staining (Figure 3.18B). Vimentin which is a fibroblast marker was detected in pCA 
but not in decellularised hSV (Figure 3.19A). Vimentin was also detected in the patent 
graft but not in the occluded grafts. On the other hand, eNOS was observed within the 
wall and not on the lumen (Figure 3.19B). SM MHC reconfirmed αSMA observation 
where the decellularised hSV was stained positive. Pig spleen was used as a positive 
control for CD203 which is a macrophage/monocyte marker (Figure 3.20A). CD203 
and SM MHC were detected in all grafts wall and especially in and around the 
















Figure 3.17 Xenograft immunohistochemistry screening staining. Representative 
images of dual immunostaining on 3-micron slices of xenograft explants stained with 
both DBA and αSMA to identify cells in the explants with H&E stained explants ring to 
show localisation. All tissues were nuclear stained with DAPI (blue), αSMA (red) and 
DBA (green) at 400X magnification. White arrow shows neovascularisation. Scale bar 
represent 80 µm and 3 mm for IHC and H&E images; respectively. 
  
Pig 1 DBA αSMA Dapi DBA αSMA Dapi 
Pig 2 DBA αSMA Dapi DBA αSMA Dapi 
















Figure 3.18 Immunostaining for cell type markers: CD31 and αSMA. (A) Control 
tissue; pre-implant pCA and 0.01% (w/v) SDS decellularised hSV stained with EC and 
SMC marker; CD31 and αSMA respectively with rabbit IgG as antibody negative 
control. (B) Representative images of dual immunostaining on 3-micron slices of 
xenograft explants stained with both CD31 and αSMA to identify cells in the explants. 
All tissues were nuclear stained with DAPI (blue), αSMA (red) and CD31 (green) at 
200X magnification. White arrow shows neovascularisation and green arrow head 
shows CD31 positive cells on the lumen. Dotted lines indicate lumen surface. Scale 
bar represent 200 µm. 
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Figure 3.19 Immunostaining for cell type markers: vimentin and eNOS. (A) 
Control tissue; pre-implant pCA and 0.01% (w/v) SDS decellularised hSV stained with 
EC and fibroblast marker; eNOS and Vimentin respectively with mouse IgG as 
antibody negative control. (B) Representative images of dual immunostaining on 3-
micron slices of xenograft explants stained with both eNOS and Vimentin to identify 
cells in the explants. All tissues were nuclear stained with DAPI (blue), eNOS (red) 
and Vimentin (green) at 200X magnification. Dotted lines indicate lumen surface. 






































































































Figure 3.20 Immunostaining for cell type markers. (A) Control tissue; porcine 
spleen, pre-implant pCA and 0.01% (w/v) SDS decellularised hSV stained with 
macrophage/monocyte and SMC marker; CD203 and SM MHC respectively with no 
primary antibody as negative control. (B) Representative images of dual 
immunostaining on 3-micron slices of xenograft explants stained with both CD203 and 
SM MHC to identify cells in the explants. All tissues were nuclear stained with DAPI 
(blue), CD203 (red) and SM MHC (green) at 200X magnification. White arrow shows 
neovascularisation and red arrow head shows CD203 positive cells in neovessels. 
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Grafting of autologous saphenous veins (SV) onto blocked coronary arteries has been 
widely utilised since its inception in 1962 by Sabiston et al. (Kakos et al. 1972; Endo 
2000). Saphenous veins (SVs) are a common conduit for CABG in patients with 
coronary atherosclerosis and for peripheral vascular grafting in patients with ischemic 
limbs. Unfortunately, following CABG the patency rate of SVs is reported be only about 
50% at 10 years after implantation, as compared to 95% of internal mammary artery 
(IMA) (de Vries et al. 2016; Taggart 2013). The patency rate of SV grafts used for 
peripheral vascular disease is even lower, with the rate of occlusion being >50% at 2 
to 4 years post-surgery.  
 
This project was undertaken to test the hypothesis that decellularised hSV is a suitable 
scaffold for arterial grafting. The properties of the venous graft are not ideal for arterial 
blood flow dynamics and this likely contributes to early vein graft thrombosis (15-20% 
at 1 year) and later on to reduced SV patency as a result of late vein graft failure. 
Hence, decellularisation of SV was undertaken (with future arterialisation in mind) 
using a simple protocol that combine both chemical (SDS) and mechanical (agitation) 
method. The effects of this protocol on the SV cellularisation and composition were 
analysed, along with its patency following arterial grafting in a porcine model.  
 
The optimal SDS concentration used in the decellularising protocol was established 
using segments of human SV left over from CABG surgery. These segments were 
taken to the laboratory where they were decellularised using different concentrations 
of SDS. Almost 65% of decellularisation was achieved with 0.01% (w/v) SDS. This 
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was considerably higher than previously reported by Schaner et al. who reported that 
0.01% SDS achieved only 32% decellularisation with hSV (Schaner et al. 2004).  
 
The effectiveness of the decellularisation protocol was further analysed by quantifying 
the dsDNA content in decellularised hSV as compared to native hSV. This results of 
the PicoGreen assay demonstrated that the amount of dsDNA was not reduced by 
SDS treatment. However, agarose gel electrophoresis showed that the majority of the 
high molecular weight DNA was lost by treatment with 0.01% (w/v) SDS. Presumably 
the dsDNA was fragmented by the SDS and remained in the vein as small fragments 
of <50 bp. Others have reported that almost 90% of DNA was eliminated using SDS 
to decellularise porcine myocardium, porcine heart valve, porcine small intestine 
submucosa and porcine and human lung (O'Neill et al. 2013; Zhou et al. 2010; Syed 
et al. 2014). However, these studies used higher concentrations of SDS ranging from 
0.1 to 1 % (w/v) SDS. To demonstrate that all venous cells were killed by the SDS 
treatment and illustrate that the residual dsDNA was not contained within viable human 
venous cells, cell proliferation was examined. Organ cultures of native and 
decellularised hSV were performed. These confirmed that proliferation did not occur 
in the decellularised hSV.  Thus confirmed that the protocol used produced a hSV 
scaffold without viable cells despite remnants of DNA which is predominantly low 
molecular weight. 
 
In terms of ECM integrity following decellularisation, Schaner et al. showed that 
treatment with 0.075% (w/v) SDS did not significantly affect the amount of collagen in 
decellularised hSV, but elastin content was significantly decreased (Schaner et al. 
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2004). In this previous study, the ECM content was quantified in sections stained by 
EVG and the percentage area occupied by both collagen and elastin calculated. This 
approach gave a significantly lower collagen content as the collagen area overlapping 
elastin were excluded thus underestimating the collagen content as reported by 
Masugi et. al  (Masugi et al. 2018). In this chapter, collagen and elastin content in 
decellularised hSV was quantified via PSR and EVG, respectively. This showed similar 
results to those reported by Schaner and colleagues in terms of collagen despite using 
a different approach. However, the findings presented in this chapter clearly 
demonstrate that the content of elastin was not affected by any of the SDS 
concentrations tested (0.01-0.1% w/v SDS), hence confirming better preservation of 
hSV ECM integrity compared to the previously published study.  
 
The discrepancies in terms of decellularisation effectiveness and protein quantification 
between the findings in this chapter and the published data from Schaner and co-
workers may be due to differences in the decellularisation protocol used. 
Decellularisation was performed using 0.075% (w/v) SDS in a shaking water bath at 
37°C for 15 hours by Schaner et al., while in this study decellularising was performed 
using 0.01% (w/v) SDS at room temperature (~27°C) for 24 hours in SDS on a roller 
followed by two PBS washes. The lower concentration of SDS and the less extreme 
treatment of the vein may be responsible for the observed results of improved 
preservation of ECM integrity in terms of protein content. Additionally, GAGs content 
was also analysed via AB staining. No significant effects on GAG content was detected 




In addition to the histological staining analysis, assays for specific ECM proteins were 
undertaken. The aim was to confirm our findings with multiple approaches since in 
published articles various groups uses different types of assays and quantification (de 
Castro Bras et al. 2013; Crapo, Gilbert, and Badylak 2011; Gilpin and Yang 2017; 
Guyette et al. 2014; Lin et al. 2018). Moreover, using these differing approaches the 
findings varied and with some contradicting others as reviewed by Bruyneel and Carr 
(Bruyneel and Carr 2017). The collagen assay using larger tissue segments revealed 
that collagen content was significantly decreased with 0.05, 0.075 and 0.1% (w/v) 
SDS, whereas elastin and GAGs content were not affected. Specific protein assays 
were considered to give a more accurate estimation of the ECM proteins after 
decellularisation as compared to using simple staining methods. The simple staining 
methods provide a snap-shot of single 5 µm tissue slices whereas for the specific 
assays, ~100 µm slices were used hence lowering potential measurement error.  
 
Moving on to mechanical properties of a vascular graft, two most important criteria are 
the burst strength and circumferential compliance. These test is an important indicator 
of a graft suitability before proceeding with ex vivo (bioreactor) or in vivo model. Normal 
arterial blood pressure at systolic are between 90-140 mmHg and at diastolic at 60-90 
mmHg. This test is done at a lower pressure of 110 mmHg the highest pressure of 150 
mmHg where the internal radius at the specified pressure. Literature search shows 
that the compliance of saphenous veins is higher than that of internal mammary artery 
(IMA). Therefore, the low percentage of compliance recorded by decellularised veins 
could be negligible as long as it is near to the compliance of IMAs.   
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Table 3.3 Mechanical properties of internal mammary artery graft and 
saphenous vein graft used in CABG as compared to decellularised veins.  
*IMA and SV data obtained from (Pashneh-Tala, MacNeil, and Claeyssens 2015). 
The mechanical testing results was compared to a review data paper by Pasneh-Tala 
et al. (Table 3.1), shows that the results obtained are closer to that of an IMA burst 
strength and compliance. Therefore, proves that the decellularised veins mechanical 
properties are suitable to be used as a graft ex vivo and in vivo. 
 
Given the toxicity of SDS, it was important to determine the efficiency of removal of 
SDS from the hSV scaffold following the decellularisation protocol. The SDS content 
in the effluents after each PBS wash and in the tissue at the end of decellularisation 
protocol was quantified, as previously described (Zvarova et al. 2016; Mathapati et al. 
2010). The first PBS wash was deemed to be efficient in removing the SDS as the 
second wash did not eliminate any additional amount of SDS from the tissue. The 
amount of SDS detected in the tissue after the washing steps was very low (0.002%). 
The biocompatibility of the decellularised hSV scaffold was directly examined by 
seeding different cell types (ADSCs, hUVECs and hSV SMCs) on to the scaffold and 
their viability in terms of proliferative capacity was assessed. It was observed that 
adherent cells were detected with all three cell types at 24 hours and importantly viable 
cells were still detected 72 hours after seeding. The cell type with the lowest number 
of adhered cells 24 hours after seeding was ADSCs. Interestingly, only with hSV SMCs 
Mechanical Properties *IMA *SV 
Decellularised 
SV 
Burst pressure (kPa) 410 285 436 
Compliance (%/100 mmHg) 11.5 25.6 8.23 
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there was a significant increase in cell numbers detected between 24 and 72 hours. 
This highlights the suitability of these scaffolds for the adherence of various cell types 
and also illustrates that these scaffolds facilitate proliferation of hSV SMCs. As 
vascular ECs are a unique type of cells that are highly sensitive to contact inhibition. 
Therefore, the reseeding outcome was expected as hUVEC will exit cell cycle and do 
not grow and proliferate once they come into contact with each other and fully covered 
the surface area in a monolayer (Suzuki et al. 2000; Olyslaegers et al. 2013; 
Lampugnani and Dejana 1997; D'Amore 1992).   
 
The results to this point demonstrate that treatment with 0.01% (w/v) SDS yields a 
hSV scaffold that is devoid of viable cells and in which DNA is fragmented but without 
a significant impact on ECM integrity. Therefore, it was considered appropriate to test 
the feasibility of the decellularised vein as a xenograft in a porcine arterial grafting 
model. This was achieved through bilateral (arterial and venous) implantation of 
decellularised hSV from two different individual into three different pigs. All implants 
showed no lumen mismatched between native pCA and decellularised hSV, with 
excellent surgical feasibility and suturability, and without rupture or anastomotic 
pseudo-aneurysm.  
 
The first arterial implant was patent at four weeks, however, there was 
expansion/dilation of the graft to almost twice the original lumen size, resembling an 
aneurysm formation. Vein to artery allograft implantation has been previously reported 
in a canine model. It was demonstrated that graft patency was 100% after two weeks 
with no graft dilation, rupture or anastomotic false aneurysm (Schaner et al. 2004). 
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After the first implant showed a patent but dilated graft, the next two implants were 
performed with decellularised hSV from the same individual grafted into two different 
animals. After four weeks both implants were occluded. The evaluation of structural 
differences between decellularised hSV and pCA pre- and post-implantation showed 
no apparent differences in terms of collagen, elastin and GAGs content. However, this 
preliminary result need future validation due to the low number of implants performed 
in this study.  
 
The cells repopulating the grafts were also analysed by staining for specific EC and 
SMC proteins that cross react with both human and pig tissue. All of the decellularised 
grafts showed considerable infiltration of host cells. Martin et. al, reported a very 
relevant study where they implanted autograft, allograft and decellularised vein in 
canine model and shows that better outcome of decellularised allograft than allograft. 
Their vein to artery allograft also shows no endothelialisation at eight weeks post 
implantation (Martin et al. 2005). The first implant was patent; endothelial cells were 
observed on the luminal surface when assessed with CD31 antibody although less 
apparent than DBA staining. CD31 and eNOS were detected in the wall of two latter 
occluded explant grafts and inside the neovessels lumen area similar to where CD203, 
a macrophage marker was observed. As both CD31 and eNOS markers also play a 
role in inflammatory mechanism the observation was not unusual as macrophages 
also express eNOS and CD31 (Woodfin, Voisin, and Nourshargh 2007; Privratsky, 
Newman, and Newman 2010; Cirino, Fiorucci, and Sessa 2003; Kim et al. 2009; 
Connelly et al. 2003). When the explant was stained with DBA, a distinct staining was 
observed on the luminal surface of the patent graft. This demonstrates regeneration 
of new endothelium from the host cells as DBA is a glycoprotein exclusively used for 
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the identification of endothelial cells of porcine origin (Darr et al. 1990; Zhang, Smith, 
and Charnock-Jones 2002; Scruggs et al. 2015; Loesch et al. 1997).  DBA also 
identified the presence of angiogenesis in all explanted grafts. The role of this 
glycoprotein is perceived crucial in the expression of adhesion molecules on 
endothelial cells as discussed by Scott and Patel (Scott and Patel 2013).  
 
αSMA and SM MHC proteins were more abundant in the second and third implant and 
less obvious in the first graft which was patent. It is important to note that these SMC 
markers detected cell remnants within the decellularised hSV prior to implantation so 
it is possible that some of the protein detected in the graft at four weeks may be of 
human origin rather than due to re-population of the scaffold. It is possible that the 
human cell remnants may promote cell infiltration via immune response and 
encourage re-population (Sanders et al. 2017). ECM from biological materials that are 
used in tissue engineering have been reported to cause an innate and acquired 
immune response by the host (Allman et al. 2002; Allman et al. 2001; Keane et al. 
2012; Daly et al. 2012). The overall mechanism of the host response to any implanted 
biological materials includes but is not just limited to T-lymphocytes and macrophages 
(Badylak and Gilbert 2008). The balance between inflammation due to immune 
response and tissue remodelling need to be achieved in order to ensure a successful 
in vivo xenograft implantation.  
 
The last two explants were occluded and showed thrombus formation which resulted 
in total occlusion of the xenograft. Therefore, our use of anti-thrombotic agent post-
surgery was reviewed. All the animals received 75 mg aspirin pre and post-operative 
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procedures with food, which is the recommended human dose by the American 
College of Cardiology/American Heart Association (ACC/AHA) (Pearson et al. 2002).  
This is due to the cardio protective benefit of aspirin to inhibit COX-1 enzymes.  which 
promotes platelet aggregation and vasoconstriction through the inhibition of 
prostaglandins and thromboxane A2 (Goldman et al. 1988; Schror 1997; Warner, 
Nylander, and Whatling 2011).   However, pigs have a higher metabolic rate compared 
to humans, hence a higher dose of aspirin may be necessary to achieve a clinically 
meaningful platelet inhibition. As such, it was concluded that for future preclinical 





To summarise, this chapter presents results of decellularisation optimisation showing 
that with as low as 0.01% (w/v) SDS it is possible to decellularised up to 65% of hSV 
without any remaining viable cells or any effect on the ECM proteins. However, it was 
noted that although DNA was fragmented the DNA content was not significantly 
reduced and SMC proteins remained in the scaffold. Importantly, the resultant 
decellularised hSV contained only low levels of SDS and was biocompatible with 
different cell types. In addition, one out of three hSV scaffolds implanted as a xenograft 
in an arterial porcine drafting model in vivo was patent at four weeks and was positive 
for a marker of luminal endothelial coverage. Unfortunately, two arterial implants were 
occluded at the same time point, suggesting a refinement of methods as well as anti-
platelet drug regimen may be needed. While these results are interesting and confirm 
the feasibility of this approach, they also suggest the need for further refinements 






4 SEEDING OF HSV SCAFFOLDS WITH CELLS FROM PORCINE CAROTID 
ARTERY AND PERIPHERAL WHOLE BLOOD (PWB)  
 Introduction 
The implantation experiments described in the previous chapter revealed that the 
decellularised hSV was not suitable as a conduit. Consequently, it was considered 
whether seeding with appropriate cell types would result in improved grafting 
outcomes. Suitable possible cell sources from the literature were considered. There 
are a number of different options such as stem cells from either embryonic, 
mesenchymal or hematopoietic origin and induced pluripotent stem cells (iPCs) 
(Adamo and Garcia-Cardena 2012; Akashi 2002; Comenzo and Berkman 1995). 
Moreover, it was recognised that autologous cell sources may be considered more 
favourable to alleviate future transplantation complications (Mirensky et al. 2010; 
Pashneh-Tala, MacNeil, and Claeyssens 2015; La and Tranquillo 2018; Ong et al. 
2017). Therefore, initially internal thoracic/mammary artery (hIMA) were salvaged from 
CABG surgery with the aim of isolating SMCs and ECs. Subsequently, SMCs and ECs 
were isolated from pCA. The aim was to determine the feasibility of seeding 
differentiated SMCs and ECs on to the hSV scaffold. Unfortunately, due to the limited 
tissue availability of surplus hIMA and the difficulty in culturing and expanding ECs in 
vitro, insufficient hIMA ECs were propagated, despite successful culture of SMCs. 
Henceforward, pCAs were utilized to determine the feasibility of the use of arterial 
origin cells for seeding onto the scaffold.  
 
Additionally, the use of peripheral whole blood (PWB) was assessed as a potential 
autologous cell source. Circulating endothelial progenitor cells (CEPC) and blood 
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outgrowth endothelial cells (BOEC) are among cell populations that are of interest 
(Ormiston et al. 2015; Martin-Ramirez et al. 2012; Asahara, Kawamoto, and Masuda 
2011). CEPC and BOEC are both cells isolated from the peripheral blood that could 
be the same population of cell but due to lack of consistency in the scientific community 
the same population of cells has several other name. Therefore, a consensus in 
naming the cells are in need and as suggested by Medina et. al. to have a more 
consistent reporting of the type of cells and avoiding confusion (Medina et al. 2017; 
Hagensen, Vanhoutte, and Bentzon 2012; Asahara, Kawamoto, and Masuda 2011; 
Ormiston et al. 2015; Punshon et al. 2008).  
   
Numerous reports on both cell type have described the ability of these cells to form 
colonies of mature endothelial cells in vitro, although having different proliferative 
capacity (Tagawa et al. 2015; Powell et al. 2005; Patel, Donovan, and Khosrotehrani 
2016; Campioni et al. 2013). In this chapter PWB as a cell source for cell seeding of 
the scaffold was examined using a bioreactor as an ex vivo circulating model. 
Therefore, two of the tissue engineering components; cells and regulatory signals 
(specifically, mechanical stimulus) were applied to achieve re-cellularisation. 
 
 Results 
 Propagation of cells from Porcine Carotid Arteries  




4.2.1.1 ECs and SMCs from pCA in vitro  
Cultured ECs showed the characteristic morphology of ECs with the ‘cobble-stone’ 
appearance in vitro (Figure 4.1 A). Positive staining was observed with biotinylated 
Dolichos Biflorus Agglutinin (DBA) and detection of platelet endothelial cell adhesion 
molecule (PECAM), also known as cluster of differentiation (CD31), using 
immunocytochemistry (Figure 4.1 B and C). pCA ECs also expressed vascular 
endothelial Cadherin (VE Cad), von Willebrand factor (vWF), and endothelial nitric 
oxide synthase (eNOS) proteins as shown in Figure 4.1 D and E.  
 
SMCs isolated from pCAs exhibited the characteristic ‘spindle-shape’ morphology 
observed with SMC in vitro (Figure 4.2 A). pCA SMCs also expressed -smooth 
muscle cells (αSMA), smooth muscle myosin heavy chain (SM MHC) and vimentin 





Figure 4.1 pCA EC morphology and characterisation. (A) ECs propagated from 
pCAs in vitro. (B) pCA ECs stained with the endothelial specific marker DBA. 
Immunofluorescence detection of endothelial specific proteins (green): CD31/PECAM 
(C), VE Cad (D), vWF (E) and eNOS (F) in pCA ECs. (G) IgG control. Nuclei are 
stained blue with DAPI in (B) – (G).  Scale bars in (A) – (E) represent 300 µm. Scale 










Figure 4.2 pCA SMC morphology and characterisation. (A) SMCs propagated from 
pCA. Scale bar represent 300µm. Immunofluorescence detection of smooth muscle 
specific proteins: αSMA - red (B) SM MHC – green, (C) and vimentin - red (D). (E) IgG 








4.2.1.2 Effect of SDS on pCA EC and SMC viability and proliferation  
SDS is known to be cytotoxic to cells and therefore, the AlamarBlue™ assay was used 
to assess the effect of four hours of exposure to SDS on pCA EC and SMC number. 
The AlamarBlue™ assay utilises the cell’s ability to reduced resazurin to resofurin and 
therefore acts as an indicator of cell health and viability. The subsequent proliferation 
of both cell types was then quantified by measuring EdU incorporation after 24 hour 
exposure to SDS. 
 
The cytotoxic threshold is set at 70% critical viability compared to the normal cell 
culture medium as suggested by ISO 10993:5 (Standard, I. Biological Evaluation of 
Medical Devices: Tests for in vitro cytotoxicity) (ISO 2009). pCA EC viability was not 
affected with SDS concentrations up to 0.0025% (w/v) (Figure 4.3 A). However, pCA 
EC proliferation was significantly impaired at ≥0.0025% (w/v) SDS (Figure 4.3 B). In 
contrast, with pCA SMCs, the viability was significantly affected at ≥0.01% (w/v) SDS 




















Figure 4.3 pCA EC viability and proliferation after exposure to SDS at different 
concentrations. (A) pCA EC viability when exposed to different concentration of SDS 
was assess using AlamarBlue™ after 4 hours exposure. Values are presented as 
mean ± SEM, 1-way ANOVA, Dunnett's multiple comparisons test, * indicates p<0.01, 
n=8. (B) Proliferation was quantified by counting positive nuclei labelled with EdU 
(pink) and total nuclei number (blue). Values are presented as mean ± SEM, 1-way 
ANOVA, Dunnett's multiple comparisons test, n=8. 













































































































































































































































Figure 4.4 pCA SMC viability and proliferation after exposure to SDS at different 
concentration. (A) pCA SMC viability when exposed to different concentration of SDS 
was assess using AlamarBlue™ after 4 hours exposure. Values are presented as 
mean ± SEM, 1-way ANOVA, Dunnett's multiple comparisons test, * indicates p<0.01, 
n=6. (B) Proliferation was quantified by counting positive nuclei labelled with EdU 
(pink) and total nuclei number (blue). Values are presented as mean ± SEM, 1-way 
ANOVA, Dunnett's multiple comparisons test, n=6. 
(B) 
(A) 

















































































































































































































 Decellularised hSV recellularisation 
4.2.2.1 PWB versus MNC cell seeding – roller set-up 
Seeding of decellularised hSV was attempted with both PWB and MNC for 48 hours 
on a roller set-up as described in methods (Section 2.17.1). Nuclei were detected in 
both PWB and MNC seeded decellularised hSV (Figure 4.5 C and D) and 
quantification of this preliminary data suggests higher numbers of cells were detected 
with MNC however statistical analysis could not be performed as only two replicates 
were performed (Table 4.1).  
 
Table 4.1 Re-cellularisation percentage calculated from H&E stained sections. 
Values are presented as mean ± SEM, n=2.   
Seeding cell source Mean ± SEM; n = 2 
MNC 84.87 ± 0.3072 
PWB 49.82 ± 30.28 









Figure 4.5 PWB versus MNC roller seeding of decellularised hSV. Representative 
image of (A) native hSV prior to the decellularisation protocol and (B) 0.01% (w/v) 
SDS decellularised hSV subjected to roller decellularisation protocol. Decellularised 
hSV after incubation with PWB (C) and MNC (D) at 200X magnification. Scale bar 
represent 200 µm. Arrows indicate some of the detected nuclei (purple-black). 
 
4.2.2.2 PWB cell seeding – flow set-up  
The first experiment with the bioreactor system was set with a flow rate similar to 
resting coronary blood flow of 200 mL/minute (Boron and Boulpaep 2008; 
Ramanathan and Skinner 2005). Unfortunately, after 24 hours, it was observed that 
the blood flowing through the system was a dark red colour that suggested that the 
blood had become deoxygenated. In addition, leakage was detected and the chamber 
holding the veins was filled with blood (Figure 4.6). Nonetheless, the vein was taken 
Decellularised hSV Native hSV 





out and analysed. Histological analysis revealed that clotted blood was present in the 
centre of the graft (Figure 4.6 A and B iii). It was noted that the lumen area was 
slightly enlarged after perfusion for 24 hours in the bioreactor. The graft wall appeared 
denser from H&E staining and the wall was thinner after the perfusion in the bioreactor. 
           
 
Figure 4.6 Perfusion of decellularised hSV with PWB at 200 mL/minute for 24 
hours. 0.01% (w/v) SDS decellularised hSV subjected to roller decellularisation 
protocol, (A) Pre-bioreactor and (B) Post-bioreactor. (i) Bioreactor chamber pre- and 
post-perfusion at 200 mL/minute.  H&E sections at (ii) 40X magnification and (iii) 200X 
magnification. Scale bar represent 200 and 20 µm for 40X and 400X magnification 
respectively. Arrows indicate some of the detected nuclei (purple-black). 
 
Seeding of decellularised hSV was also attempted with PWB for 48 hours using the 
bioreactor set-up as described earlier (Section 2.17.2). After flowing PWB through 
decellularised hSV at 25 mL/minute, that the number of nuclei in the decellularised 





























of flowing fluid through the scaffold removed donor cell debris. It was noticeable that 
the tissue ECM was more disrupted after 48 hours in the bioreactor than prior to 
flowing fluid through the scaffold (Figure 4.6).  
 
    
Figure 4.7 Perfusion of decellularised hSV with PWB at 25 mL/minute for 48 
hours. H&E stained sections of (A) Native hSV prior to decellularisation protocol, (B) 
0.01% (w/v) SDS decellularised hSV subjected to roller decellularisation protocol (C) 
0.01% (w/v) SDS decellularised hSV after perfusion with PWB at 25 mL/minute in 
bioreactor at 200X magnification. Scale bar represent 200 µm and applies to all 
panels. Arrows indicate some of the detected nuclei (purple-black). 
   
PWB seeded 
decellularised hSV Decellularised hSV Native hSV 




The findings from the porcine arterial xenograft implantation reported in chapter 3 
showed mixed results, where one out of three implants was patent and the other two 
were occluded. This strengthened the proposition that seeding of the decellularise 
scaffold with arterial cells would improve graft patency. Therefore, possible sources of 
arterial cells were investigated. Isolation of EC and SMC from small segments of 
surplus hIMA but with little success due to the limited amount of surplus tissue 
available. With the intention in implanting decellularise hSV in the porcine model, 
therefore the isolation and expansion of both pCA ECs and SMCs was attempted. All 
analysis was undertaken with primary in vitro cultured cells that are no more than 
passage 5 (P5) and all cells still expressed their immunophenotypical and 
ultrastructural features and showed no obvious signs of de-differentiation.      
 
Prior to seeding of cells onto the scaffolds which contain residual amounts of SDS 
(0.002% (w/v), see 3.2.4) the effect of SDS on pCA EC and SMC viability and 
proliferation was crucial. SDS is an anionic detergent that acts on the cell membrane 
and is largely used in molecular research to extract cellular content (Woldringh and 
van Iterson 1972; Tukmachev et al. 1979). At high SDS concentrations SDS has the 
capability to denature proteins and is used for studying protein folding and 
conformation (Xu and Keiderling 2004; Parker and Song 1992; Sun et al. 2015). Even 
though, SDS is widely use to decellularised tissue and organs, limited reports 
determine the cytotoxicity of SDS on mammalian cells with the decellularisation 
protocol. Mathapati et al. reported the presence of residual SDS in tissue after a 
decellularisation protocol and suggested that with 0.1% (w/v) SDS this equates to 16 
mg of SDS in 20 g of implanted saphenous vein which is less than 125 mg that would 
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be sufficient to cause toxic effect to the human system in general (Mathapati et al. 
2010). However, the effect of the localised concentration of SDS in the scaffold on cell 
seeding capacity and proliferation has not been established. Therefore, Zvarova et al. 
analysed the level of cytotoxicity of SDS on several different representative human 
cell types commonly used in lung recellularisation and showed that the cytotoxicity 
threshold varied according to cell types. They reported that human pulmonary vascular 
endothelial cells has the lowest cytotoxicity threshold at 0.00012% SDS (w/v) (Zvarova 
et al. 2016). Consequently, determination of pCA EC and SMC (or any other future 
cells to be use in recellularisation of decellularised hSV) cytotoxicity threshold need to 
be established before moving forward with recellularisation.  
 
As a result, both pCA ECs and SMCs cytotoxic threshold is shown to be at 0.0025% 
(w/v) SDS taking into account both viability and proliferation of cells. ECs are more 
susceptible to lower SDS concentration, but they would be in contact with SDS only 
on the basolateral cell surface as they are expected to repopulate the luminal surface 
of the vein. On the other hand, SMCs are anticipated to invade the tissue and 
repopulate the medial layer of the vein scaffold, hence it is likely that they will be 
exposed to more of the residual SDS that is trapped inside the scaffold after 
decellularisation protocol.  
 
The susceptibility of cells towards any surfactant are not just based on the surfactant 
critical micelle concentration (CMC) but also on the cell membrane arrangement and 
polarisation (Inacio et al. 2011). As shown in previous chapter the level of SDS 
detected in the tissue after the decellularisation protocol were at 0.002% (w/v) SDS 
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(see 3.2.4), similar to level of cytotoxic threshold of both pCA EC and SMC. The data 
also shows that after 48 hours of exposure to 0.001% (w/v) SDS, about 30% of pCA 
EC were observed to be able to proliferate (Figure 4.3B). In a dynamic environment, 
EC would be exposed to shear stress which would change the alignment of EC in the 
direction of flow and this is achieved with the change of cell polarisation (Wojciak-
Stothard and Ridley 2003). Therefore, it is important that EC needed to be first 
established in vitro before being exposed to a dynamic environment. This is done and 
presented in the next chapter as a proof of biocompatibility (Figure 5.4). 
 
Other sources of cells for seeding were also explored. Since the discovery of stem 
cells in peripheral blood between 1960 to 1970s, the potential use of peripheral blood 
in diverse disease therapies has been considered (Tripura and Pande 2013; 
McCredie, Hersh, and Freireich 1971; Martin-Ramirez et al. 2012; Goodman and 
Hodgson 1962). In  the context of tissue engineering and regenerative medicine 
research the potential use of peripheral blood derived cells to recellularise vein grafts 
especially decellularised xenograft or allograft with autologous PWB has been 
investigated (Rambol et al. 2018; Olausson et al. 2014; Punshon et al. 2008). PWB 
has been used in combination with a dynamic seeding both in vivo or ex vivo (Tripura 
and Pande 2013; Rambol et al. 2018; Olausson et al. 2012). Hence, the ability of PWB 
and PWB-derived cells to repopulate the decellularised hSV was considered. 
 
Initially decellularised vein scaffolds were rolled in either PWB or MNC isolated from 
PWB (see Section 2.16). PWB consists of a whole range of blood cells including; red 
blood cells (RBC), white blood cells (WBC), and platelets. Whereas, MNC isolated 
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from PWB consists mainly of lymphocytes and monocytes. The use of PWB eliminated 
the initial step of MNC isolation but has the downfall of being a mixture of cell types 
some of which may not be useful for seeding of the scaffold and may interfere with the 
repopulation of decellularised hSV. The preliminary results showed that both 
conditions resulted in increased numbers of nuclei throughout the decellularised 
scaffold. More cells appeared to be present in the decellularised hSV seeded with 
MNC than those perfused with PWB. This may be due to the ratio of PWB to MNC 
used being 1:2 therefore more cells were present in the MNC preparation than in PWB. 
To be able to directly compare the recellularisation procedures, it would be advisable 
to dilute the PWB to achieve the same concentration of cells. Unfortunately, this was 
not done due to time limitation, thus more assays and analysis with optimisation in 
terms of time, temperature and rolling speed of the seeding protocol are required.  
 
A dynamic seeding protocol was also examined using PWB for seeding the 
decellularised hSV in a bioreactor. In setting up the bioreactor system itself, a lot of 
hurdles were faced, e.g. part malfunctions, system failure, and deoxygenation of whole 
blood when it was perfused for 24 hours. In the first run of the bioreactor system with 
a flow of 200 mL/minutes was used that equates to a pressure of about 250 – 350 
mmHg in the bioreactor system. The resultant tissue was observed to have an 
expanded lumen size and the scaffold wall appeared denser (compacted). Noting the 
high pressure of the bioreactor system that would induce high shear stress to the 
scaffold, perfusion of decellularised hSV at a lower flow rate was also attempted. 
Olausson et al. previously implemented a very low flow at 2 mL/minute of PWB for 48 
hours (Olausson et al. 2014), but our system could not generate a flow rate as low as 
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2 mL/minute, hence we adapted the flow to the lowest the system could manage at 25 
mL/minute.   
 
The bioreactor system ran for 48 hours with laminar flow at 25 mL/minute at 39°C. 
Filters were introduced on the chambers to allow gas exchange and the blood was 
changed after 24 hours to minimise the likelihood of deoxygenation that was previously 
observed. The histological analysis showed that perfusion of the PWB through the 
decellularised vein scaffold did not enable large numbers of PWB cells to enter the 
scaffold however it did appear to remove some of the donor cell nuclei and debris. 
This may be due to a range of reasons, such as fluid drags and the effect of gravity 
within the system as higher flow rates could impart shear stress to the scaffold but 
lower flow rates may cause sedimentation of PWB cells in the system before reaching 
the scaffold (Marin et al. 2017).  
       
 Conclusion 
In summary, a number of cell sources were considered for their suitability to seed 
decellularised hSV scaffolds. The use of ECs and SMCs from pCA were the most 
feasible cell source to prove the concept of recellularisation with arterial cells on 
decellularised hSV in porcine arterial xenografting. However, utilisation of PWB and 
its derivative cells are seen to be more feasible for translational application. The 
preliminary studies have revealed some success in seeding scaffolds with cells. A 
more detailed understanding and knowledge of various interdisciplinary fields e.g. 
rheology, mechanical stimulation etc. are vital in adapting the bioreactor system to 
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recellularise any grafts in the future and overcome difficulties and limitations with the 





5 DECELLULARISATION LARGER SEGMENTS OF HUMAN SAPHENOUS FOR 
IN VIVO TESTING  
 Introduction 
In this chapter a methodological upgrading of the protocol of hSV decellularisation was 
attempted. In keeping with the previous protocol described in Chapter 2 Subsection 
2.2.1, this modified protocol also included 24-hour incubation of hSV in SDS at room 
temperature, followed by washing twice with PBS for 24 hours (as shown in Figure 
3.1). The modification consisted of using a flow system where SDS was circulated 
through the vein and around the outside of the vein at a flow of 6 mL/min to ensure 
exposure of all parts of the hSV to SDS. The set up for this modified decellularisation 
protocol is shown in Figure 2.1 iii. In brief, veins were cut into 2 segments with one 
segment being cannulated at either end with the tubing and the chamber primed using 
120 mL of 0.01% (w/v) SDS. As a comparison, the other segment of the same hSV 
was placed in a 50 mL universal in 40 mL of 0.01% (w/v) SDS and rolled at 60 rpm 
(Figure 2.1 ii). In both protocols the veins were exposed to SDS for 24 hours.  
 
 Results 
 Decellularisation of hSV using a flow-based system 
As reported for the initial protocol of hSV decellularisation, the effect of the flow-based 
system versus the roller-based system was evaluated. The following parameters were 
assessed: cell content, tissue integrity (focussing on ECM composition), 
biocompatibility of the resultant scaffold for seeding of cells for the purpose of 
recellularisation, and the feasibility of in vivo recellularisation by host cells as a 
xenograft in the porcine carotid artery model.        
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 Effectiveness of decellularisation protocol  
The effectiveness of the decellularisation was determined with several assays 
including H&E staining, dsDNA quantification using the PicoGreen assay and gel 
electrophoresis of DNA fragments. The two decellularisation protocols were compared 
and showed that the percentage of decelluarisation achieved was significantly greater 
with the roller protocol than with the flow apparatus (Figure 5.2 A). As observed in 
chapter 3 (Section 3.4), the DNA content was not affected by treatment with SDS 
using either protocol (Figure 5.2 B and C). Gel electrophoresis revealed similar results 





   
Figure 5.1 Effectiveness of decellularisation: flow vs. roller protocols. (A) The 
percentage of decellularisation was calculated by quantifying the nuclei (blue) in H&E 
stained sections of decellularised and native veins. Values are presented as mean ± 
SEM, 1-way ANOVA, Dunnett's multiple comparisons test, * indicates p<0.01, n=6. 
Representative images of native hSV and 0.01% SDS (w/v) flow versus roller 
decellularised hSVs are shown. Arrows indicate some haematoxylin stained nuclei. 
Scales bar represent 300 µm. (B) PicoGreen assay quantification of dsDNA from 
0.01% SDS (w/v) flow versus roller decellularised and native hSVs. Values are 
presented as mean ± SEM, 1-way ANOVA, Dunnett's multiple comparisons test, n=6. 
(C) Representative gel electrophoresis image of native hSV and 0.01% SDS (w/v) flow 
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 Effect of decellularisation protocol on tissue integrity  
The impact of the two protocols on the ECM integrity was analysed. Since it is 
established that the specific assay gave better representation in presenting the ECM 
integrity as shown in section 3.2.3. Therefore, only quantitative ECM protein assays 
were done and they showed that collagen, elastin and content were not significantly 
reduced compared to the native hSV using either protocol (Figure 5.2 A-C). Specific 
staining for each ECM components were done as a qualitative observation (Figure 
5.2 A-C). Collagen and elastin were observed to be lesser in the flow decellularisation 
protocol than in the native and roller protocol. No apparent differences could be 






Figure 5.2 ECM protein content after decellularisation with flow and roller 
protocols. (A) Quantification of collagen, (B) elastin and (C) GAGs content using 
Hydroxyproline, Fastin Elastin™ and Blyscan™ assays, respectively.  Values are 
presented as mean ± SEM, * indicates p<0.05, 1-way ANOVA, Dunnett's multiple 
comparisons test, n=6. Representative images for ECM proteins of flow versus roller 
decellularised and hSVs. PSR (collagen is red), EVG (elastic fibres are stained purple-
black, collagen is red and other tissue elements are yellow) and alcian blue (GAGs 
are stained blue, nuclei are stained red and cytoplasm are stained pink). Scale bar 
represent 300 µm. 
(A) 
 








Native Flow Roller 
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 Biocompatibility assay of decellularised tissue  
As shown in chapter 3, the first washing step for both protocols significantly reduced 
the SDS content by 10 times as compared to the initial 0.01% (w/v) SDS effluent 
followed by another 100 times reduction of SDS content in the second washing 
effluent. The amount of SDS detected in the tissue after decellularisation was similar 
in both methods of either flow or roller-based protocol. The results reconfirm the results 
obtain in the previous chapter with SDS detection at 0.002%, 0.002% and 0.0005% 
for first wash, second wash and in the tissue, respectively.     
 
Figure 5.3 Effectiveness of the removal of SDS in the decellularisation protocol 
The concentration of SDS in the effluent for both protocols after decellularisation with 
0.01% (w/v) SDS and the residual amount in SV tissue at the end of the 
decellularisation protocol was determined using the methylene blue assay. Values are 
presented as mean ± SEM, repeated measure 2-way ANOVA, Sidak's multiple 








































The decellularised hSVs from both decellularisation protocols were then seeded with 
pCA ECs for 48 hours. Formalin fixed hSVs were stained with H&E (Figure 5.5 A) and 
subsequently immunostained for EC and SMC markers; CD31 and αSMC, 
respectively (Figure 5.5 B). Native hSVs before decellularisation were used as 
controls (Figure 5.4 A i). The pCA ECs seeded could be observed on both H&E 
(Figure 5.4 A ii and iii) and IHC images with green arrow heads showing nucleated 
ECs (Figure 5.4 B ii and iii). The decellularised hSV showed there are left over nuclei 
in decellularised hSV and they are stained positive with αSMA; indicated by red arrow 
and nuclei with blue arrow (Figure 5.4 B i). This observation shows that pCA EC could 
survive on decellularised hSV regardless of the decellularisation protocol employed. 
More nuclei are detected in the wall of roller decellularised hSV and some CD31 with 
nuclei staining in the wall of roller decellularised hSV (Figure 5.4 B iii). This might be 
due to the cells migrating through the bottom of CellCrown and repopulate the tissue 
from the bottom.  












 Figure 5.4 Assessment of biocompatibility using EC seeding and histological 
analyses. (A) Representative images of H&E stained sections of (i) native hSV, (ii) 
flow and (iii) roller decellularised hSVs that were seeded with pCA EC for 48 hours. 
Black arrow showing nuclei. Scale bars represent 200 µm. (B) Representative images 
of dual immunohistochemistry for αSMA (red arrow) and CD31 (green arrow head and 
arrow) in (i) decellularised hSV; and the seeded (ii) flow and (iii) roller decellularised 
hSVs. Nuclei are stained with DAPI (blue arrow). Scale bars represent 100 µm. n=5. 
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 Implantation of decellularised human saphenous veins as a xenograft in 
a porcine model 
The comparisons undertaken with a limited number in each group suggested that the 
flow-based protocol of decellularisation was not superior to the roller-based system. 
The only tangible translational benefit associated with the flow-based protocol of 
decellularisation is that this system allowed to decellularise longer segment of veins, 
something of key importance when undertaking aorto-coronary or peripheral bypass 
grafts.  
 
Three decellularised hSV subjected to roller decellularisation protocol with 0.01% (w/v) 
SDS were implanted as a xenograft in the porcine model. As 2/3 of previous carotid 
implants showed severe luminal thrombosis resulting in complete occlusion, in this 
subsequent group of in vivo implants a more aggressive anti-platelet dose of aspirin 
of 300 mg/day was employed from 4-hour post-surgery until termination. This 
approach was thought to be more appropriate and in line with current clinical practice.  
In addition, vascular Doppler evaluation was undertaken for functional evaluations. 
Doppler ultrasound was used before and after implantation of the scaffold to determine 
patency, flow dynamics, and wall thickness, whereas in the previous study, patency 
was determined manually by confirming persistence of distal pulse in artery verified by 
the surgeon.  
 
Doppler readings of flow velocities and indices were assessed and compared soon 
after surgical post-implant and just before pre-explant at termination (n=2, one graft 
was occluded) to see the changes soon after graft implantation and before the graft 
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was explanted. Doppler spectrum of the carotid artery shows a low resistance pattern 
(<0.7) with sufficient diastolic antegrade flow post implantation in all pigs (Figure 5.5). 
On the other hand, the pre-explant reading varies between animals. The first hSV graft 
was occluded. The second hSV graft has almost similar RI index post-implantation 
and pre-explantation (0.6 and 0.61; respectively). Whereas, the RI index in the third 
graft increased 1.6 times higher at pre-explantation; 1.01 than at post-implantation; 
0.65 (Figure 5.6).  
 
 
Figure 5.5 Post-implant observation. (A) Gross morphology of the 0.01% (w/v) SDS 
decellularised hSVs immediately after implantation within the carotid artery. (i) first 
graft, (ii) second graft and (iii) third graft. (B) Doppler ultrasound screen capture of the 
flow velocity of each graft. Maximum systolic velocity; Vmax, mean diastolic velocity; 
MDV, end-diastolic velocity; EDV, resistivity index; RI, pulsatility index; PI and 
systolic/diastolic ratio; S/D. 
 
 
i ii iii (A) 





Figure 5.6 Pre-explant observation at 4 weeks. (A) Gross morphology of the 0.01% 
(w/v) SDS decellularised hSVs immediately before the graft was extracted. (i) first 
graft, (ii) second graft and (iii) third graft. (B) Doppler ultrasound screen capture of the 
flow velocity of each graft before extraction. Maximum systolic velocity; Vmax, mean 
diastolic velocity; MDV, end-diastolic velocity; EDV, resistivity index; RI, pulsatility 
index; PI and systolic/diastolic ratio; S/D. 
 
Summary of Doppler based flow velocities for native pCA, post-implantation and pre-
explantation are shown in Table 5.1. There are no significant differences observed in 
all flow velocities and waveforms between the decellularised hSV right after 
implantation and before the graft being taken out. The Doppler in situ lumen 
measurement shown in Table 5.1 corroborate later H&E lumen diameter analysis as 
shown in Figure 5.7A. At explantation, Doppler reading of the native pCA proximal and 
distal to the graft and inclusive of the middle of the graft are presented in Table 5.2 
(occluded graft recorded as 0). Maximum velocity (Vmax) of the pCA proximal to the 
i ii iii 
(A) 
(B) i ii iii 
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graft are observed to be significantly lower as compared to the velocities in the graft 
and distal to the graft (Table 5.2: Vmax). 
 









Vmax (cm/s) 155 ± 39 141 ± 51 180 ± 107 
EDV (cm/s) 38 ± 5 54 ± 16 72 ± 43 
MDV (cm/s) 23 ± 20 54 ± 16 32 ± 30 
TAP (cm/s) 51 ± 8 56 ± 15 83 ± 53 
S/D 4 ± 2 2 ± 0.2 1.7 ± 0.8 
RI 0.7 ± 0.1 0.6 ± 0.04 0.4 ± 0.2 
PI 3 ± 2 1 ± 0.09 2 ± 0.2 
ID (cm) 0.5 ± 0.1 0.3 ± 0.01 0.3 ± 0.3 
OD (cm) 0.6 ± 0.2 0.4 ± 0.03 0.4 ± 0.3 
Maximum systolic velocity: Vmax, mean diastolic velocity: MDV, end-diastolic velocity: 
EDV, resistivity index: RI, pulsatility index: PI, systolic/diastolic ratio: S/D, internal 





Table 5.2 Flow velocities and waveforms at pre-explant comparing native pCA 
proximal to the graft, hSV graft and distal to the graft procedures.  
 Proximal pCA hSV graft Distal pCA 
Vmax (cm/s) 35.9 ± 12 *180 ± 106 *171 ± 118 
EDV (cm/s) 13 ± 6 71 ± 43 14 ± 12 
MDV (cm/s) 15 ± 7 32 ± 29 14 ± 12 
TAP (cm/s) 15 ± 8 84 ± 53 74 ± 50 
S/D 3 ± 0.4 2 ± 0.8 29 ± 27 
RI 0.8 ± 0.2 0.4 ± 0.2 0.6 ± 0.3 
PI 5 ± 3 2 ± 1 1 ± 0.7 
ID (cm) 0.4 ± 0.1 0.3 ± 0.3 0.3 ± 0.2 
OD (cm) 0.5 ± 0.1 0.4 ± 0.3 0.3 ±0.2 
Maximum systolic velocity: Vmax, mean diastolic velocity: MDV, end-diastolic velocity: 
EDV, resistivity index: RI, pulsatility index: PI, systolic/diastolic ratio: S/D, internal 
diameter: ID and outer diameter: OD. * indicates p<0.05, 2-way ANOVA, Bonferroni’s 
multiple comparisons test, n=3. 
 
Additionally, histology was performed to analyse the graft structure and composition. 
The lumen diameter calculated from fixed tissues corroborate the Doppler ultrasound 
reading taking into account in situ measurements which is under perfusion and up to 
30% shrinkage of tissue due to tissue fixation and processing. Of note, the lumen 
diameter and wall thickness were similar of the decellularised hSV, pre-implant and 
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post-implant pCA are similar (Figure 5.7 A and B) although the velocities were noted 
to be significantly different between flow in the pCA proximal to the graft and within the 
grafts onward. All three explants gave differing but interesting results. The first graft 
was occluded whereas the other two grafts were both patent at 4 weeks post-surgery. 
These two grafts however, showed obvious differences in structure and composition 
and flow velocity from the Doppler evaluation. Noticeably, the second graft was dilated 
with a larger lumen diameter compared with that of the native artery and the hSV at 
implant. The third graft was also patent but showing a lumen diameter more similar to 
that of the native pCA or hSV at implant. In all grafts the wall thickness was increased. 
Of note, ECM protein assays for ECM proteins (collagen, elastin and GAGs) showed 
no apparent differences between decellularised hSV and pCA pre- and post-implant 
(Figure 5.8 – 5.10).  
 
H&E staining shows marked cell infiltration in all graft wall (Figure 5.11 i). The 
explanted grafts were then subjected to immuhistolochemistry to identify cell types 
markers as in chapter 3 (SMC: αSMA and SM MHC, EC: CD31 and eNOS, 
macrophage/monocytes: CD203 and fibroblast: vimentin). Immunostaining of all three 
grafts with the EC specific antibodies revealed the presence of CD31 and eNOS 
positive cells (EC) in the medial layer of the grafts (Figure 5.11). A streak of CD31 
positive staining could be observed on the section of the lumen (Figure 5.11B iii).  
 
Of note, αSMA was detected in the medial layer of graft 4 and 6, despite the first graft 
being occluded and the third graft showing a thick wall (Figure 5.11 A iii and C iii). 
As observed in the first set of implants, these might be donor cell remnants from the 
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implanted decellularised hSV as previously observed (Figure 3.14). Additionally, faint 
staining for αSMA was noted in the graft 2, which was also patent (Figure 5.11 B iii). 
Vimentin which is a fibroblast and synthetic SMC marker was not detected in the three 
grafts (Figure 5.11 v). CD203 which is a marker for macrophage/monocyte for swine 
was also not detectable in all three graft (Figure 5.11 iv). Noteworthy, the detection of 
neovascularisation in the adventitial layer of the grafts as shown in Figure 5.11 A iv 
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Figure 5.7 Structural characteristics of pCA and decellularised vein pre- and post-implant. (A) Lumen diameter pre- and post-
implant of pCA and 0.01% (w/v) SDS decellularised hSV and. Values are presented as mean ± SEM, Repeated measure 2-way 
ANOVA, Sidak's multiple comparisons test, n=3. (B) Wall thickness pre- and post-implant of pCA and 0.01% (w/v) SDS decellularised 
hSV. Values are presented as mean ± SEM, Repeated measure 2-way ANOVA, Sidak's multiple comparisons test, n=3. (C) H&E 
images for pre- and post-implant of pCA and 0.01% (w/v) SDS decellularised hSV. Collagen and muscle are stained pink, cytoplasm 
is stained purple-red, nuclei are purple-blue and red blood cells stained cherry red. ;  and  4, 5 and 6 indicate explants from pig 



















Figure 5.8 Collagen content of pCA and decellularised vein pre- and post-implant. (A) Quantification of collagen content within 
pre- and post-implant of pCA and 0.01% (w/v) SDS decellularised hSV using hydroxyproline assay. Values are presented as mean 
± SEM, Repeated measure 2-way ANOVA, Sidak's multiple comparisons test, n=3. (B) PSR images for pre- and post-implant of pCA 
and 0.01% (w/v) SDS decellularised hSV where collagen is red on a pale-yellow background at 200X magnification. ;  and  
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Figure 5.9 Elastin content of pCA and decellularised vein pre- and post-implant. (A) Quantification of elastin content within pre- 
and post-implant of pCA and 0.01% (w/v) SDS decellularised hSV using Fastin Elastin™ assay. Values are presented as mean ± 
SEM, Repeated measure 2-way ANOVA, Sidak's multiple comparisons test, n=3. (B) EVG images for pre- and post-implant of pCA 
and 0.01% (w/v) SDS decellularised hSV where elastic fibres are stained purple-black, collagen is red and other tissue elements are 































































































































Figure 5.10 GAGs content of pCA and decellularised vein pre- and post-implant. (A) Quantification of GAGs content within pre- 
and post-implant of pCA and 0.01% (w/v) SDS decellularised hSV using Blyscan™ assay. Values are presented as mean ± SEM, 
Repeated measure 2-way ANOVA, Sidak's multiple comparisons test, n=3. (B) GAGs images for pre- and post-implant of pCA and 
0.01% (w/v) SDS decellularised hSV where GAGs are stained blue, nuclei are stained red and cytoplasm are stained pink at 200X 
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Figure 5.11 Xenograft immunohistochemistry screening staining. Representative 
images of dual immunostaining on 3-micron slices of xenograft explants stained with 
both EC and SMC marker to identify cells in the explants with (i) H&E stained explants 
ring to show localisation and (ii) cell infiltration (nuclei are stained purple black). All 
slides were nuclear stained with (iii) αSMA (red) and DBA (green); (iv) SM MHC 
(green) and CD203 (red); (v) Vimentin (green) and eNOS (red) with nuclei stained 
DAPI (blue), at 200X magnification. Green arrow indicates CD31 positive cells. White 
arrow shows neovascularisation. Scale bar represent 200 µm for both high 
magnification IHC and H&E images and 3 mm for lower magnification H&E images.  
(C) Pig 3 
Vimentin eNOS Dapi 









Perfusion systems have been employed to decellularise a range of whole organs, for 
example heart, lung, liver (Gilpin et al. 2014; Wu et al. 2015; Gerli et al. 2018). This 
approach provides a more thorough exposure to the detergent utilised for 
decellularisation of tissues. Therefore, a simple perfusion system was used in this 
chapter as a comparison with the previous decellularisation protocol using a roller, 
with the aim to obtain a more translational decellularised hSV that when implanted in 
vivo would gave a more effective and consistent outcome. Decellularisation was 
achieved with the perfusion system but with no apparent differences with the 
previously employed roller decellularisation protocol in terms of decellularisation 
efficiency, DNA elimination, ECM integrity and biocompatibility. Subsequent 
experimental work is required to further enhance the decellularisation protocol. It is 
possible that increasing the flow rate would help in increasing the decellularisation 
efficiency of the flow decellularisation protocol and this could be attempted in the 
future. One advantage of using the perfusion system is the ability to decellularise 
longer segments of hSV and this would be advantageous in terms of preparing a graft 
for use in CABG. The guidelines for vein harvest are based on the artery occlusion to 
be bypassed. The shortest vein needed for grafting at the left anterior descending 
artery is at least 10 to 15 cm whereas the longest would be 20 cm to be grafted at the 
posterolateral artery (Barner and Farkas 2012; Barner 2013).  
 
The biocompatibility of the resultant scaffolds was proven via pCA EC reseeding on 
the decellularised hSV in vitro. The purpose of the xenografting was to assess the 
patency and the repopulation of the scaffold in vivo by host cells. Three in vivo implants 
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of decellularised hSV were prepared with the roller decellularisation protocol and 
implanted with improved antiplatelet therapy. This overall approach aimed to improve 
the graft patency by reducing the likelihood of thrombus formation, and thus prevent 
graft occlusion (Goldman et al. 1988; Stein et al. 2004; Poston et al. 2006). Aspirin 
was given with a daily dose of 300 mg for a week before surgery and from 4-hour post-
surgery, daily until termination as opposed to 75 mg daily aspirin in the first batch of 
three decellularised hSV implants. The outcome of all three implants varied, and given 
the limited number of implants undertaken it is not possible to reach firm conclusions 
on the differences observed between the first and the second group of in vivo implants.   
 
Doppler ultrasonography has widely been used to assess various vascular diseases 
(Cooperberg 1992; Vriens et al. 2001; Jahromi et al. 2005). Doppler ultrasound 
observation verified the patency of graft immediately after implantation. Dynamic 
information of blood flow was crucial in analysing the spectral waveform and may 
assist in predicting future outcome of the implants. Doppler ultrasound readings of the 
native right carotid arteries didn’t deviate from the reference range reported by other 
groups for several other species e.g. minipig, dogs, cows, and human (Jung et al. 
2010; Cooperberg 1992; Vriens et al. 2001; Jahromi et al. 2005; Braun and Fohn 2005; 
Svicero et al. 2013). The degree of stenosis, based on values suggested by North 
American Consensus Criteria (NACC) where value of peak systolic velocity (PSV) at 
<125 cm/s for 50% stenosis, >230 cm/s for 70% stenosis and >400 cm/s for ≥90% 
stenosis showed that even the values of native pCA are >150 cm/s which if according 
to NACC has a degree of stenosis between 5 to 69% (Grant et al. 2003). It is important 
to note that the pre-explanted and post-explanted graft has a high Vmax value of 142 
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cm/s and 180 cm/s which falls in the same interpretation with native pCA according to 
NACC (Cooperberg 1992; Grant et al. 2003; Jahromi et al. 2005). Therefore, the 
baseline reference level captured in these experiments for this particular model will be 
helpful for future implant studies.  
  
Histological staining results proved that there was no lumen mis-match between the 
decellularised hSV and the pre-implant pCA at the time of surgical implantation. 
Persistent change in vessel size in atherosclerosis were apparent hence the term 
arterial remodelling was coined to describe these changes because in the presence 
of stable lesion, arterial remodelling and not plaque size is the main determinant of 
lumen size (Sipahi et al. 2006; Ward et al. 2000). The wall thickness increased in all 
grafts although only one showed an increased lumen diameter which is similar to the 
first batch of grafts. Thus, the expansion of grafts is in agreement to the arterial 
remodelling where a compensatory dilatation of vessels occurs to accommodate any 
plaque formation without any lumen loss (Glagov et al. 1987; Glagov et al. 1988; Sipahi 
et al. 2006; Davies 2000; Murphy and Angelini 2004). Collagen, elastin and GAGs 
showed no differences pre- and post-implantation and between native pCA shows the 
suitability of the graft as a xenograft.   
 
Histological staining showed a marked infiltration of host cells into the wall of the 
scaffold. Endothelial markers CD31 and eNOS were detected in all grafts 
predominantly within the wall at level of the medial layers. As discussed in earlier 
chapters, both markers are also expressed in inflammatory cells, hence highlighting 
the inflammatory response of host cells to the vein xenografts (Kim et al. 2009; 
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Connelly et al. 2003). SMC markers, especially αSMA were apparent in all graft 
explants along with many nuclei. It is hard to confirm whether these SMC are remnants 
of human cells after decellularisation or new SMC derived from recruited host cells. Of 
note, we observed αSMA in the decellularised hSV before surgical implant as shown 
initially in chapter 3. There is the possibility of SMC invasion from porcine host cells 
through the anastomosis region as demonstrated by Liang et. al in studying the 
neointima formation in arteriovenous fistulas that was attributed to SMC from the artery 
side of the fistula (Liang et al. 2015). Vimentin staining was not detectable suggesting 
that the cells were fibroblasts or synthetic SMCs that are associated with the venous 
phenotype (Asada et al. 2005; Beamish et al. 2010; Worth et al. 2001; Zhou et al. 
2007).      
 
It has been demonstrated that initially, recellularisation of any graft, be it synthetic or 
biological, leads to marked macrophage recruitment, representing the host immune 
response to the foreign tissue implanted (Kim et al. 2009; Badylak 2014). This 
triggering of immune response may be beneficial. The tissue engineering and 
regenerative medicine research communities are looking at this matter in a positive 
light as macrophage recruitment is seen as a means to recellularisation of any graft 
especially biological grafts (Badylak and Gilbert 2008; Badylak 2014; Moroni and 
Mirabella 2014). The subsequent aim after macrophage recruitments and graft 
infiltration are directing the macrophage phenotype from pro-inflammatory (M1) to anti-
inflammatory (M2) (Novak and Koh 2013; Lech and Anders 2013; Badylak 2014; Wynn 
and Vannella 2016).                      
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The swine macrophage/monocyte marker CD203 was initially chosen as it is 
expressed when monocytes differentiate into macrophages. However,  CD203 has 
been used to identify macrophages with M2 polarisation (Singleton et al. 2016; 
Jacobsen et al. 2016; Franzoni et al. 2017). M2 macrophages are associated with the 
anti-inflammatory and cell repair function which are the main subtype of macrophages 
that would be beneficial in the repopulation of the graft and direct tissue remodelling 
and regeneration of the decellularised graft. CD203 staining was not detected in the 
wall of the grafts. Therefore, other macrophage marker regardless of their phenotype 
like CD68, CD163 or CD80 would be of use here but was not possible due to limited 
availability of suitable antibodies that recognise porcine antigens (Badylak et al. 2008; 






This chapter showed that the two decellularisation protocols used are reasonably 
effective in decellularisation without damaging the ECM integrity. There were no 
apparent differences in effectiveness between the two approaches however, except 
for the capacity of the flow decellularisation apparatus to accommodate longer lengths 
if vein which would be beneficial toward translations of this protocol for CABG 
applications. No obvious improvement in the group with 300 mg aspirin vs the 75 mg 
used in the previous pilot study, no conclusive inference can be made with this 
increase of antiplatelet therapy and any benefits it may imposed. Nonetheless, future 
implants should employ the higher dose of antiplatelet therapy which is at par with the 
current clinical practise in humans. Finally, for the porcine arterial xenografting, 
vascular Doppler ultrasound analysis was a very effective functional scan in assessing 
graft patency in vivo. A baseline reading of control pigs could be established to get a 
better degree of stenosis extrapolation.            
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6 GENERAL DISCUSSION AND FUTURE WORK 
 General discussion 
The emergence of tissue engineering and regenerative medicine (TERM) approaches 
facilitates the idea of ‘From Bench to Bedside’ research towards the translational 
stage. The multidisciplinary nature of TERM allows the collaborative effort between 
science, medicine and engineering to a common goal in treating diseases and saving 
patients lives. For that reason, in this thesis the tissue engineering framework that 
encompass three components which are biomaterial, cells and signalling was adopted 
in the project. Starting off with the biomaterial it was assessed whether it is possible 
to increase the patency of the SV, which is the most commonly used bypass graft for 
coronary and peripheral applications. It is well established that IMA grafts have 
significantly higher patency than SV grafts and numerous reasons for the difference in 
patency have been identified. Aside from the anatomical and the physiological 
differences, the phenotype of the cells within the arterial and venous grafts differ (dela 
Paz and D'Amore 2009; Hirashima and Suda 2006; Kim et al. 2004) .  
 
Therefore, the hypothesis was to remove the cellular materials from SVs and obtain a 
vascular ECM which could be utilised an ‘acellular’ graft or seeded with cells prior to 
implantation. One might suggest an alternative approach whereby the venous cells 
could be arterialised with the hemodynamic forces mimicking the arterial system 
consequently might increase vein graft patency. Haemodynamic forces may have an 
impact on directing the change of cell from venous to arterial phenotype, although their 
mechanistic role in vascular tissue engineering need to be elucidated further. The 
possibility of in vivo arterialisation of veins is disputed by the findings of Kuto et al., 
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who reported that vein graft adaptation does not change the molecular identity of the 
vein to an artery as vein grafts lost their venous markers but did not gain any arterial 
markers (Kudo et al. 2007). These findings are further corroborated by Berard et al. in 
their ex vivo perfusion system (Berard et al. 2013). These findings confirm that the 
genetic make-up of mature cells are pre-determined during development. Hence, 
decellularising human veins into acellular vascular scaffolds and re-seeding the 
decellularised ECM with arterial cells possibly under dynamic conditions was deemed 
a suitable aim. In keeping with this rationale, the ECM or any TEVG should be re-
seeded with cells that either come from in vivo arterial origin or are derived from any 
available pluripotent or multipotent cells in vitro. It is proposed that this approach may 
achieve an arterialised conduit with an improved patency through remodelling of the 
graft towards arterial characteristics.  
 
The decellularisation of veins has been performed previously, and used particularly 
for allografts and xenografts (Martin et al. 2005; Ketchedjian et al. 2005; Schaner et 
al. 2004). The efficacy of a decellularisation protocol is generally based on assessing 
the amount of residual  donor cell nuclei and quantifying the DNA content after 
decellularisation, while other cellular debris (including plasma cell membrane, and 
cytoplasmic proteins) are neglected (Crapo, Gilbert, and Badylak 2011). Most reports 
of decellularisation approaches cover very little quantitative results and focus more of 
a representative qualitative staining images (Bruyneel and Carr 2017). Thus, in this 
study a quantitative approach was utilised wherever possible to enable the 
decellularisation protocol efficacy to be accurately assessed.  
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The use of decellularised ECM has potential benefits over synthetic scaffolds as the 
ECM scaffold facilitates and inhibits recruitment of various cell types, and can undergo 
remodelling, which are features lacking in synthetic grafts. The characteristic of ECM 
mediated constructive remodelling includes the degradation of ECM proteins that can 
release signalling molecules, modulate the inert immune response and promote 
recruitment of endogenous stem cells (Voytik-Harbin et al. 1997; Robinson et al. 2005; 
Badylak and Gilbert 2008; Reing et al. 2009; Vorotnikova et al. 2010; Hammond et al. 
2011; Badylak 2014). Matrix-bound nanovesicles (MBVs) have been demonstrated to 
be an integral and functional component of ECM bioscaffolds which are released via 
constructive remodelling (Huleihel et al. 2016). MBVs promote the M2-like anti-
inflammatory macrophage phenotype and T cells towards the Th2-like immune 
response that stimulate remodelling rather than rejection (Allman et al. 2001; Huleihel 
et al. 2016). MVBs are similar to exosomes which is a subset of extracellular vesicles 
(EVs) (van Niel, D'Angelo, and Raposo 2018). MVBs, like EVs, have a varied cargo 
including microRNA (miRNA), cytokines, chemokines, proteins, and lipids (Choi et al. 
2015; Maas, Breakefield, and Weaver 2017). It has been shown that the contents of 
EBVs play some positive roles in the regulation of immune response (Robbins and 
Morelli 2014).   
 
It is possible that MBVs contribute at least in part to the variable in vivo porcine arterial 
xenograft results. After analysing the initial 3 xenografts, an improvement of the 
decellularisation protocol was thought to be necessary, to eliminate any residual DNA 
as it was the possible culprit for the adverse outcome. Although the lack of EC 
coverage could feasibly lead to large thrombus formation. A modified protocol was 
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established, but to no avail as the perfusion decellularisation protocol rendered similar 
results to the roller decellularisation protocol in terms of DNA content and ECM 
integrity. However, the perfusion decellularisation proved to be more effective that the 
roller decellularisation protocol as it permitted the use of a longer segment of hSV, 
something critical for future possible translation to bedside. The results from the 
porcine arterial xenografts confirmed that the cell infiltration inside the grafts. Granting 
that no evidence was shown in this project due to limitation in optimising working 
porcine cell markers, the immune response of host cells to the graft may be due not 
just to remnants of DNA in the graft but also be mediated by MBVs in the ECM. 
Previous studies have highlighted that residual DNA and cell debris mediate the host 
macrophage infiltration into the graft (Sanders et al. 2017; Wong et al. 2008). The host 
immune response will direct macrophages into the graft, and cytokine, chemokines, 
miRNAs released from MBVs may direct the polarisation of macrophages to the anti-
inflammatory phenotype (M2) that contribute to tissue remodelling (Lech and Anders 
2013; Badylak 2014).   
 
From the six xenografts a 50% success rate was recorded which is low compared to 
other reported large animal model arterial xenograft transplantation studies with 100% 
patency at 3 and 5 months in an ovine model and at 10 months in a canine model 
(Clarke et al. 2001; Affonso da Costa et al. 2004). Long-term implantations of seeded 
grafts would be beneficial to ascertain the progress of arterial remodelling in the 
porcine model used in this study and eliminate and enhance the repopulation of the 
grafts. Preclinical testing with short-term implantations often used in small animal 
models with as short as 2 weeks evaluations and larger animal models usually are 
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done longer (Lopez-Soler et al. 2007; Gui et al. 2009; Xiong et al. 2013; Negishi et al. 
2015; Amensag et al. 2017). The increase of aspirin as an antiplatelet therapy in the 
second pilot study was initially thought to improve the implantation protocol but the 
outcome of the implantation is not conclusive due to too small n number. 
           
It is commonly perceived that ex vivo seeding of ECM scaffolds has potential for 
recellularisation of the graft and creation of an arterialised vein before surgical implant 
(Quint et al. 2011; Kaushal et al. 2001; Villalona et al. 2010). By reseeding the graft 
ex vivo to create an endothelial lining in the lumen, the patency of the graft could be 
preserved as demonstrated by Yang et al. where native grafts and reseeded acellular 
allografts produced 100% patency after 6 months, but only 50% of naked acellular 
grafts were patent (Yang et al. 2009). Hence, a variety of recellularisation techniques 
have been developed to achieve the best recellularisation, be it static or dynamic 
seeding (Mirensky et al. 2010; Punshon et al. 2008; Villalona et al. 2010; Yang et al. 
2009). Static seeding includes injecting, dripping or bathing cells onto the 
decellularised ECM. The static method has as the benefit that it is the simplest 
application, hence easier to manipulate and thus more feasible for translation and 
most economical. Static seeding was undertaken in this project to assess the 
biocompatibility of the decellularised hSV with pCA ECs where decellularised tissue 
was fixed on a CellCrown™ insert to hold the tissue and then cells were seeded on 
top of the tissue hence preventing the migration of cell onto the culture plate. This 
method worked for a small piece of the tissue but scaling up of this approach to reseed 
the whole decellularised lumen will present a challenge.  
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Alternatively, the use of a dynamic system presents a more comprehensive approach 
in reseeding an acellular vascular graft. The dynamic environment that a bioreactor 
system provides with different variables that could be manipulated such as the flow 
pattern, may be vital in the arrangement of ECs on the surface of the acellular graft. 
Aligning ECs on the luminal surface will prevent the adhesion of monocytes and 
therefore should improve graft patency (Shin et al. 2016; Huang et al. 2013). The 
bioreactor system is widely used in TERM research as a combinatory approach using 
cells, scaffolds and regulatory signalling to achieve a functional tissue (Nieponice et 
al. 2008; Schulte et al. 2014; Catto et al. 2014; Pashneh-Tala, MacNeil, and 
Claeyssens 2015).  
 
In exploiting the bioreactor system, PWB was used as a cell source due to limited 
number of primary pCA ECs that could be extracted from arteries and the time needed 
to expand the cell culture to achieve enough number to be used in the system. The 
aim was to prove that  PWB contains cells that could potentially recellularise the 
decellularised vein similar to described by Olausson et al. (Olausson et al. 2012; 
Olausson et al. 2014). Unfortunately, there was insufficient time to optimise the 
utilisation of the bioreactor system e.g. the flow, pressure for this project. The results 
were based on several attempts that were successful but not comparable as they 
utilised differing protocols. But based on the bioreactor attempts that were successful, 
it was noted that high flow with high pressure (200 mL/minute, 250-350 mmHg) 
resulted in a slight increase of lumen diameter and more compact decellularised hSV 
wall. Whereas, lower flow with slightly lower pressure (25 mL/minute, 100-200 mmHg) 
208 
 
did not affect the tissue appearance and therefore appears more suitable in terms of 
seeding of cells for future studies.  
 
The reason for utilising the high flow, was first to mimic the flow condition in the internal 
carotid artery which is reported as 238.84 mL/min (Oktar et al. 2006). Unfortunately, 
the PWB perfusion in the bioreactor system at high flow did not show any cells 
attached on the lumen surface, and instead blood clots were observed. The flow was 
then decreased to 25 mL/minute but the resultant tissue still did not show any cell 
attachment except for a few streaks of red blood cells. This might suggest that even 
lower flow rates are needed. Olausson et al. in their recellularisation process applied 
a very low flow at 2 mL/minute which is equivalent to 0.6 dyne/cm2. Their decision to 
use such a flow rate was based on various report of fluid shear stress at this level 
move the differentiation of endothelial progenitor cells to endothelial-like cells and the 
expression of these cells towards arterial endothelial cell (Obi et al. 2012; Ankeny et 
al. 2012; Egorova et al. 2012; Adamo and Garcia-Cardena 2012; Obi et al. 2009; 
Yamamoto et al. 2003). Further optimisation is therefore needed on the system to 
circumvent the problem of gravity and sedimentation of cells early on in the system 




 Overall findings and conclusion 
Development of new arterial-like vascular conduits for coronary and peripheral bypass 
grafting surgery is desirable to overcome the limitations of currently available biological 
and/or synthetic grafts and thereby reduce the incidence of early thrombosis, late 
intimal thickening and infection. One alternative is to use arterialised decellularised 
venous scaffolds. The aim of this PhD project was to assess the feasibility and 
suitability of hSV decellularisation as a way to obtain an effective biological acellular 
scaffold for vascular grafting.  
 
We identified an optimal low SDS concentration (0.01%) to decellularise short 
segments of hSVs (~0.5cm), but this approach was not effective in removing nuclei 
when using ~4cm long hSVs. However, a modified flow technique of decellularisation 
was established with successful decellularisation of longer hSV segments, with 
translational potential. Biocompatibility and integrity of decellularised hSVs were 
evaluated. Methylene blue assay detected only trivial residual concentrations of SDS 
after decellularisation. This was biocompatible as this residual amount of SDS did not 
affect the viability of porcine carotid artery endothelial cells (pCA ECs) to populate the 
acellular hSV (AlamarBlue) and to proliferate (EdU proliferation assays). The ECM 
integrity of acellular hSVs was assessed by quantifying major ECM proteins (collagen, 
elastin and GAGs). Results revealed that decellularisation with ≤0.01% (v/v) SDS did 
not have a significant impact on the ECM content. The feasibility, safety and capacity 
of acellular hSVs to act as an end-to-end anastomoses in pigs without 
immunosuppression was tested. This pilot study showed that porcine carotid artery 
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xenograft of decellularised hSV was feasible and safe, with 50% graft patency rate at 
4 weeks and signs of in situ vascular tissue engineering by host cells.  
 
In conclusion, taken together, this project suggests that effective decellularisation of 
hSV is feasible, safe and reproducible as potential acellular vascular scaffolds. 
Acellular hSVs may be used as vascular acellular scaffolds either for in situ vascular 
engineering by host cells or following ex vivo manipulation before implantation. 
However, this approach need significant refinement and warrants further future 
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